{"title": "Caracterização de um regulador de secreção não convencional na patogênese de Cryptococcus neoformans", "authors": ["Godinho, Rodrigo Maciel da Costa", "Rodrigues, Marcio Lourenço orient.", "Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes"], "abstract": "O complexo Cryptococcus neoformans é formado pelas espécies C. neoformans e C. gattii, ambos patógenos associados a altos índices de letalidade em humanos. A patogenicidade destes fungos é dependente da produção e secreção de polissacarídeos capsulares, pigmentação e enzimas líticas. O fator de virulência mais importante utilizado por esses microrganismos é a glucuronoxilomanana (GXM), principal polissacarídeo capsular. A GXM é sintetizada no citoplasma e transferida para a superfície celular em vesículas secretoras que possivelmente originam-se de compartimentos endocíticos e apresentam características morfológicas que se assemelham as de exossomos, vesículas extracelulares secretadas por vários eucariotos. A proteína Snf7 é um dos reguladores da formação de exosomos. Sua função está associada ao endereçamento de proteínas transmembranares para a via de formação de corpos multivesiculares (MVBs), necessários para formação e secreção de exossomos. Neste trabalho, foram avaliados o papel de Snf7p na secreção de fatores de virulência no complexo de espécies C. neoformans e os impactos desses efeitos em um modelo de infecção murino. A deleção de SNF7 tanto em C. neoformans quanto em C. gatti, por técnicas de biolística e recombinação homóloga, não provocou alterações marcantes no crescimento dos fungos mutantes a temperaturas de 30 e 37ºC, mas impactou levemente o crescimento dos mesmos em condições de privação de cobre. Snf7p mostrou-se necessária para o crescimento de ambos os fungos estudados em pHs superiores a 7,5. Os mutantes também mostraram acentuada sensibilidade a LiCl2. Através de técnicas de qPCR, observamos que os mutantes snf7Δ apresentaram modulação negativa da expressão do RNAm de RIM101, gene necessário para adaptação a variações no pH e outros fatores físico-químicos.A deleção de SNF7 afetou a capacidade de pigmentação em ambos os mutantes quando cultivados a 30 ou 37ºC na presença de diferentes substratos utilizados pelo fungo para pigmentação. A perturbação da maquinaria de formação de MVBs causou uma redução expressiva na secreção de GXM, conforme quantificado através de ensaios imunoenzimáticos. A secreção defeituosa de GXM observada nos mutantes snf7Δ foi traduzida na formação de cápsulas significativamente reduzidas em ambos os mutantes, conforme observado por técnicas de microscopia de luz e eletrônica de varredura. Os mutantes mostraram-se avirulentos em um modelo intranasal de infecção murina com C. neoformans ou C. gattii, fato provavelmente ligado aos defeitos de secreção de polissacarídeos, formação de cápsula e pigmentação descritos acima. A secreção atenuada de GXM in vivo foi também associada a uma maior susceptibilidade de C. neoformans aos mecanismos de defesa do hospedeiro. Estes resultados demonstram que o gene SNF7 tem papel central na virulência do complexo C. neoformans através da participação em eventos necessários à secreção de polissacarídeos e pigmentação relacionados à sobrevivência do fungo durante a interação com o hospedeiro.", "bibliography_pages": [41, 70], "keywords": ["Cryptococcus", "Cápsulas", "Virulência"], "urls": ["http://objdig.ufrj.br/57/teses/907662.pdf", "http://lattes.cnpq.br/5593991918808836"], "pdf_url": "http://objdig.ufrj.br/57/teses/907662.pdf", "id": "907662", "sentences": ["VI Lista de Abreviaturas ABC – Cassete ligador de ATP (do inglês: ATP binding cassete) AIDS – Síndrome da Imunodeficiência Adquirida – (Do inglês: Acquired Imunnodeficience Sindrome) cAMP – Adenosina monofosfato cíclica (do inglês: cyclic adenosine monophosphate) CD – (Do ingles: Cluster of Diferenciation) CUPS – Compartimento para secreção não convencional de proteínas ( do inglês: compartment for unconventional protein secretion) CWI – Integridade da parede celular (do inglês: cell wall integrity) DMEM – (Do Inglês: Dulbecco's Modified Eagle's Medium) ESCRT – Complexo de seleção endossomal necessário para transporte (do inglês: endosomal sorting complexes required for transport) FasL – Ligante de Fas FGF – Fator de crescimento de fibroblasto (do inglês: fibroblast growth factor) GRASP – Proteína de reestruturação e montagem do Golgi ( do inglês: Golgi reassembly and stacking protein) GTP – Guanosina trifosfato GXM – Glucuronoxilomanana GXMGal - Glucuronoxilomanogalactana HIV – Vírus da Imunodeficiência Humana – (Do Inglês: Human Immunodeficience Virus) Ig – Imunoglobulina ILV – Vesícula intraluminal (do inglês: intralumenal vesicle) INF – Interferon kDa – Kilo Dalton L-DOPA - 3,4-L-diidroxifenilalanina – (Do Inglês: L-3,4- dihydroxyphenylalanine) MHC – Complexo principal de histocompatibilidade (do inglês: major histocompatibility complex) MVB – Corpos multivesiculares – (Do inglês: Multivesicular bodies) NSF – Fator sensível a N-etilmaleimida (do inglês: N-ethylmaleimide sensitive factor) ºC – Graus Célsius PBMC – células mononucleares de sangue periférico – (Do inglês peripheral blood mononuclear cell) PBS – Solução Salina - (Do Inglês: Phosphate Buffered Saline) VII PCR – Reação em Cadeia da Polimerase - (Do Inglês: Polymerase Chain Reaction) pH – Potencial hidrogeniônico PKA – Proteína cinase A (do inglês: protein kinase A) RE – Retículo endoplasmático RNA – Ácido ribonucleico (do inglês: ribonucleic acid) RNAm – RNA mensageiro SNARE – Receptor de NSF solúvel (do inglês: soluble NSF receptor) SNF – Não fermentador de sucrose ( do inglês: sucrose non-fermenting) SRP – Partícula de reconhecimento de sinal ( do inglês: signal recognition particle) TcR – Receptor de célula T (do inglês: T cell receptor) TGF – Fator de transformação do crescimento (em inglês: transforming growth factor) TGN – Rede trans-Golgi (do inglês: trans-Golgi network) TLR – Receptor do tipo Toll - (Do Inglês: Toll Like Receptor) TNF – Fator de Necrose Tumoral - (Do Inglês: Tumor Necrosis Factor) Vps – Proteína de seleção vacuolar (do inglês: Vacuolar protein sorting) WGA – Lectina do Germe de Trigo - (Do Inglês: Wheat Germ Agglutinin) 1 Resumo: O complexo Cryptococcus neoformans é formado pelas espécies C. neoformans e C. gattii, ambos patógenos associados a altos índices de letalidade em humanos. A patogenicidade destes fungos é dependente da produção e secreção de polissacarídeos capsulares, pigmentação e enzimas líticas. O fator de virulência mais importante utilizado por esses microrganismos é a glucuronoxilomanana (GXM), principal polissacarídeo capsular. A GXM é sintetizada no citoplasma e transferida para a superfície celular em vesículas secretoras que possivelmente originam-se de compartimentos endocíticos e apresentam características morfológicas que se assemelham as de exossomos, vesículas extracelulares secretadas por vários eucariotos. A proteína Snf7 é um dos reguladores da formação de exosomos. Sua função está associada ao endereçamento de proteínas transmembranares para a via de formação de corpos multivesiculares (MVBs), necessários para formação e secreção de exossomos. Neste trabalho, foram avaliados o papel de Snf7p na secreção de fatores de virulência no complexo de espécies C. neoformans e os impactos desses efeitos em um modelo de infecção murino. A deleção de SNF7 tanto em C. neoformans quanto em C. gatti, por técnicas de biolística e recombinação homóloga, não provocou alterações marcantes no crescimento dos fungos mutantes a temperaturas de 30 e 37ºC, mas impactou levemente o crescimento dos mesmos em condições de privação de cobre. Snf7p mostrou-se necessária para o crescimento de ambos os fungos estudados em pHs superiores a 7,5. Os mutantes também mostraram acentuada sensibilidade a LiCl2. Através de técnicas de qPCR, observamos que os mutantes snf7∆ apresentaram modulação negativa da expressão do RNAm de RIM101, gene necessário para adaptação a variações no pH e outros fatores físico-químicos. A deleção de SNF7 afetou a capacidade de pigmentação em ambos os mutantes quando cultivados a 30 ou 37ºC na presença de diferentes substratos utilizados pelo fungo para pigmentação. A perturbação da maquinaria de formação de MVBs causou uma redução expressiva na secreção de GXM, conforme quantificado através de ensaios imunoenzimáticos. A secreção defeituosa de GXM observada nos mutantes snf7Δ foi traduzida na formação de cápsulas significativamente reduzidas em ambos os mutantes, conforme observado por técnicas de microscopia de luz e eletrônica de varredura. Os mutantes mostraram-se avirulentos em um modelo intranasal de infecção murina com C. neoformans ou C. gattii, fato provavelmente ligado aos defeitos de secreção de polissacarídeos, formação de cápsula e pigmentação descritos acima. A secreção atenuada de GXM in vivo foi também associada a uma maior susceptibilidade de C. 2 neoformans aos mecanismos de defesa do hospedeiro. Estes resultados demonstram que o gene SNF7 tem papel central na virulência do complexo C. neoformans através da participação em eventos necessários à secreção de polissacarídeos e pigmentação relacionados à sobrevivência do fungo durante a interação com o hospedeiro. Palavras chaves: Cryptococcus, SNF7, secreção não convencional, melanização, glucuronoxilomanana, cápsula, virulência.", "3 Abstract Cryptococcus neoformans complex is formed by two species, C. neoformans and C. gattii, that are pathogens associated with high mortality rates in humans. The pathogenicity of these fungal species is dependent on the production and secretion of capsular polysaccharides, pigmentation, and lytic enzymes. The most important virulence factor used by these microrganisms is glucuronoxilomanan (GXM), the main capsular polysaccharide. GXM is synthesized in the cytoplasm and transferred to the cell surface in secretory vesicles, which possibly originate from endocytic compartments and exhibit morphological characteristics that resemble those of exosomes, extracellular vesicles secreted by various eukaryotes. The Snf7 protein (Snf7p) is a regulator of exosome formation. Its function is associated with addressing transmembrane proteins to the multivesicular bodies (MVBs) formation pathway, which is required for the biogenesis and secretion of exosomes. In this work, we evaluated the role of Snf7p in C. neoformans species complex secretion of virulence factors and its impact in a murine infection model. Deletion of SNF7 in both C. neoformans and C. gattii by biolistic techniques and homologous recombination did not cause marked changes in fungal growth at both 30 and 37ºC, but slightly affected growth under copper deprivation conditions. Snf7p was necessary for fungal growth at pH's greater than 7.5. The mutants also showed increased sensitivity to LiCl2. Through qPCR, we observed that snf7Δ mutants showed downregulation of RIM101 mRNA expression, a gene needed for pH sensing and response to other physicochemical changes. Deletion of SNF7 affected the ability of the mutants to produce pigments when cultured at either 30 or 37°C in the presence of different substrates used by the fungus for pigmentation. Disturbance of the MVB machinery caused a significant reduction in GXM secretion, as determined by enzymatic immunoassays. The defective GXM secretion observed in snf7Δ mutants was translated into a significantly reduced capsule formation in both species, as observed by optical and scanning electron microscopy approaches. The mutants were avirulent in a murine intranasal model of infection with either C. neoformans or C. gattii. These properties are likely linked to the defects in polysaccharides secretion, capsule formation and pigmentation described above. The attenuated secretion of GXM in vivo was also associated with a higher susceptibility of C. neoformans to defense mechanisms of the host. These results demonstrate that SNF7 plays a central role in virulence traits of the C. neoformans species complex through participation in events required for polysaccharide 4 secretion and pigmentation, which are required for fungal survival during interaction with the host. Key words: Cryptococcus, SNF7, unconventional secretion, melanization, glucuronoxylomannan, capsule, virulence.", "5 Introdução: As infecções fúngicas tornaram-se causas importantes de doenças em indivíduos imunocomprometidos ou hospitalizados (NAGGIE & PERFECT, 2009; KRIENGKAUYKIAT et al., 2011; TUREL, 2011; GODBOLE & GANT, 2013; PERFECT, 2014). O grupo de pacientes susceptível a contrair micoses graves inclui indivíduos com síndrome da imunodeficiência humana adquirida (AIDS), pacientes submetidos a terapias imunossupressoras, como é o caso de transplantados ou pacientes tratados com quimioterápicos, e indivíduos submetidos a procedimentos relacionados ao uso de cateteres e próteses intravasculares (PERLROTH et al., 2007; RICHARDSON & LASS-FLORL, 2008; NEOFYTOS et al., 2009; GODBOLE & GANT, 2013; PERFECT, 2014; SEGHIR et al., 2014). A frequência das micoses graves em humanos vem aumentando progressivamente, associada a altas taxas de morbidade e mortalidade (WILSON et al., 2002; PFALLER & DIEKEMA, 2007; 2010; PERFECT, 2014). Diversos fungos são responsáveis por doenças de alta mortalidade, incluindo Candida albicans, Aspergillus fumigatus e Cryptococcus neoformans (PFALLER & DIEKEMA, 2004; PROCOP & ROBERTS, 2004; PFALLER et al., 2006; ZILBERBERG et al., 2008). Tais características estão associadas, em muitos casos, a um diagnóstico deficiente e ao tratamento marcado por efeitos colaterais expressivos (CHAPMAN et al., 2008; WHITE et al., 2009; BASKOVA & BUCHTA, 2012). As similaridades entre as estruturas presentes em células fúngicas e aquelas observadas nas células do hospedeiro humano limitam a quantidade de alvos de ação terapêutica eficiente (CHAPMAN et al., 2008; PASQUALOTTO & DENNING, 2008). Fatores relacionados ao estado imunológico do hospedeiro contribuem diretamente para o desenvolvimento das doenças fúngicas, o que é evidenciado pela clara associação entre imunodeficiência e a ocorrência de micoses sistêmicas (PASQUALOTTO & DENNING, 2008). Por exemplo, espécies do gênero Aspergillus causam dano, preferencialmente, a indivíduos submetidos a transplantes, ao passo que o gênero Cryptococcus tem um maior incidência em pacientes com AIDS (sindrôme da imunodeficiência humana adquirida, em inglês: acquired immunodeficiency syndrome) (NEOFYTOS et al., 2009). No Brasil, dentre os vários patógenos fúngicos de importância clínica, Cryptococcus neoformans destaca-se como o principal causador de micoses letais em pacientes com AIDS 6 (PRADO et al., 2009). Nesses pacientes, espécies pertencentes ao gênero Cryptococcus representam 50,9% das causas de morte por micoses sistêmicas (PRADO et al., 2009). Estatísticas do ano de 2009 mostraram que a ocorrência global de C. neoformans em pacientes portadores do HIV (vírus da imunodeficiência humana, em inglês: human immunodeficiency virus) gira em torno de um milhão de novos casos por ano, dos quais, em média, seiscentos mil resultam em morte em três meses após manifestação inicial dos sintomas (PARK et al., 2009). O gênero Cryptococcus Os membros do gênero Cryptococcus são basidiomicetos que, tradicionalmente, apresentam-se como leveduras haploides, esféricas e circundadas por uma cápsula polissacarídica (MCFADDEN, ZARAGOZA, et al., 2006; LIN, 2009) (Figura 1). São fungos cosmopolitas e saprófitos, que, apesar de colonizarem humanos causando doenças, não necessitam desse hospedeiro para completar seu ciclo de vida (ELLIS & PFEIFFER, 1990).", "7 são também classificadas usualmente através de genotipagem (MEYER & MITCHELL, 1995). De acordo com essa classificação, C. neoformans pode ser classificado nos genótipos VNI, VNII e VNB (sorotipo A), VNIV (sorotipo D) e VNIII (sorotipo AD) (MEYER et al., 2009). Já o C. gattii é subdividido nos genótipos VGI e VGII (sorotipo B), e VGIII e VGIV, (sorotipo C) (MEYER et al., 2009).", "8 AMERICAN SOCIETY FOR MICROBIOLOGY", ", 2011; NEGRONI, 2012)", " Surtos de criptococose por C", " gattii foram reportados no norte dos Estados Unidos e no Canadá (KIDD et al", ", 2004; BYRNES et al", ", 2009)", " O surto que acometeu a ilha de Vancouver atingiu proporções alarmantes, apresentando números mais altos que aqueles observados em regiões endêmicas da criptococose, como a Austrália (KIDD et al", ", 2004; CHAYAKULKEEREE & PERFECT, 2006)", " Acredita-se que esse fenômeno esteja relacionado a eventos de recombinação genética, envolvendo cepas da região amazônica e resultando em cepas ambientais hipervirulentas (KIDD et al", ", 2004; HAGEN et al", ", 2013)", " A infecção por estes fungos se dá através da inalação de basidiósporos ou leveduras dessecadas presentes em ambientes contaminados (LIN & HEITMAN, 2006; LIN, 2009)", " Uma vez inalados, os fungos atingem o espaço alveoar para então colonizarem a mucosa do pulmão (Figura 3)", " Em pacientes imunocompetentes, a replicação do fungo é normalmente contida pelo sistema imunológico", " De fato, estima-se que grande parte da população mundial apresente anticorpos contra proteínas do Cryptococcus sem apresentar histórico clínico de doença (CHEN et al", ", 1999)", " O fungo pode permanecer no hospedeiro em estado de latência, até que o hospedeiro eventualmente passe a um estado de imunocomprometimento, resultando em doença (HEITMAN & AMERICAN SOCIETY FOR MICROBIOLOGY", ", 2011) Em indivíduos imunocomprometidos, o fungo dissemina-se pela corrente sanguínea até atingir o sistema nervoso central, causando um quadro de meningoencefalite com inflamação no espaço subaracnóideo e no parênquima cerebral (STEENBERGEN & CASADEVALL, 2003) (Figura 3)", " A meningite criptocócica é a principal causa de mortes associadas a infecções do sistema nervoso central (PARK et al", ", 2009)", " 9 predadores", " Além disso, a levedura interage com outros microrganismos", " Em humanos, a infecção pulmonar começa pela inalação de esporos, que pode evoluir para uma meningite de alta mortalidade", " (Adaptado de LIN & HEITMAN, 2006)", " Para gerar dano aos diversos tecidos infectados, C", " neoformans e C", " gattii produzem um vasto arsenal de fatores de virulência, incluindo a produção de polissacarídeos capsulares, pigmentos, lipídeos e hidrolases (PERFECT & CASADEVALL, 2002)", " Fatores de Virulência Fatores de virulência representam mecanismos utilizados pelo patógeno para causar dano ao hospedeiro", " Por conceito, a inativação de genes relacionados à produção desses fatores acarreta em atenuação na capacidade do patógeno de causar danos no hospedeiro animal (revisto por FALKOW, 1988; 2004)", " É esperado que a complementação ou restauração exógena desses genes ou seus produtos restaure as características de virulência do patógeno (STEENBERGEN & CASADEVALL, 2003)", " C", " neoformans e C", " gattii produzem diversos fatores de virulência que garantem sua capacidade de se estabelecer, sobreviver e causar dano ao organismo hospedeiro", " Os principais mecanismos de virulência em Cryptococcus são sua capacidade de crescer a 37ºC, a produção de cápsula polissacarídica, a síntese de melanina e a produção de enzimas hidrolíticas secretadas ou associadas às células (COX et al", ", 2000; STEENBERGEN & CASADEVALL, 2003)", " Cada uma dessas características contribui de uma determinada maneira para o ciclo patogênico do fungo", " Por exemplo, a capacidade de se replicar a 37ºC, relacionada à colonização de mamíferos, encontra-se sob um sofisticado controle genético, demonstrado inicialmente por Kwon-Chung e Rhodes (1986)", " A partir desse estudo, vários genes foram identificados como envolvidos no processo de sobrevivência a 37ºC, como CNA1 (calcineurina A), COX1 (subunidade 1 da citocromo oxidase) e AOX1 (oxidase alternativa) (ODOM et al", ", 1997; AKHTER et al", ", 2003; TOFFALETTI et al", ", 2003)", " Além do crescimento a 37ºC, outro fator relevante para a virulência de C", " neoformans e C", " gattii é a síntese do pigmento melanina, característica presente em vários outros fungos patogênicos, conforme revisto por outros (JACOBSON, 2000; EISENMAN & CASADEVALL, 2012)", " A síntese de melanina é efetuada através da atividade da enzima lacase, responsável pela produção da melanina a partir de compostos fenólicos como L-DOPA, dopamina, norepinefrina e epinefrina (WILLIAMSON, 1997)", " Esse pigmento tem alta carga negativa e está envolvido com vários eventos relacionados à virulência, como 10 manutenção da integridade da parede celular, proteção do microrganismo contra fagocitose mediada por anticorpos e neutralização de agentes antioxidantes (WILLIAMSON, 1997; LIU et al", ", 1999; NOSANCHUK, RUDOLPH, et al", ", 1999; NOSANCHUK, VALADON, et al", ", 1999; STEENBERGEN & CASADEVALL, 2003)", " As hidrolases extracelulares são essenciais para a patogênese de C", " neoformans e C", " gattii (COX et al", ", 2001)", " A fosfolipase B hidrolisa ligações do tipo éster presentes em fosfolipídeos, removendo suas cadeias de ácidos graxos (COX et al", ", 2001)", " Essa atividade possibilita ao fungo destruir membranas ricas em fosfolipídeos nos tecidos do hospedeiro (LATOUCHE et al", ", 2003) e clivar o principal surfactante dos tecidos pulmonares (dipalmitoil fosfatidilcolina), facilitando assim a disseminação do patógeno pelo organismo (STEENBERGEN & CASADEVALL, 2003; DJORDJEVIC, 2010)", " Essa enzima encontra-se sob a regulação de um único gene (PLB1) em C", " neoformans, que está presente em isolados clínicos (GHANNOUM, 2000; SANCHEZ et al", ", 2008)", " A deleção desse gene acarreta em diminuição da virulência em C", " neoformans (COX et al", ", 2001)", " Outra hidrolase extracelular relacionada à patogenicidade em Cryptococcus é a urease, cuja atividade consiste na converção de ureia em amônia e carbamato e consequente aumento de pH (COX et al", ", 2000)", " A atividade de urease está presente em isolados clínicos de C", " neoformans (COX et al", ", 2000; LIAW et al", ", 2010) e mutações em genes relacionados à sua produção geraram diminuição da patogenicidade (COX et al", ", 2000), caracterizando a produção de urease como um fator de virulência (COX et al", ", 2000)", " Recentemente, Shi e colaboradores demonstraram que a urease tem um papel relevante na transmigração do C", " neoformans para o cérebro de camundongos (SHI et al", ", 2010)", " Aparentemente esse efeito da urease está relacionado com o número de sítios de transmigração do fungo ao longo dos capilares sanguíneos em direção ao cérebro, bem como a danos causados pelo fungo nas paredes desses vasos (OLSZEWSKI et al", ", 2004; SHI et al", ", 2010)", " O fator de virulência mais importante e melhor definido das espécies C", " neoformans e C", " gattii é a capacidade de produzir polissacarídeos capsulares", " A produção de cápsula parece ser desfavorecida no ambiente e, por outro lado, estimulada por diversas condições disponíveis durante o processo infeccioso, como variações de pH, altos níveis de CO2 e privação de metais (GRANGER et al", ", 1985; VARTIVARIAN et al", ", 1989; DOERING, 2000; D'SOUZA & HEITMAN, 2001; PERFECT & CASADEVALL, 2002; JANBON, 2004; KLUTTS et al", ", 2006; RODRIGUES et al", ", 2009; ZARAGOZA et al", ", 2009b)", " Essas condições exigem intenso rearranjo das vias metabólicas do C", " neoformans, necessárias para suprir as demanda energética envolvida nesses processos (O'MEARA & ALSPAUGH, 2012)", " 11 Tal característica, além de relevante sob o ponto de vista médico, torna Cryptococcus um modelo biológico singular", " O gênero Cryptococcus compreende os únicos patógenos eucarióticos encapsulados, característica comum a um grande número de patógenos procarióticos", " Além de ancorados à superfície celular, os polissacarídeos celulares são secretados para o ambiente externo, onde modulam a resposta imune do hospedeiro em favor da infecção (DOERING, 2000; JANBON, 2004)", " Foram descritas na literatura diferenças funcionais e estruturais entre os polissacarídeos que compõem a cápsula e os secretados (FRASES et al", ", 2008)", " Mutantes acapsulares são avirulentos (PERFECT & CASADEVALL, 2002) e, nesse sentido, vários estudos nos últimos anos visaram demonstrar o potencial terapêutico e vacinal dos polissacarídeos capsulares de Cryptococcus (CASADEVALL & PIROFSKI, 2005a; CASADEVALL & PIROFSKI, 2005b; c)", " A cápsula produzida por C", " neoformans e C", " gattii é altamente hidratada, apresentando um conteúdo de água que pode atingir até 99% de seu peso total", " Os dois polissacarídeos principais que compõem a cápsula destes fungos são a glucuronoxilomanana (GXM) e glucuronoxilomanogalactana (GXMGal)", " A GXMGal compõe 5-8% do total de polissacarídeos capsulares que, junto com uma pequena fração de manoproteínas, formam a parte minoritária da cápsula (VARTIVARIAN et al", ", 1989)", " Outros componentes, como proteínas de choque térmico (SILVEIRA et al", ", 2013), lipídeos (RHOME et al", ", 2011), glucanas (CORDERO et al", ", 2011) e oligômeros de quitina (RODRIGUES, ALVAREZ, et al", ", 2008) foram recentemente identificados como parte dessa estrutura", " O principal polissacarídeo capsular nos fungos do gênero Cryptococcus é a GXM (DOERING, 2000; JANBON, 2004)", " A GXM compõe aproximadamente 90% da massa capsular (MCFADDEN, DE JESUS, et al", ", 2006; MAXSON et al", ", 2007)", " O polissacarídeo apresenta diferenças estruturais entre os sorotipos de Cryptococcus (Figura 4)", " 12 Figura 4: Principais padrões estruturais dos componentes da GXM nos diversos sorotipos de Cryptococcus", " Adaptado de (ZARAGOZA et al", ", 2009a)", " A literatura indica que o tamanho capsular está diretamente ligado ao comprimento individual das fibras de GXM", " Frases e colaboradores propuseram que as fibras de GXM com dimensões elevadas determinam o comprimento total da cápsula, servindo de molde para a associação de moléculas de GXM de dimensões menores (FRASES et al", ", 2009) através de interações mediadas por cátions divalentes (NIMRICHTER et al", ", 2007)", " Isso ocorreria especialmente na região da cápsula mais próxima à parede celular que, por esse motivo, teria uma densidade maior em relação às porções mais distais", " A GXM é constitutivamente secretada para o meio extracelular (BLOOMFIELD et al", ", 1963; ADAMS, 2004; KUMAR et al", ", 2011)", " Em modelos de interação com células hospedeiras, a GXM tem a capacidade de interagir com diversos receptores, incluindo CD18 (DONG & MURPHY, 1997), CD14 (YAUCH et al", ", 2004; BARBOSA et al", ", 2007), e receptores do tipo Toll (TLR), incluindo TLR-2 e TLR-4 (YAUCH et al", ", 2004) e também heterodímeros TLR1/6 e TLR2/6 (FONSECA et al", ", 2010)", " Dentre as propriedades desse polissacarídeo estão várias atividades imunomodulatórias, como a inibição da liberação de citocinas pró-inflamatórias (VECCHIARELLI et al", ", 1995; LENDVAI et al", ", 2000), a supressão da proliferação de células T (RETINI et al", ", 1998; SYME et al", ", 1999) e a inibição 13 da ativação e maturação de células dendríticas (VECCHIARELLI et al", ", 2003)", " Além disso, a GXM é eficiente em modular negativamente a enzima fosfofrutoquinase 1 (PFK-1) de macrófagos murinos (GRECHI et al", ", 2011) e de induzir a apoptose mediada por caspase em macrófagos e células T através do acúmulo de Fas e FasL nessas células (MONARI et al", ", 2008; VILLENA et al", ", 2008)", " A biossíntese e a exportação de GXM são considerados os eventos celulares mais importantes para a patogênese no gênero Cryptococcus (MCCLELLAND et al", ", 2005)", " A GXM é formada por um esqueleto linear de unidades de manose unidas por ligações \u00011,3 com substituições diversas", " As unidades de manose podem estar ligadas a ácido glucurônico (nas posições \u00021,2) ou xilose (nas posições \u00021,2 ou \u00021,4), além de serem O-acetiladas no carbono 6 (ZARAGOZA et al", ", 2009a)", " O polissacarídeo, que tem massa molecular na faixa entre 1 e 7 milhões de Daltons (MCFADDEN, DE JESUS, et al", ", 2006; FRASES et al", ", 2008), é sintetizado no aparato de Golgi (FELDMESSER et al", ", 2001; GARCIA-RIVERA et al", ", 2004; YONEDA & DOERING, 2006; OLIVEIRA et al", ", 2009)", " Essa observação contrasta com a maioria absoluta dos polissacarídeos microbianos de superfície ou secretados, cuja síntese e arquitetura final são realizadas na membrana plasmática ou em faces externas da parede celular (RAETZ & WHITFIELD, 2002; WHITFIELD et al", ", 2003; WHITFIELD, 2006)", " O fato de que as células fúngicas apresentam parede celular associado a comprovação de que a GXM é sintetizada no ambiente intracelular para depois ser secretada (MCFADDEN, ZARAGOZA, et al", ", 2006; MCFADDEN, DE JESUS, et al", ", 2006; YONEDA & DOERING, 2006) apontam para uma das questões centrais desse trabalho: é ainda preliminar o conhecimento de mecanismos pelos quais esse polissacarídeo alcança o meio extracelular em Cryptococcus", " Diferentes estudos sugeriram que a GXM intracelular é transferida para a superfície celular em vesículas secretórias (FELDMESSER et al", ", 2001; GARCIA-RIVERA et al", ", 2004; YONEDA & DOERING, 2006; RODRIGUES et al", ", 2007; RODRIGUES, NAKAYASU, et al", ", 2008)", " Recentemente, estudos independentes mostraram que células de C", " neoformans mutadas em genes reguladores de etapas da secreção dependentes das funções do aparato de Golgi afetam o transporte vesicular de GXM (YONEDA & DOERING, 2006; HU et al", ", 2007; PANEPINTO et al", ", 2009)", " Entretanto, vesículas derivadas do Golgi, pelas vias convencionais de secreção, fundem-se com a membrana plasmática (MALLABIABARRENA & MALHOTRA, 1995)", " Tal fato explicaria como a GXM atinge o 14 espaço periplasmático, mas não como o polissacarídeo atinge o ambiente extracelular", " Essa hipóstese está de acordo com a observação de que os mutantes deficientes na expressão de reguladores da secreção pós-Golgi apresentam fenótipos capsulares normais (YONEDA & DOERING, 2006; PANEPINTO et al", ", 2009)", " Sendo assim, mecanismos alternativos de secreção vesicular de GXM devem ocorrer no gênero Cryptococcus", " Liberação de vesículas extracelulares por fungos Acredita-se que todos os seres vivos produzem vesículas extracelulares (KIM et al", ", 2014)", " Nos últimos 15 anos, as publicações nessa área aumentaram consideravelmente (KIM et al", ", 2014), demonstrando a importância do entendimento tanto da função quanto dos mecanismos de formação dessas estruturas", " Células fúngicas produzem vesículas extracelulares, conforme revisto por vários autores (NOSANCHUK et al", ", 2008; OLIVEIRA et al", ", 2013; RODRIGUES et al", ", 2013)", " Até o momento, nove diferentes espécies foram implicadas na secreção dessas vesículas incluindo C", " neoformans, Alternaria infectoria, Candida albicans, Candida parapsilosis, Histoplasma capsulatum, Malassezia sympodialis, Paracoccidioides brasiliensis, Saccharomyces cerevisiae e Sporothrix schenckii (ALBUQUERQUE et al", ", 2008; GEHRMANN et al", ", 2011; VALLEJO et al", ", 2011; SILVA et al", ", 2014)", " A importância da produção de vesículas por fungos patogênicos é evidente", " Componentes dessas vesículas são reconhecidos por anticorpos do soro de indivíduos infectados com H", " capsulatum, P", " brasiliensis, C", " albicans ou C", " neoformans (PITARCH et al", ", 2001; ALBUQUERQUE et al", ", 2008; RODRIGUES, NAKAYASU, et al", ", 2008; VALLEJO et al", ", 2011; VARGAS et al", ", 2014)", " Além disso, essas vesículas foram associadas com a indução da produção de diversas citocinas através do contato com células do hospedeiro", " Foi observado que a interação com vesículas extracelulares de Malassezia sympodialis induziu a secreção de TNF\u0001 em células mononucleares de sangue periférico (PBMC) (GEHRMANN et al", ", 2011)", " Em macrófagos estimulados com vesículas secretadas por C", " neoformans observou-se a secreção de TNFα, TGFβ e IL-10 (OLIVEIRA, FREIRE-DE-LIMA, et al", ", 2010)", " Semelhante modulação foi observada em C", " albicans, no qual Vargas e colaboradores (VARGAS et al", ", 2014) observaram a indução de IL-12, TGFβ e IL-10 mediante a internalização das vesículas extracelulares por macrófagos", " No mesmo trabalho, os autores observaram que a interação dessas vesículas com células dendríticas induziu, além das citocinas descritas em macrófagos, a secreção de TNFα e a regulação 15 positiva de moléculas coestimulatórias como CD86 e MHC-II", " Além disso, o tratamento prévio de larvas de Galleria mellonella com vesículas purificadas de C", " albicans seguido de desafio com esse fungo induziu uma grande redução na sobrevivência fúngica dentro deste hospedeiro", " Resultado semelhante foi observado com vesículas extracelulares de C", " neoformans, que aumentaram o potencial fungicida de macrófagos (OLIVEIRA, FREIRE-DE-LIMA, et al", ", 2010)", " Em C", " neoformans, vesículas extracelulares foram implicadas na secreção de muitos componentes relacionados à virulência, como GXM, GXMGal, urease, lacase, fosfatase ácida, proteínas de choque térmico e várias proteínas antioxidantes (RODRIGUES et al", ", 2007; RODRIGUES, NAKAYASU, et al", ", 2008; DE JESUS et al", ", 2009)", " A capacidade para secretar vesículas contendo polissacarídeos não parece estar restrita ao gênero Cryptococcus", " Foi demonstrado que P", " brasiliensis é capaz de secretar, no interior de vesículas, polissacarídeos que apresentam propriedades sorológicas e funcionais semelhantes as da GXM de C", " neoformans (ALBUQUERQUE et al", ", 2012)", " Evidências apontam para a existência de mais de um mecanismo de formação de vesículas extracelulares em fungos, dadas às diferenças morfológicas observadas nestes compartimentos através técnicas de microscopia eletrônica (WOLF et al", ", 2014)", " Além disso, mutações em genes necessários para o transporte de vesículas pós-Golgi ou para a formação de MVBs no modelo de S", " cerevisiae afetaram composição e quantidade de vesículas extracelulares, mas não interromperem sua biogênese (OLIVEIRA, NAKAYASU, et al", ", 2010)", " Embora a origem exata das vesículas extracelulares de fungos ainda não tenha sido determinada (OLIVEIRA et al", ", 2013), é fato que essas estruturas se assemelham a exossomos de mamíferos em aspectos morfológicos e composicionais (TAKEO et al", ", 1973; RODRIGUES, NAKAYASU, et al", ", 2008; WOLF et al", ", 2014)", " A primeira sugestão da ocorrência de vesículas direcionadas ao espaço extraceular em células de C", " neoformans foi apontada por Takeo e colaboradores há mais de 40 anos, através de microscopia eletrônica de transmissão em criopreparações (Figura 5 E) (TAKEO et al", ", 1973)", " A observação de vesículas potencialmente liberadas no espaço periplasmático desse fungo levantou questões sobre a possibilidade de que essas estruturas sejam capazes de atravessar a parede celular", " Nosso grupo e outros mostraram a existência de estruturas vesiculares em estreita associação com a parede celular de fungos (Figura 5 A-D) (RODRIGUES et al", ", 2007; VALLEJO et al", ", 2011; GIL-BONA et al", ", 2014; VARGAS et al", ", 2014; WOLF et al", ", 2014)", " Em várias espécies, vesículas em aparente rota de saída da célula foram observadas em 16 diferentes camadas da parede celular, incluindo camadas mais próximas à membrana plasmática e em direto contato com o meio extracelular (Figura 5)", " Até o momento, estruturas semelhantes a poros ou canais potencialmente necessários para a passagem de vesículas através da parede celular em C", " neoformans são desconhecidas (WOLF et al", ", 2014)", " Sugere-se, portanto, que enzimas capazes de degradar a parede celular estejam associadas à membrana vesicular ou sejam secretadas em conjunto com as vesículas extracelulares para promover passagem pela parede celular (WOLF et al", ", 2014)", " De fato, análises composicionais por proteoma de vesículas extracelulares de fungos revelaram a presença de hidrolases capazes de degradar polissacarídeos de parede (OLIVEIRA, NAKAYASU, et al", ", 2010; VALLEJO et al", ", 2011)", " Essas observações sugerem que, apesar de ainda pouco compreendidos, os mecanismos de passagem de vesículas através da parede celular de fungos são plenamente funcionais e necessitam ser compreendidos em maior profundidade", " 17 Secreção em Eucariotos Secreção convencional: a exportação pós-Golgi de proteínas A via secretória convencional em células eucarióticas compreende uma série de organelas pelas quais proteínas são transferidas do ambiente citoplasmático para a superfície celular (MALLABIABARRENA & MALHOTRA, 1995)", " Há cerca de 40 anos, estudos pioneiros de Palade (1975) demonstraram o transporte de vesículas através dos diversos compartimentos celulares", " Esses estudos foram a base para a criação dos modelos de transporte vesicular de proteínas em S", " cerevisiae usando mutantes termo-sensíveis, gerados por Schekman e colaboradores (NOVICK et al", ", 1980)", " A base de estudos acima mencionada permitiu o estabelecimento de vários conceitos seminais sobre o tráfego celular de proteínas, que serão abordados em detalhes a seguir", " A entrada de proteínas no RE é a etapa inicial da secreção proteica convencional (BONIFACINO & LIPPINCOTT-SCHWARTZ, 2003; CROSS et al", ", 2009)", " Esse evento requer nessas proteínas uma sequência sinal específica composta por resíduos de aminoácidos hidrofóbicos que se ligam a proteínas de citoplasma, como por exemplo as moléculas SRP (do inglês signal recognition particle) (LEE & BERNSTEIN, 2001; POOL, 2005)", " Nas proteínas secretórias essa sequencia sinal normalmente se encontra na porção N-terminal, sendo clivada na passagem pela membrana do RE", " Proteínas transmembranares podem possuir um domínio N-terminal removível ou serem direcionadas para a membrana por sua região transmembrana hidrofobica (CROSS et al", ", 2009)", " O papel dessas sequências hidrofóbicas no direcionamento de proteínas para a exportação é um fator altamente conservado entre eucariotos e procariotos (EMANUELSSON & VON HEIJNE, 2001; BENDTSEN et al", ", 2004)", " O sistema de tráfego intracelular convencional de proteínas inclui etapas nas quais as proteínas necessitam ser transportadas em vesículas intracelulares", " Proteínas direcionadas para a membrana plasmática ou ao ambiente extracelular são encaminhadas para o aparato de Golgi, onde recebem diversas modificações pós-transcricionais para posterior endereçamento para a superfície celular (BONIFACINO & LIPPINCOTT-SCHWARTZ, 2003)", " Na passagem do RE para a rede cis-Golgi é caracterizado o movimento denominado anterógrado", " Nessa etapa, nos sítios de saída do RE, vesículas são formadas pela agregação ordenada de um complexo proteico de revestimento conhecido como COPII (BARLOWE et al", ", 1994; 18 KIRCHHAUSEN, 2000)", " COPII é recrutado para o sítio de montagem de vesículas pela proteína Sar1p ativada, que interage com diversos produtos de genes SEC, como é o caso do complexo formado por Sec24p/Sec23p, que recruta proteínas transmembranares receptoras de cargo importantes na seleção do conteúdo dessas vesículas, além de interagir com Sec13p e Sec31p, que atuam no processo de cisão dessas vesículas", " Os complexos proteicos de COPII se dissociam da vesícula formada num processo dependente da atividade GTPase da molécula de Sar1p (BARLOWE et al", ", 1994)", " As proteínas que chegam na face cis do Golgi em vesículas de COPII sofrem diversas alterações específicas em cada cisterna dessa organela (LOSEV et al", ", 2006; MALHOTRA & MAYOR, 2006)", " As proteínas residentes do RE, que momentaneamente trafegam pelo Golgi, necessitam ser transportadas de volta em um sistema de transporte chamado retrógrado, que ocorre no lúmen de vesículas formadas pela associação de proteínas do complexo COPI às membranas do Golgi (ORCI et al", ", 1997; KIRCHHAUSEN, 2000)", " A montagem desse complexo inicia-se pela ativação da proteína Arf1p que, associada à GTP, expõe uma cauda miristoilada que se insere na membrana do Golgi, recrutando os demais componentes de revestimento de COPI", " Acredita-se que a seleção de receptores de cargo bem como a seleção de proteínas cargo transmembrana se dá pela associação dessas moléculas com a subunidade γ do revestimento de COPI (HARTER et al", ", 1996)", " De maneira semelhante às vesículas de COPII, acredita-se que a atividade GTPase da molécula Arf1p seja responsável pelo desnudamento dessas vesículas (GOLDBERG, 1999)", " As proteínas que atravessam o Golgi são endereçadas para as vias de secreção no interior de vesículas originadas na TGN (rede trans-Golgi, do inglês: trans-Golgi network)", " Ao contrário das vesículas de COPI e II, essa etapa de secreção não tem uma maquinaria de formação de vesículas conhecida (IKONEN et al", ", 1996; MARSH & HOWELL, 2002; PAPANIKOU & GLICK, 2014), embora algumas proteínas presentes na TGN tenham sido descritas como fazendo parte dessas estruturas vesiculares (GLEESON et al", ", 1996; IKONEN et al", ", 1996)", " Mecanismos específicos de reconhecimento atuam para garantir a fusão correta das membranas das vesículas secretoras com seus compartimentos aceptores", " Dentre as moléculas necessárias para esses eventos, destacam-se proteínas Rab-GTPases", " Essas proteínas possuem a capacidade de associar-se a membranas através de um grupamento geranilgeranil exposto quando as enzimas estão ligadas a moléculas de GTP", " Uma vez associadas a membranas, as Rab-GTPases podem recrutar diferentes proteínas efetoras que desempenham funções relacionadas a eventos de secreção como, por exemplo, proteínas motoras (miosina) nos 19 melanossomos (HUME & SEABRA, 2011)", " Dentre os efetores associados a Rab-GTPases, destacam-se proteínas quinase e fosfatase, que geram alterações na composição lipídica das membranas nos diferentes compartimentos intracelulares", " Essa diversidade lipídica atua como um mecanismo de diferenciação de compartimentos intracelulares, contribuindo para o endereçamento de vesículas (SONNICHSEN et al", ", 2000)", " Além disso, as Rabs atuam em outros estágios da secreção, recrutando proteínas efetoras de ligação a distância que medeiam a ligação entre as membranas vesiculares e aceptoras", " Um exemplo dessa função é a associação entre a Rab Sec4p (presente em vesículas secretoras) e Sec15p, parte de um complexo octamérico conhecido como exocisto (LIU & GUO, 2012)", " As Rabs podem interagir com uma outra classe de proteínas fundamentais no processo de reconhecimento de membranas intracelulares, as SNAREs (do inglês soluble NSF receptor) (SEGEV, 2001; JAHN et al", ", 2003; OHYA et al", ", 2009)", " Caracterizadas por uma estrutura de superhélice voltada para o citosol por sua porção N-terminal, essas moléculas são divididas em dois grandes grupos denominados R-SNAREs (SNAREs contendo arginina) e Q-SNAREs (SNAREs contendo glutamina)", " Essa classificação é baseada na composição de resíduos altamente conservados presentes em seus domínios estruturais (FASSHAUER et al", ", 1998)", " As SNAREs são capazes de formar um complexo que favorece a fusão das vesículas com suas membranas aceptoras, uma vez que auxiliam na remoção de moléculas de água entre as superfícies hidrofílicas e na superação de forças de repulsão iônicas existentes (SUTTON et al", ", 1998; BOCK et al", ", 2001)", " Posteriormente, essas moléculas são liberadas com a ajuda das proteínas NSF (Sec18p) e α-SNAP (Sec17p) que, mediante consumo de energia, promovem a dissociação dos pares complementares de SNAREs no sítio de fusão (MAYER et al", ", 1996)", " Dessa forma, as proteínas SNARE são liberadas para serem recicladas para o compartimento doador do qual as vesículas se originaram (RICE & BRUNGER, 1999; BONIFACINO & GLICK, 2004; HASAN et al", ", 2010)", " Foi proposto que a interação entre SNAREs vesículares e das membranas aceptoras teria um papel relevante na fusão, mas não no processo de endereçamento das vesículas (CHEN & SCHELLER, 2001)", " No entanto, estudos demonstrando a afinidade seletiva entre diferentes pares de SNAREs associados a uma distribuição heterogênea das mesmas entre os compartimentos celulares, levam a crer que haja um mecanismo de endereçamento no qual essas moléculas participariam (MCNEW et al", ", 2000; SCALES et al", ", 2000; HASAN et al", ", 2010)", " Estruturas vesiculares também medeiam intenso influxo de moléculas extracelulares através de mecanismos de endocitose", " Vesículas originadas de invaginações da membrana plasmática revestidas por clatrina brotam para o interior da célula e podem seguir dois 20 caminhos distintos: reciclagem e redirecionamento para a superfície celular ou fusão com o endossomo primário, que é acidificado através da atividade de hidrolases e H+-ATPases para transformar-se em endossomo tardio", " Essa organela posteriormente funde-se aos lisossomos", " Nesse caso, as moléculas no lúmen dos endossomos serão degradadas (KORNFELD & MELLMAN, 1989)", " O mapeamento das vias de formação de vesículas intracelulares foi o ponto de partida para a identificação de diversos genes com produtos relacionados às vias secretórias", " Schekman e colaboradores (revisto por SCHEKMAN & NOVICK, 2004) identificaram uma família de genes em S", " cerevisiae envolvida em processos secretórios, os chamados genes SEC", " Diversas células mutadas nos diferentes genes SEC foram geradas (revisto por SCHEKMAN & NOVICK, 2004) e a caracterização dos mutantes revelou a existência de fenótipos com acúmulo de membranas, resultando em bloqueio do tráfego de vesículas a partir do RE ou do aparato de Golgi para a superfície celular", " Essas descobertas renderam a Randy Schekman o Prêmio Nobel de Medicina e Fisiologia em 2013, compartilhado com James Rothman e Thomas Südhof (http://www", "nobelprize", "org/nobel_prizes/medicine/laureates/2013/press", "html)", " O primeiro gene SEC caracterizado foi o SEC1, que codifica uma proteína reguladora de fusão de membranas (NOVICK et al", ", 1980)", " A mutação sec1Δ age, portanto, no último evento da via secretória, bloqueando a fusão de vesículas secretórias com a membrana plasmática (NOVICK & SCHEKMAN, 1979)", " Mutantes deficientes em etapas anteriores ao processo de fusão de membrana foram também caracterizados", " Mutantes sec32", "1Δ, por exemplo, são deficientes na capacidade de regular a fidelidade de endereçamento de vesículas derivadas do RE para o Golgi (WUESTEHUBE et al", ", 1996)", " Mutantes sec4Δ, com expressão deficiente de uma Rab-GTPase (Rab8p) altamente conservada e essencial para processos exocíticos (LYMAN & SCHEKMAN, 1996; SPANG & SCHEKMAN, 1998), acumulam vesículas pós-Golgi de aproximadamente 100 nm de diâmetro em temperaturas restritivas (NOVICK et al", ", 1992)", " É sabido que os genes SEC apresentam homólogos em vários outros eucariotos, incluindo C", " neoformans", " Uma das GTPases regulando a exocitose em S", " cerevisiae, a Sec4p, é um membro altamente conservado da subfamília Sec4/Rab8 das Rab GTPases (SCHEKMAN & NOVICK, 2004)", " Um homólogo da Sec4p, Sav1p, foi descrito em C", " neoformans (YONEDA & DOERING, 2006)", " Mutações no gene SAV1 geraram o acúmulo de vesículas pós-Golgi contendo GXM (YONEDA & DOERING, 2006)", " Além disso, mutantes de C", " neoformans com expressão defectiva do gene SEC6 demonstraram capacidade reduzida 21 de secretar GXM e falhas na produção de vesículas extracelulares (PANEPINTO et al", ", 2009)", " Esses estudos reforçam observações prévias que sugeriam que o polissacarídeo é sintetizado no Golgi e transferido para a superfície celular em vesículas (FELDMESSER et al", ", 2001; GARCIA-RIVERA et al", ", 2004)", " Esses dados demonstram que as vias secretórias de S", " cerevisiae e C", " neoformans compartilham elementos comuns", " Estudos recentes em de S", " cerevisiae permitiram a identificação por proteoma de uma série de proteínas extracelulares produzidas nesse fungo", " Essas moléculas estão primariamente envolvidas em funções celulares como metabolismo de carboidratos, aminoácidos e nucleotídeos (COURTNEY et al", ", 2014)", " Das proteínas identificadas, 95% não possuíam o sinal de translocação para o RE e, por consequência, eram secretadas pela via de secreção não convencional", " Esses resultados levam a conclusão de que a secreção não convencional é a via mais importante de exportação de proteínas nesse modelo (COURTNEY et al", ", 2014)", " Muitas das proteínas secretadas de forma não convencional nos modelos fúngicos foram identificadas em outros organismos, incluindo bactérias e humanos", " Essa observação sugere que a secreção não convencional é um fenômeno importante e conservado entre espécies (revisto por STEIN & CHIANG, 2014) ", " Mecanismos não convencionais de secreção Embora grande parte das proteínas produzidas destinadas ao espaço extracelular sejam sintetizadas via RE/Golgi, existem proteínas encontradas no ambiente extracelular que, por não possuírem o peptídeo sinal direcionador para o lúmen do RE, são secretadas por vias alternativas chamadas de secreção não convencional (NICKEL & RABOUILLE, 2009)", " O primeiro relato de uma proteína extracelular que não continha o sinal de translocação para o lúmen do RE data de 1984, quando Auron e colaboradores estudaram a distribuição extracelular da interleucina (IL)-1(AURON et al", ", 1984)", " O estabelecimento da existência de uma via de secreção paralela à convencional se caracterizou seis anos mais tarde, quando Rubartelli e colaboradores determinaram que a inibição das vias convencionais de secreção por agentes químicos (como brefeldina e monensina) não causava nenhum efeito sobre a secreção de IL-1ß (RUBARTELLI et al", ", 1990)", " Hoje é clara a percepção de que uma série de proteínas que não possuem sequência sinal para secreção pela via clássica atinge o meio extracelular (revisto por MALHOTRA, 2013) ", " Até o momento, alguns mecanismos de secreção não convencional foram descritos, com classificação em dois grandes grupos: independentes ou dependentes de vesículas, conforme revisto por Nickel (2005)", " 22 Proteínas que não contém peptídeo sinal podem atingir o espaço extracelular através de transporte mediado por proteínas residentes na membrana plasmática", " Um exemplo deste transporte é a secreção de moléculas de FGF-2 (do inglês fibroblast growth fator), uma importante proteína de efeito pró-angiogênico que não possui a sequência sinal de secreção convencional, porém é secretada por células normais e neoplásicas (revisto por MIGNATTI & RIFIKIN, 1991; NICKEL, 2005)", " Schäfer e colegas (SCHAFER et al", ", 2004) usando um elegante sistema de vesículas formadas com fragmentos purificados de membrana plasmática com topologia invertida inside-out demonstraram que essas proteínas eram translocadas para o interior dessas vesículas artificiais, além disso, a remoção de proteínas associadas a membrana impede que esse fenômeno aconteça sugerindo fortemente que proteínas residentes de membrana, ainda sem identificação precisa, são responsáveis pela secreção de FGF-2 (SCHAFER et al", ", 2004)", " Mecanismos similares podem ser fundamentais para tratamento de infecções fúngicas, conforme exemplificado através do estudo do transportador AFR1 de C", " neoformans (SANGUINETTI et al", ", 2006)", " Foi descrito que essa proteína, que faz parte da família dos transportadores ABC (do inglês ATP binding cassette), é capaz de realizar o efluxo de fluconazol através da membrana plasmática de C", " neoformans, aumentando sua resistência ao tratamento", " Mutantes afr1Δ foram mais susceptíveis ao fluconazol in vivo (SANGUINETTI et al", ", 2006)", " Além disso, o produto desse gene é capaz de modular a resposta de células fagocíticas ao C", " neoformans diminuindo a acidificação do vacúolo fagocítico e favorecendo as células fúngicas (ORSI et al", ", 2009)", " Os lisossomos secretórios são um exemplo de mecanismo de secreção não convencional independente de vesículas intracelulares (BLOTT & GRIFFITHS, 2002)", " Presentes em células especializadas do sistema imune, como as células T e as células NK", " Nas primeiras, quando o receptor da célula T (TcR) é ativado essas estruturas fundem-se a membrana plasmática da célula de maneira dependente de cálcio (BOSSI & GRIFFITHS, 1999), externalizando importantes moléculas da resposta imune, uma delas, o ligante de Fas (FasL) (BOSSI & GRIFFITHS, 1999)", " Essa proteína de 40 kDa da família dos fatores de necrose tumorais (TNF do inglês tumour necrosis factor) é responsável por induzir apoptose nas células alvo através da interação com seu ligante (FasL) (SCHNEIDER et al", ", 1998; TANAKA et al", ", 1998)", " O domínio citoplasmático de FasL rico em prolina atua como um sinal de direcionamento para o interior dos lisossomos secretórios (BLOTT et al", ", 2001) como um mecanismo de controle da presença desse ligante na superfície celular e de sua secreção mediada por metaloproteases (SCHNEIDER et al", ", 1998; TANAKA et al", ", 1998)", " 23 A formação de vesículas extracelulares pode se dar na membrana plasmática", " Esse processo é conhecido como brotamento de membrana e parece ter ligação com a composição lipídica diferencial das faces citoplasmática e extracelular da membrana plasmática, além de depender de rearranjos estruturais do citoesqueleto (AKERS et al", ", 2013)", " Em C", " neoformans, foi demonstrado por nosso grupo recentemente que a deleção da flipase Apt1 alterou propriedades físico-químicas de vesículas extracelulares (RIZZO et al", ", 2014), sugerindo que a arquitetura da membrana plasmática pode estar ligada com a formação de vesículas extracelulares em fungos", " Uma outra via de secreção não convencional que envolve a participação de vesículas extracelulares é a liberação de exossomos", " Exossomos podem ser liberados para o ambiente extracelular de maneira constitutiva ou induzida (THERY et al", ", 2009)", " Como antes mencionado, esses compartimentos membranosos são formados através da invaginação de membranas dos endossomos, que brotam para o lúmen dos mesmos formando pequenas vesículas intraluminais (ILVs, do inglês intralumenal vesicles), configurando o MVB (MICHELET et al", ", 2010)", " Os MVBs podem seguir duas rotas alternativas, incluindo fusão com os lisossomos para que seu conteúdo seja degradado (GRUENBERG & STENMARK, 2004; PIPER & KATZMANN, 2007) ou fusão com a membrana plasmática, gerando assim a liberação das vesículas contidas em seu lúmen", " Nessa fase, as ILVs passam a ser denominadas exossomos (SAKSENA et al", ", 2007; LAKKARAJU & RODRIGUEZ-BOULAN, 2008; SCHOREY & BHATNAGAR, 2008; SIMONS & RAPOSO, 2009; THERY et al", ", 2009)", " Dada a importância desse mecanismo para o desenvolvimento dessa Tese, esse tema será abordado em maior profundidade adiante", " Exossomos: vesículas extracelulares carreadoras de uma vasta gama de biomoléculas Exossomos são definidos como vesículas de diâmetro na faixa entre 50 e 100 nm envolvidas por uma bicamada fosfolipídica, semelhante à membrana plasmática", " O termo exossomos foi usado pela primeira vez por Trams e colaboradores para descrever vesículas observadas em diversas culturas de células (TRAMS et al", ", 1981) supostamente resultantes da liberação de porções da membrana plasmática", " Sua relação com mecanismos de secreção foi evidenciada pelos estudos de Harding e colaboradores (HARDING et al", ", 1985) e de Pan e colaboradores (PAN et al", ", 1985)", " Estudos seminais desenvolvidos por esses grupos demonstraram, através do emprego de técnicas de microscopia eletrônica, que o receptor de transferrina, presente na membrana 25 aminoácidos (revisto por SHIELDS & PIPER, 2011)", " A molécula de ubiquitina é reconhecida por ESCRT-0", " Este complexo de proteínas é composto por duas subunidades, Vps27p e Hse1p, ambas capazes de reconhecimento de conteúdo proteico via domínio de interação ubiquitina (UIM, do inglês ubiquitin-interacting motif) e domínios VHS", " A presença de um domínio do tipo “dedo de zinco” (zinc finger em língua inglesa) em Vps27p assegura a afinidade do complexo às membranas através da sua interação com moléculas de fosfatidilinositol-3-fosfato (PtdIns3P) (ASAO et al", ", 1997; RAIBORG et al", ", 2001)", " O próximo passo para a formação do MVB é o recrutamento do segundo complexo de proteínas, ESCRT-I", " Composto por quatro subunidades (Vps23p, Vps28p, Vps37p, Mvb12p), este complexo interage com o domínio semelhante à PTAP de ESCRT-0 contido em Vps27p através da sua subunidade Vps23p (KATZMANN et al", ", 2001; KATZMANN et al", ", 2003; KOSTELANSKY et al", ", 2006)", " ESCRT-I também é capaz de reconhecimento de conteúdo proteico, uma vez que contém um domínio de ubiquitina variante E2 (UEV) em Vps23p e também um domínio UBD em Mvb12p", " A correta localização de ESCRT-I nos sítios de membrana apropriados é dependente ESCRT-0 (KATZMANN et al", ", 2001; BACHE et al", ", 2003; KATZMANN et al", ", 2003; LU et al", ", 2003)", " ESCRT-II é composto por Vps22p, Vps25p e Vps36p (BABST, KATZMANN, SNYDER, et al", ", 2002; LANGELIER et al", ", 2006)", " Vps36p é responsável pela interação entre este complexo com ESCRT-I via domínio de ligação de ubiquitina semelhante a GRAM (GLUE, do inglês GRAM-like ubiquitin-binding in EAP45) através de Vps28p (TEO et al", ", 2006; GILL et al", ", 2007)", " ESCRT-II possui forma de \"Y\" e cópias de Vps25p, que interagem com alta afinidade com Vps20p formam suas ramificações (HIERRO et al", ", 2004; TEO et al", ", 2004)", " Vps20p é um dos constituintes do complexo ESCRT-III, juntamente com Snf7p, Vps24p e Vps2p (BABST, KATZMANN, ESTEPA-SABAL, et al", ", 2002)", " Este é o único componente dos ESCRTs que não forma complexos estáveis no citoplasma", " Após a interação com Vps20p, Vps25p começa a recrutar monômeros de Snf7p que passam a formar longos filamentos", " Quando o alongamento forma uma ILV incompleta, Vps24p recruta Vps2p para completar a formação do complexo ESCRT-III (TEO et al", ", 2004; TEIS et al", ", 2008; SAKSENA & EMR, 2009)", " A remoção da ubiquitinação é realizada pelas proteínas acessórias Bro1/Alix e DOA4, recrutadas por Snf7p (ODORIZZI et al", ", 2003; LUHTALA & ODORIZZI, 2004)", " A dissociação de ESCRT-III da membrana do MVB requer energia que é fornecida pelo último componente máquinas ESCRT: o complexo proteico Vps4-Vta1, destacando-se a observação 26 de que Vps4p é uma ATPase AAA de classe I (BABST et al", ", 1998)", " Este complexo associa-se com os domínios MIM (ausente na metástase, em inglês missing in metastasis) de ESCRT-III via domínios MIT (interação e tráfego de microtúbulos, do inglês microtubule interacting and trafficking)", " Acredita-se que assim é mediada a remoção ESCRT-III da membrana da vesícula, através de um poro central existente no complexo Vps4-Vta1 (BABST et al", ", 1997; SCOTT et al", ", 2005)", " Aparentemente, o controle da oligomerização de Snf7p é uma das funções celulares de Vps24p e Vps2p, que regulam a adição sequencial de Snf7p e recrutam o complexo Vps4p-Vta1p para a liberação de ESCRT-III antes da liberação das ILVs no lumen dos MVBs (TEIS et al", ", 2010; HENNE et al", ", 2011)", " Mutantes deficientes na síntese de proteínas Vps, portanto do sistema ESCRT, acumulam membranas endossomais e exibem defeitos na formação das vesículas componentes dos corpos multivesiculares (HURLEY & EMR, 2006)", " Sendo assim é plausível imaginar que tais mutantes apresentariam também dificuldades na formação de exossomos", " 28 interage com a molécula adaptadora Rim20p, capaz de ativar o fator de transcrição Rim101 (LI & MITCHELL, 1997; LAMB et al", ", 2001), responsável pela indução da expressão de diversos genes responsivos a alterações de pH (LAMB et al", ", 2001; LAMB & MITCHELL, 2003) (Figura 7)", " Análises de complementação mostraram que o gene SNF7 é um alelo do gene de classe E VPS32 de S", " cerevisiae (TU et al", ", 1993), cuja deleção resulta em acúmulo de endossomos tardios e MVBs de morfologias aberrantes (BOWERS & STEVENS, 2005)", " O SNF7 é responsável pela produção de uma proteína hidrofílica de 240 aminoácidos e massa molecular de 27 kDa com motivos coiled coil (LUPAS et al", ", 1991)", " A proteína é caracterizada como o componente mais abundante da subunidade III da maquinaria ESCRT (WEISS et al", ", 2009)", " A proteína Snf7p possui domínios de interação com outras proteínas desse complexo, como por exemplo Vps24p (Figuras 6 e 7)", " Acredita-se que Snf7p possui papel importante na separação das ILVs da membrana dos MVBs, como discutido acima (SHESTAKOVA et al", ", 2010)", " 29 MVBs (RODRIGUES et al", ", 2007)", " Essas vesículas também demonstraram conter diversos outros fatores de virulência (RODRIGUES et al", ", 2007; RODRIGUES, NAKAYASU, et al", ", 2008)", " Dessa forma, seria razoável supor que a deleção do gene SNF7 em C", " neoformans e C", " gattii geraria impacto em diversos eventos relacionados à fisiologia e à capacidade patogênica destes fungos, como resultado da desorganização dos MVBs e de sua secreção na forma de exossomos", "", "30 Justificativa A base conceitual deste trabalho é a observação, consolidada na literatura, de que a atividade secretória nesses organismos é essencial para a arquitetura capsular e, consequentemente, para a virulência. Nos baseamos nos modelos estabelecidos por nosso grupo para avaliar a correlação entre secreção e patogênese nestes fungos, além de traçar paralelos entre entre os defeitos de secreção no mutante snf7Δ e os demais mutantes gerados em nosso laboratório. Objetivos Objetivos gerais Esta tese tem como objetivo estudar o papel da proteína Snf7p na secreção de polissacarídeos e outros eventos fisiológicos nos organismos patogênicos C. neoformans e C. gattii. Sendo assim, supomos ser possível estabelecer as funções da secreção não convencional no modelo de Cryptococcus. Objetivos específicos: 1) Produção de mutantes snf7Δ e linhagens complementadas (snf7Δ:SNF7) através de técnicas de biolística usando as espécies C. neoformans e C. gattii. 2) Caracterização fenotípica das células mutantes e complementadas, com foco em: • Adaptação a diferentes condições de cultivo • Formação de estruturas capsulares • Capacidade de pigmentação • Virulência em modelo murino de infecção intranasal • Sobrevivência e secreção de polissacarídeos capsulares durante interação com células do hospedeiro in vivo. 31 Trabalhos publicados • Where do they come from and where do they go: candidates for regulating extracellular vesicle formation in fungi • The vacuolar-sorting protein Snf7 is required for export of virulence determinants in members of the Cryptococcus neoformans complex.", "International Journal of Molecular Sciences www.mdpi.com/journal/ijms Review Where Do They Come from and Where Do They Go: Candidates for Regulating Extracellular Vesicle Formation in Fungi Débora L. Oliveira 1,*, Juliana Rizzo 2, Luna S. Joffe 2, Rodrigo M. C. Godinho 2 and Marcio L. Rodrigues 2,3,* 1 The Michael Smith Laboratories, Depart ment of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T1Z4, Canada 2 Paulo de Góes Microbiology Institute, Fe deral University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil; E-Ma ils: juju.rizzo@gmail.com (J.R.); lujoffe@gmail.com (L.S.J.); godinho.r@gmail.com (R.M.C.G.) 3 O s w a l d o C r u z F o u n d a t i o n – F i o c r u z , C e n t r e f o r T echnological Development in Health CDTS), Rio de Janeiro 21040-900, Brazil * A u t h o r s t o w h o m c o r r e s p o n d e nce should be addressed; E-Mails: debora_leite@yahoo.com.br (D.L.O.) ; marciolr@cdts.fiocruz.br (M.L.R.); Received: 29 March 2013; in revised form : 11 April 2013 / Accepted: 17 April 2013 / Published: 2 May 2013", "Abstract: I n t h e p a s t f e w y e a r s , e x t r a c e l l u l a r v e sicles (EVs) from at l e a s t e i g h t f u n g a l species were characterized. EV proteome in four fungal species i n d i c a t e d p u t a t i v e biogenesis pathways and suggested interest ing similarities with m a m m a l i a n e x o s o m e s . Moreover, as observed for mammalian exosomes , fungal EVs were demonstrated to be immunologically active. Here we review the seminal and most recent findings related to the production of EVs by fungi. Based on the cu rrent literature about secretion of fungal molecules and biogenesis of EVs in eukar yotes, we focus our discussion on a list of cellular proteins with the potential to regulate vesicl e biogenesis in the fungi. Keywords: fungal extracellular vesicles; extrace llular vesicle biogenesis; exosomes; flippases; GRASP", "OPEN ACCESS", "1. Introduction", "Fungi are eukaryotic organisms that use complex intracellular trafficki ng pathways for sorting proteins and lipids to their final cellular sites. Extr acellular sites are the final destination of cell wall components, digestive enzymes and, in the pathoge nic species, many virulence factors [1–3]. In eukaryotes, the classical secretory pathway has been widely investigated and pr oteins that undergo this route are synthesized at the endoplasmic reticu lum. However, it has been shown that typical intracellular proteins produced by fungi are also f ound at the extracellular space, playing additional biological functions [4–7]. Efforts to understand how such molecules are driven to the extracellular space led to the finding of a novel secretory mechanism: the release of extracel lular vesicles (EVs) by fungal cells. As discussed below, t h e c u r r e n t l i t e r a t u re about fungal EVs still does not allow accurate differentiation between microvesicles, e xosomes, ectosomes, apoptotic bodies and other extracellular, vesicle-like structures. Therefore, in this manuscript, we use the term EV to generally define extracellular compartments composed of lip id bilayers forming compartments ranging from 50 to 400 nm in diameter that can be isolated from fungal cultures and/or infect ed host cells [8–11]. Fungal EVs have been analyzed by a number of a pproaches that revealed important morphological features and complex composition [6,9–13]. Mo dels of stimulation of host cells in vitro and in vivo with fungal EVs clearly demonstrat ed that these compartments ar e immunologically active and have the potential to regulate key pat hogenic steps during fungal infec tions [6,10,11,14]. On the other hand, mechanisms required for biogenesis of fungal EVs stil l consist of an open field with more questions than answers [11,15,16]. In the next sections, we summarize the current knowledge on the structural and functional properties of fungal EVs. We also discuss pathways with the potential to regulate EV biogenesis in fungi, with focus on three classes of proteins with still poor ly explored physiological roles in pathogenic fungi: endosomal proteins, fli ppases and Golgi reassembly and stacking protein (Figure 1).", "2. An Overview on Molecular Traffic and EV Release", "EV export has been proven to be essential to a variety of cellula r systems. For instance, in the Prokaryotes, the ability of Gram-negative bacteria t o p r o d u c e o u t e r m e m b rane-derived vesicles (OMVs) carrying virulence factor s has been documented in deta il [17–19]. Gram-positive bacteria including Staphylococcus aureus a n d Bacillus anthracis were also demonstr ated to produce EVs related to virulence, al though their cellular origin is so fa r poorly understood [ 20,21]. Comparative genomic analysis revealed that members of th e Archaea domain produce proteins responsible for membrane remodeling and vesicle formation [22]. In fact, EVs were isolated from members of the Sulfolobales and Thermococci orders as part of the response to vi ral infections [23,24].", "In mammalians, the release of vesicles to the ex tracellular space has been widely studied for the past two decades. Mammalian cells produce di fferent types of EVs, including secretory lysosomes, multi-vesicular bodies (MVB)- derived exos omes or microvesicles shed from the plasma membrane [25–27]. Exosomes are pr obably the most well studied t ype of mammalian EVs. These compartments were originally reported to be involv ed in reticulocyte matura tion [28], but it is now clear that they are involved in multiple biologi cal events. Exosomes are required for antigen", "37. Cox, G. M. et al. Extracellular phospholipase activity is a virulence factor for", "Cryptococcus neoformans .Mol Microbiol 39, 166–75 (2001).", "38. Park, M., Do, E. & Jung, W. H. Lipolytic enzymes involved in the virulence of", "human pathogenic fungi. Mycobiology 41, 67–72 (2013).", "39. Kronstad, J. W. et al. Expanding fungal pathogenesis: Cryptococcus breaks out of", "the opportunistic box. Nat Rev Microbiol 9, 193–203 (2011).", "40. O’Meara, T. R. & Alspaugh, J. A. The Cryptococcus neoformans capsule: a sword", "and a shield. Clin Microbiol Rev 25, 387–408 (2012).", "41. Rodrigues, M. L. et al. Vesicular transport systems in fungi. Future Microbiol 6,", "42. Noverr, M. C., Cox, G. M., Perfect, J. R. & Huffnagle, G. B. Role of PLB1 in", "pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun", "43. Santangelo, R. et al. Role of extracellular phospholipases and mononuclear", "phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun", "44. Wright, L. C. et al. Cryptococcal phospholipases: a novel lysophospholipase", "discovered in the pathogenic fungus Cryptococcus gattii. Biochem J 384, 377–84 45. Eisenman, H. C., Frases, S., Nicola, A. M., Rodrigues, M. L. & Casadevall, A.", "Vesicle-associated melanization in Cryptococcus neoformans .Microbiology 155,", "46. Turner, K. M., Wright, L. C., Sorrell, T. C. & Djordjevic, J. T. N-linked", "glycosylation sites affect secretion of cryptococcal phospholipase B1, irrespective of glycosylphosphatidylinositol anchoring. Biochim Biophys Acta 1760 , 1569–79", "47. Hanson, P. I. & Cashikar, A. Multivesicular body morphogenesis. Annu Rev Cell", "48. Panepinto, J. et al. Sec6-dependent sorting of fungal extracellular exosomes and", "laccase of Cryptococcus neoformans .Mol Microbiol 71, 1165–76 (2009).", "49. Yoneda, A. & Doering, T. L. A eukaryotic capsular polysaccharide is synthesized", "intracellularly and secreted via exocytosis. Mol Biol Cell 17, 5131–40 (2006).", "50. Hu, G. et al.Cryptococcus neoformans requires the ESCRT protein Vps23 for iron", "acquisition from heme, for capsule formation, and for virulence. Infect Immun 81,", "51. Oliveira, D. L. et al. Characterization of yeast extracellular vesicles: evidence for", "the participation of different pathways of cellular traffic in vesicle biogenesis. PLoS", "52. Albuquerque, P. C. et al. Vesicular transport in Histoplasma capsulatum : an", "effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol 10, 1695–710 (2008).", "53. Duran, J. M., Anjard, C., Stefan, C., Loomis, W. F. & Malhotra, V.", "Unconventional secretion of Acb1 is mediated by autophagosomes. J Cell Biol", "54. Manjithaya, R., Anjard, C., Loomis, W. F. & Subramani, S. Unconventional", "secretion of Pichia pastoris Acb1 is dependent on GRASP protein, peroxisomal functions, and autophagosome formation. J Cell Biol 188, 537–46 (2010).", "55. Oliveira, D. L. et al. Biogenesis of extracellular vesicles in yeast: Many questions", "with few answers. Commun Integr Biol 3, 533–5 (2010).", "56. Burgoyne, T. et al. Expression of OA1 limits the fusion of a subset of MVBs with", "lysosomes - a mechanism potentially involved in the initial biogenesis of melanosomes. J Cell Sci 126, 5143–52 (2013).", "57. Kim, S. J. & Brandizzi, F. The Plant Secretory Pathway: An Essential Factory for", "Building the Plant Cell Wall. Plant Cell Physiol 55, 687–693 (2014).", "58. Kmetzsch, L. et al. Role for Golgi reassembly and stacking protein (GRASP) in", "polysaccharide secretion and fungal virulence. Mol Microbiol 81, 206–18 (2011).", "59. Hu, G. & Kronstad, J. W. A putative P-type ATPase, Apt1, is involved in stress", "tolerance and virulence in Cryptococcus neoformans .Eukaryot Cell 9, 74–83", "60. Rizzo, J. et al. Role of the Apt1 Protein in Polysaccharide Secretion by", "Cryptococcus neoformans. Eukaryot Cell 13, 715–26 (2014).", "61. Nosanchuk, J. D. & Casadevall, A. Impact of melanin on microbial virulence and", "clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother 50,", "62. Tu, J., Vallier, L. G. & Carlson, M. Molecular and genetic analysis of the SNF7 gene", "inSaccharomyces cerevisiae .Genetics 135, 17–23 (1993).", "63. Xu, W., Smith, F. J., Subaran, R. & Mitchell, A. P. Multivesicular body-ESCRT", "components function in pH response regulation in Saccharomyces cerevisiae and Candida albicans. Mol Biol Cell 15, 5528–37 (2004).", "64. Kullas, A. L., Li, M. & Davis, D. A. Snf7p, a component of the ESCRT-III protein", "complex, is an upstream member of the RIM101 pathway in Candida albicans.", "65. Tilburn, J., Sa ´nchez-Ferrero, J. C., Reoyo, E., Arst, H. N. & Pen ˜alva, M. A.", "Mutational analysis of the pH signal transduction component PalC of Aspergillus nidulans supports distant similarity to BRO1 domain family members. Genetics", "66. Pen ˜alva, M. A. & Arst, H. N. Regulation of gene expression by ambient pH in", "filamentous fungi and yeasts. Microbiol Mol Biol Rev 66, 426–46, table of contents", "67. Rizzo, J. et al. Role of the Apt1 protein in polysaccharide secretion by Cryptococcus", "neoformans .Eukaryot Cell 13, 715–726 (2014).68. Jacobson, E. S., Goodner, A. P. & Nyhus, K. J. Ferrous iron uptake in Cryptococcus neoformans .Infect Immun 66, 4169–75 (1998).", "69. Lian, T. et al. Iron-regulated transcription and capsule formation in the fungal", "pathogen Cryptococcus neoformans. Mol Microbiol 55, 1452–72 (2005).", "70. Fraser, J. A., Subaran, R. L., Nichols, C. B. & Heitman, J. Recapitulation of the", "sexual cycle of the primary fungal pathogen Cryptococcus neoformans var.gattii :", "implications for an outbreak on Vancouver Island, Canada. Eukaryot Cell 2,", "71. Idnurm, A., Reedy, J. L., Nussbaum, J. C. & Heitman, J. Cryptococcus neoformans", "virulence gene discovery through insertional mutagenesis. Eukaryot Cell 3, 420–9", "72. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–8", "73. Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using", "maximum likelihood, evolutionary distance, and maximum parsimony methods.", "74. Garcı ´a-Pedrajas, M. D. et al. DelsGate, a robust and rapid gene deletion", "construction method. Fungal Genet Biol 45, 379–88 (2008).", "75. Kmetzsch, L. et al. The vacuolar Ca(2)( 1) exchanger Vcx1 is involved in", "calcineurin-dependent Ca(2)( 1) tolerance and virulence in Cryptococcus neoformans . inEukaryot Cell, Vol. 9, 1798–805 (2010).", "76. Kmetzsch, L. et al. The GATA-type transcriptional activator Gat1 regulates", "nitrogen uptake and metabolism in the human pathogen Cryptococcus neoformans. Fungal Genet Biol 48, 192–9 (2011).", "77. Schneider Rde, O. et al. Zap1 Regulates Zinc Homeostasis and Modulates", "Virulence in Cryptococcus gattii .PLoS One 7, e43773 (2012).", "78. Toffaletti, D. L., Rude, T. H., Johnston, S. A., Durack, D. T. & Perfect, J. R. Gene", "transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol", "79. Kmetzsch, L. et al. Role for Golgi reassembly and stacking protein (GRASP) in", "polysaccharide secretion and fungal virulence. Mol Microbiol 81, 206–18 (2011).", "80. Baker, L. G., Specht, C. A., Donlin, M. J. & Lodge, J. K. Chitosan, the deacetylated", "form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans.", "81. Rodrigues, M. L., Alvarez, M., Fonseca, F. L. & Casadevall, A. Binding of the wheat", "germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell", "82. Casadevall, A., Mukherjee, J. & Scharff, M. D. Monoclonal antibody based ELISAs", "for cryptococcal polysaccharide. J Immunol Methods 154, 27–35 (1992).", "83. Fonseca, F. L. et al. Structural and functional properties of the Trichosporon asahi i", "glucuronoxylomannan. Fungal Genet Biol 46, 496–505 (2009).", "84. Price, M. F., Wilkinson, I. D. & Gentry, L. O. Plate method for detection of", "phospholipase activity in Candida albicans. Sabouraudia 20, 7–14 (1982).", "85. Chen, S. C., Muller, M., Zhou, J. Z., Wright, L. C. & Sorrell, T. C. Phospholipase", "activity in Cryptococcus neoformans : a new virulence factor? J Infect Dis 175, 86. Kwon-Chung, K. J., Wickes, B. L., Booth, J. L., Vishniac, H. S. & Bennett, J. E.", "Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans. Infect", "87. Selvig, K. & Alspaugh, J. A. pH Response Pathways in Fungi: Adapting to Host-", "derived and Environmental Signals. Mycobiology 39, 249–56 (2011).", "88. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using", "real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, Acknowledgments We thank Fernanda L. Fonseca for help with microscopy tests and Debora L. Oliveira for help with in vivo experimentation. We are also grateful to Drs. Josh Nosanchuk, Maurizio Del Poeta and Leonardo Nimrichter for helpful suggestions. This work was supported by grants from the Brazilian agencies CNPq, CAPES, FAPERJ and MCT/FINEP/Rede GENOPROT (grant number 01.07.0552.00). JC received a scholarship (grant number 201227/2009-6) for a 6 months stay at The Scripps Research Institute, USA. The authors also acknowledge support from the Instituto Nacional de Cie ˆncia e Tecnologia de Inovac ¸a,o em Doenc ¸as Negligenciadas (INCT-IDN).", "Author contributions prepared all figures; R.M.C.G., J.C., G.S.A., S.F. and L.K. conducted the experiments.", "reviewed the manuscript.", "Additional information Competing financial interests : The authors declare no competing financial interests.", "How to cite this article: da C", " Godinho, R", "M", " et al", " The vacuolar-sorting protein Snf7 is required for export of virulence determinants in members of the Cryptococcus neoformans www", "nature", "com/ scientificreports SCIENTIFIC REPORTS | 4 : 6198 | DOI: 10", "1038/srep06198 10 This work is licensed under a Creative Commons Attribution-NonCommercial- ShareAlike 4", "0 International License", " The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the CreativeCommons license, users will need to obtain permission from the license holder in order to reproduce the material", " To view a copy of this license, visit http:// creativecommons", "org/licenses/by-nc-sa/4", "0/ www", "nature", "com/ scientificreports SCIENTIFIC REPORTS | 4 : 6198 | DOI: 10", "1038/srep06198 11 32 Discussão A atividade secretória é fundamental para a patogênese no gênero Cryptococcus", " A grande maioria dos determinantes moleculares de virulência caracterizados nesse fungo é extracelular, incluindo GXM, urease e fosfolipase B (COX et al", ", 2001; NOVERR et al", ", 2003; SANTANGELO et al", ", 2004; WRIGHT et al", ", 2004; RODRIGUES, NAKAYASU, et al", ", 2008)", " Além disso, a melanina, também fundamental para a virulência, é exportada para a superfície celular por mecanismos dependentes de vesículas (RODRIGUES, NAKAYASU, et al", ", 2008; EISENMAN et al", ", 2009)", " Com exceção da fosfolipase B, nenhum dos fatores de virulência acima mencionados carrega sinais necessários para a secreção através da via convencional (COX et al", ", 2001; NOVERR et al", ", 2003; SANTANGELO et al", ", 2004; WRIGHT et al", ", 2004; RODRIGUES, NAKAYASU, et al", ", 2008)", " Esta observação e a percepção de que a maioria das proteínas fúngicas extracelulares não possuem marcas de direcionamento para secreção convencional (RODRIGUES, NAKAYASU, et al", ", 2008) sugerem fortemente que os mecanismos de secreção não convencionais e a virulência de fungos estejam intimamente ligados", " Devido à alta eficácia de C", " neoformans e C", " gattii em exportar grandes quantidades de polissacarídeos, utilizamos este modelo para investigar as ligações entre a secreção não convencional de moléculas e a patogênese fúngica", " A maquinaria ESCRT participa na formação dos MVBs (revisto em BABST, 2011; HANSON & CASHIKAR, 2012), que são necessários para a liberação dos exossomos para o espaço extracelular", " Snf7p, um dos componentes do complexo proteico ESCRTIII, é responsável pela formação das ILVs dos MVBs (HANSON & CASHIKAR, 2012)", " Portanto, considerando que as células fúngicas podem usar vesículas semelhantes a exossomos para a transferência de polissacarídeos para o meio extracelular (RODRIGUES, NAKAYASU, et al", ", 2008) parece razoável supor que Snf7p é necessária para exportação não convencional de GXM nesses fungos", " Esta hipótese é apoiada pelo fato de que mutantes de C", " neoformans com defeitos na expressão dos genes SEC apresentam cápsulas normais (YONEDA & DOERING, 2006; PANEPINTO et al", ", 2009)", " A regulação da exportação de moléculas de natureza não-proteica, incluindo os pigmentos e polissacarídeos, é pouco conhecida", " Em células de mamíferos, MVBs foram correlacionadas com a biogênese inicial de melanossomos (BURGOYNE et al", ", 2013), o que implica em conexões entre a secreção não convencional e o tráfego de pigmentos em alguns organismos", " Nas células vegetais, endomembranas participam no tráfego de polissacarídeos 33 (KIM & BRANDIZZI, 2014), mas a identidade dos componentes necessários para o transporte de enzimas da parede celular e polissacarídeos não é conhecida", " Neste estudo, a deleção de SNF7 resultou em eficiências reduzidas de pigmentação, secreção de GXM e formação de cápsula em C", " neoformans e C", " gattii", " A deficiência de pigmentação variou entre as espécies de maneira dependente da temperatura de cultivo, bem como do substrato usado para a indução da pigmentação", " Levando em conta que o crescimento de ambos os fungos mutantes a 30 ou 37ºC, em diferentes condições (privação de cobre, por exemplo), não apresentou variações acentuadas, supomos que as variações metabólicas observadas são intrínsecas de cada espécie e podem estar relacionadas a seu potencial patogênico diferenciado (BYRNES et al", ", 2011)", " No entanto, a possibilidade de que a atividade da enzima lacase, responsável pelo processo de melanização, tenha sido alterada pela deleção de SNF7 não pode ser descartada", " Para esclarecer essa possibilidade testes in vitro da atividade desta enzima seriam necessários", " Os níveis de atividade de urease e fosfolipase foram apenas levemente afetados pela deleção de SNF7", " A atividade fosfolipase não alterada está de acordo com a descrição de mecanismos de secreção convencionais dessa enzima dependentes de SEC14 em C", " neoformans (CHAYAKULKEEREE et al", ", 2011)", " Nossas observações sugerem que a formação de MVBs e os mecanismos de secreção não convencionais participam diretamente da exportação de moléculas de superfície e/ou moléculas extracelulares de natureza não-proteica", " Essa hipótese está de acordo com a observação de que, em C", " neoformans, a proteína de reorganização e empilhamento do Golgi (Golgi reassembly and stacking protein; GRASP) e a flipase Apt1, ambos reguladores da secreção não convencional, são relevantes para a exportação de polissacarídeo (KMETZSCH et al", ", 2011; RIZZO et al", ", 2014)", " A deleção dos genes necessários para expressão das proteínas em questão, de fato, causou atenuação da virulência de C", " neoformans (HU & KRONSTAD, 2010; KMETZSCH et al", ", 2011; RIZZO et al", ", 2014)", " Nesse estudo, a deleção de SNF7 também interferiu com a tolerância ao pH alcalino e a altas concentrações de cloreto de lítio em C", " neoformans e C", " gattii", " Estes dados estão de acordo com a literatura disponível para S", " cerevisiae (XU et al", ", 2004), C", " albicans (KULLAS et al", ", 2004; WOLF & DAVIS, 2010) e A", " nidulans (TILBURN et al", ", 2005), sugerindo a participação de Snf7p na cascata de sinalização de RIM101", " A família de proteínas RIM inclui uma proteína sensora (Rim21p) e um complexo catalítico (Rim20p em associação com Rim13p) capaz de induzir a ativação proteolítica de Rim101p", " A falta de Snf7p foi correlacionada com a incapacidade de ativação do fator de transcrição RIM101 34 independentemente da presença de Rim20p e Rim13p, mimetizando um fenótipo anteriormente descrito para mutantes rim101Δ de C", " albicans (KULLAS et al", ", 2004; WOLF & DAVIS, 2010) e C", " neoformans (O'MEARA et al", ", 2010)", " A forma ativa de Rim101p supostamente modula a expressão de vários genes envolvidos na adaptação a diferentes ambientes (PEÑALVA & ARST, 2002), além de modular a sua própria expressão (PEÑALVA & ARST, 2002)", " Essas observações estão de acordo com a redução na expressão relativa do RNAm de RIM101 observada neste trabalho, implicando uma menor ativação deste fator de transcrição em ambos os mutantes snf7\u0001", " Recentemente, O'Meara e colaboradores mostraram que Rim101p também é essencial para o crescimento da cápsula de C", " neoformans (O'MEARA et al", ", 2010)", " Embora não seja necessária para biossíntese e secreção de GXM, essa proteína regula vários genes envolvidos na biossíntese de parede celular (O'MEARA et al", ", 2010)", " Curiosamente, o mutante rim101Δ mostrou-se hipocapsular, mas apresentou secreção normal de GXM e virulência similar à apresentada por células selvagens em um modelo murino de infecção intranasal", " Diante disso, os autores levantaram a hipótese de que a secreção de GXM poderia imunomodular as células hospedeiras e contribuir para a virulência, independente da formação de cápsula do mutante rim101Δ (O'MEARA et al", ", 2010)", " Em nosso modelo, os fenótipos observados para os mutantes snf7Δ poderiam, pelo menos em parte, apontar na mesma direção da proposta seguida por O'Meara e colaboradores (O'MEARA et al", ", 2010)", " Observamos in vivo que a secreção defeituosa de GXM está correlacionada com uma sobrevivência reduzida de C", " neoformans no ambiente pulmonar do hospedeiro", " A melanização reduzida nos mutantes snf7Δ, observada in vitro, é também provavelmente essencial, conforme demonstrado anteriormente (GOMEZ & NOSANCHUK, 2003; MEDNICK et al", ", 2005; QIU et al", ", 2012)", " Futuros estudos sobre como os mutantes rim101∆ e snf7∆ interferem com mecanismos de imunidade podem contribuir com o entendimento dos possíveis papéis de cada via no processo patogênico", " Curiosamente, o processo de melanização, embora dependente de eventos da secreção não convencional (RODRIGUES, NAKAYASU, et al", ", 2008; EISENMAN et al", ", 2009), parece operar sob mecanismos de regulação que incluem também genes relacionados para secreção convencional, como SEC6 (PANEPINTO et al", ", 2009)", " A diminuição da expressão desse gene em C", " neoformans por RNA de interferência causou impacto negativo no processo de melanização, acúmulo de vesículas intracelulares e desaparecimento das populações de vesículas extracelulares (PANEPINTO et al", ", 2009)", " A indução da expressão de proteína cinase A (PKA) ou a desativação de seu repressor também geraram células deficientes na 35 capacidade de melanização (CHOI et al", ", 2012)", " Esses estudos em associação ao presente trabalho indicam uma alta complexidade e envolvimento de vias celulares múltiplas no processo de pigmentação em C", " neoformans", " A observação de que alterações no nível de PKA não favorecem a melanização pode estar ligada a alterações na composição e/ou estrutura da parede celular", " Sabe-se que vias de sinalização ligadas à ativação de PKA e a produção de cAMP possuem grande sobreposição e capacidade de controle de vários genes em comum, como é o caso da via de integridade da parede celular (CWI) (DONLIN et al", ", 2014) e de sensibilidade a alterações de pH por RIM101 (O'MEARA et al", ", 2010)", " Ambas as vias controlam, aparentemente de maneira antagônica, a expressão de genes estruturais da parede celular, conforme concluído pela observação de que mutações nos genes da via CWI (BCK1, MKK2 e MPK1) geram predominância de quitosana na composição da parede celular, em detrimento da presença de quitina (DONLIN et al", ", 2014)", " Essas observações contrastam com o perfil de expressão gênica induzido por mutações na via de RIM101 (DONLIN et al", ", 2014)", " Além disso, alterações na via da CWI induzem sensibilidade a agentes estressores de parede celular, como vermelho do congo e calcofluor (DONLIN et al", ", 2014)", " Os mutantes rim101∆ em C", " neoformans não apresentam essas características", " Aparentemente, nenhuma dessas duas vias atua na secreção de GXM (O'MEARA et al", ", 2010; DONLIN et al", ", 2014)", " Já foi proposto que frações de GXM capsular e secretada apresentam propriedades físico-químicas e biológicas diferenciadas (FRASES et al", ", 2008)", " É especulado que essas frações polissacarídicas seriam exportadas através de mecanismos distintos de secreção", " Essa hipótese, de fato, encontra argumentos sólidos na literatura", " Yoneda e Doering geraram um mutante delecional de um gene homólogo de SEC4/RAB8 de S", " cerevisiae, denominado SAV1 em C", " neoformans (YONEDA & DOERING, 2006)", " Esse mutante acumulou vesículas citoplasmáticas derivadas do Golgi contendo GXM", " Entretanto, o mutante sav1Δ apresentou cápsula de dimensões normais e níveis inalterados de secreção de GXM (YONEDA & DOERING, 2006; 2009)", " De forma similar, mutantes incapazes de expressar os genes SEC14 e SEC6 apresentaram cápsulas normais (PANEPINTO et al", ", 2009; CHAYAKULKEEREE et al", ", 2011)", " Por outro lado, estudos desenvolvidos por nosso grupo e outros apontaram para o envolvimento de vários genes não relacionados à secreção convencional na formação da cápsula de C", " neoformans (O'MEARA et al", ", 2010; KMETZSCH et al", ", 2011; DONLIN et al", ", 2014; GODINHO et al", ", 2014; RIZZO et al", ", 2014)", " Como mencionado antes, mutantes grasp∆ e snf7∆ apresentaram diminuição tanto na secreção de polissacarídeos como na montagem da cápsula", " Aparentemente o mecanismo de secreção de GXM impactado em 36 ambos os casos parece ser independente de mecanismos convencionais de secreção, embora o mutante grasp∆ apresente alterações na morfologia do aparato de Golgi (KMETZSCH et al", ", 2011)", " O presente estudo e os acima mencionados apontam para conexões importantes entre elementos da secreção pós-Golgi e reguladores de secreção não convencional", " Muitas lacunas persistem no conhecimento sobre como os componentes capsulares são secretados", " Por exemplo, mutantes apt1∆ e sec6∆ apresentam dimensões capsulares normais, mas níveis reduzidos de GXM extracelular (PANEPINTO et al", ", 2009; HU & KRONSTAD, 2010; RIZZO et al", ", 2014)", " As razões por trás dessas observações são desconhecidas", " É possível que, como mencionado anteriormente, frações capsulares e extracelulares sejam secretadas através de mecanismos distintos", " Essas observações sugerem ainda que a quantidade mínima de GXM necessária para a montagem da cápsula seja inferior àquela normalmente secretada por C", " neoformans", " As observações relacionadas às vias de sinalização de RIM101 e CWI estão de acordo com a proposição de que elementos da parede celular serviriam para o ancoramento das moléculas de GXM secretadas", " Foi demonstrado em uma série de estudos desenvolvidos por nosso grupo que oligômeros de quitina presentes na parede celular de C", " neoformans são capazes de interagir com moléculas de GXM formando compostos com características biológicas únicas (FONSECA et al", ", 2009; RAMOS et al", ", 2012)", " O bloqueio da interação GXM/oligômeros de quitina, através do uso de lectina do germe de trigo (WGA, do inglês wheat germ agglutinin), diminuiu o crescimento capsular de C", " neoformans in vitro (FONSECA et al", ", 2013)", " Células fúngicas pré-tratadas com WGA apresentaram secreção reduzida de GXM e atenuação da virulência no modelo murino de infecção", " É interessante observar que a produção de quito-oligômeros está associada à expressão de RIM101 (O'MEARA et al", ", 2014), reforçando a percepção de que a regulação da exportação de GXM e a arquitetura da superfície celular estão associadas em níveis múltiplos", " Embora os fatores de virulência no complexo de espécies C", " neoformans estejam claramente sob múltiplos sistemas de regulação envolvendo sensores ambientais e sinalização através de fatores de transcrição sobrepostos, a exportação desses fatores de virulência, especialmente os relacionados com a secreção não convencional, mostrou-se uma condição indispensável para a patogênese de C", " neoformans e C", " gattii", " Recentemente, Huang e colaboradores demonstraram que a interação entre vesículas secretadas por C", " neoformans modulam a interação desse patógeno com células endoteliais humanas aumentando a carga fúngica no microambiente do sistema nervoso central (HUANG et al", ", 2012)", " Aparentemente esse mecanismo envolve um remodelamento de plataformas lipídicas da superfície da célula 37 hospedeira, direcionando a molécula de CD44, considerada um receptor de Cryptococcus em células endoteliais microvasculares humanas, para essas regiões (JONG et al", ", 2008; JONG et al", ", 2012; LONG et al", ", 2012)", " No mesmo estudo, os autores demonstraram a existência de vesículas de origem fúngica no interior de células infectadas, permitindo imaginar que elas possam ter sido secretadas no interior da célula hospedeira ou internalizadas pela mesma", " De uma maneira ou de outra, o fato dessas vesículas carrearem não só proteínas do metabolismo fúngico como também fatores de virulência (RODRIGUES, NAKAYASU, et al", ", 2008) e, possivelmente RNAm (dados não publicados, Lysangela Alves, Fiocruz), poderia sugerir uma modulação da maquinaria celular do hospedeiro em favor da infecção", " Nossas observações indicam que a expressão da Snf7p regula a virulência em C", " neoformans e C", " gattii, interferindo com a exportação de polissacarídeos, formação de cápsula e pimentação", " Dada à relevância da secreção destas moléculas no processo patogênico, é possível imaginar que diversas vias de secreção possam atuar de maneira redundante para a exportação dos fatores de virulência", " Nosso trabalho se soma aos estudos de outros genes relacionados com a secreção não convencional (GRASP e APT1) demonstrando a necessidade desses mecanismos para a exportação de biomoléculas no gênero Cryptococcus", " Em todos os três casos, a capacidade de geração de dano ao hospedeiro foi atenuada, em diferentes graus (HU & KRONSTAD, 2010; KMETZSCH et al", ", 2011; OLIVEIRA et al", ", 2013; GODINHO et al", ", 2014; RIZZO et al", ", 2014)", " É possível que os fenótipos observados nesses mutantes requeiram ações coordenadas das três proteínas", " Apt1p está diretamente ligada a internalização de membrana e na formação de endossomos (HU & KRONSTAD, 2010)", " O mutante apt1∆ em C", " neoformans apresenta deficiência na formação de compartimentos endocíticos (HU & KRONSTAD, 2010; RIZZO et al", ", 2014), o que pode prejudicar a formação de MVBs", " Essa hipótese é justificada pelo fato de que a membrana dos endossomos é o sítio de montagem da maquinaria ESCRT para produção de ILVs, que originam os exossomos (SAKSENA et al", ", 2007; LAKKARAJU & RODRIGUEZ-BOULAN, 2008; SCHOREY & BHATNAGAR, 2008; SIMONS & RAPOSO, 2009; THERY et al", ", 2009; MICHELET et al", ", 2010)", " Foi proposto que GRASP pode interagir com estruturas membranares chamadas CUPS (do inglês: compartment for unconventional protein secretion), observada em células cultivadas em condições de privação de nutrientes", " CUPS está associada a proteínas reguladoras de autofagia, como Atg9p, Atg8p e Vps23p, um componente de ESCRTI (DURAN et al", ", 2010; BRUNS et al", ", 2011; MALHOTRA, 2013)", " Essa estrutura também foi associada à secreção não convencional em leveduras (DURAN et al", ", 2010; BRUNS et al", ", 2011)", " Foi proposto (MALHOTRA, 2013) que vesículas cuja 38 biogênese dependeria dessas estruturas poderiam carregar moléculas selecionadas pelo domínio PDZ de GRASP em sua face citoplasmática e fundir-se a membrana do endossomo", " A presença de proteínas da maquinaria ESCRT nas vesículas derivadas de CUPS possibilitaria a formação de MVBs carregando moléculas aderidas a sua face citoplasmática para o interior das ILVs geradas, com posterior secreção na forma de vesículas semelhantes a exossomos (MALHOTRA, 2013) (Figura 8)", " A correlação entre seleção de cargo dos MVBs e CUPS no modelo de Cryptococcus ganha mais significância quando considerado o fato que mutações no gene VPS23, compartilhadas entre as duas vias, geraram indivíduos com um fenótipo hipocapsular, de baixa secreção de melanina e hipovirulentos em C", " neoformans (HU et al", ", 2013)", " 39 fortemente a existência de mecanismos ainda pouco claros para a exportação de moléculas de natureza não-proteica em eucariotos", " 40 Conclusões 1) A proteína Snf7 é essencial para a regulação da virulência de C", " neoformans e C", " gattii", " 2) Mecanismos de secreção não convencional relacionados a Snf7p são importantes nos eventos de melanização, secreção de GXM e montagem da cápsula polissacarídica em fungos do complexo de espécies C", " neoformans", " 3) A deleção de SNF7 altera a capacidade de sobrevivência de C", " neoformans e C", " gattii em pHs alcalinos e mediante a exposição a cloreto de lítio, provavelmente por impactar a via de sinalização de dependente da proteína relacionada Rim101", " 4) A deleção de SNF7 em C", " neoformans e C", " gattii provocou a perda de virulência desses microrganismos em um modelo murino de infecção intranasal", " Esse efeito provavelmente está ligado a menor secreção de GXM e a maior susceptibilidade do fungo in vivo conforme observados para C", " neoformans", " 5) Os resultados acima descritos indicam que reguladores de mecanismos não convencionais de secreção estão potencialmente envolvidos na patogênese fúngica", " Essa observação abre perspectivas relacionadas a identificação da função de outros reguladores de secreção não convencional em fungos patogênicos", " 41 Bibliografia ADAMS, D", " J", " Fungal cell wall chitinases and glucanases", " Microbiology, v", " 150, n", " Pt 7, p", " 2029-35, Jul 2004", " AKERS, J", " C", "; GONDA, D", "; KIM, R", "; CARTER, B", " S", "; CHEN, C", " C", " Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies", " J Neurooncol, v", " 113, n", " 1, p", " 1-11, May 2013", " AKHTER, S", "; MCDADE, H", " C", "; GORLACH, J", " M", "; HEINRICH, G", "; COX, G", " M", "; PERFECT, J", " R", " Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans", " Infect Immun, v", " 71, n", " 10, p", " 5794-802, Oct 2003", " ALANIO, A", "; DESNOS-OLLIVIER, M", "; DROMER, F", " Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans", " MBio, v", " 2, n", " 4, 2011", " ALBUQUERQUE, P", " C", "; CORDERO, R", " J", "; FONSECA, F", " L", "; PERES DA SILVA, R", "; RAMOS, C", " L", "; MIRANDA, K", " R", "; CASADEVALL, A", "; PUCCIA, R", "; NOSANCHUK, J", " D", "; NIMRICHTER, L", "; GUIMARAES, A", " J", "; RODRIGUES, M", " L", " A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan", " Fungal Genet Biol, v", " 49, n", " 11, p", " 943-54, Nov 2012", " ALBUQUERQUE, P", " C", "; NAKAYASU, E", " S", "; RODRIGUES, M", " L", "; FRASES, S", "; CASADEVALL, A", "; ZANCOPE-OLIVEIRA, R", " M", "; ALMEIDA, I", " C", "; NOSANCHUK, J", " D", " Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes", " Cell Microbiol, v", " 10, n", " 8, p", " 1695-710, Aug 2008", " ASAO, H", "; SASAKI, Y", "; ARITA, T", "; TANAKA, N", "; ENDO, K", "; KASAI, H", "; TAKESHITA, T", "; ENDO, Y", "; FUJITA, T", "; SUGAMURA, K", " Hrs is associated with STAM, a signal-transducing adaptor molecule", " Its suppressive effect on cytokine-induced cell growth", " J Biol Chem, v", " 272, n", " 52, p", " 32785-91, Dec 26 1997", " AURON, P", " E", "; WEBB, A", " C", "; ROSENWASSER, L", " J", "; MUCCI, S", " F", "; RICH, A", "; WOLFF, S", " M", "; DINARELLO, C", " A", " Nucleotide sequence of human monocyte interleukin 1 precursor cDNA", " Proc Natl Acad Sci U S A, v", " 81, n", " 24, p", " 7907-11, Dec 1984", " 42 BABST, M", " MVB vesicle formation: ESCRT-dependent, ESCRT-independent and everything in between", " Curr Opin Cell Biol, v", " 23, n", " 4, p", " 452-7, Aug 2011", " BABST, M", "; KATZMANN, D", " J", "; ESTEPA-SABAL, E", " J", "; MEERLOO, T", "; EMR, S", " D", " Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting", " Dev Cell, v", " 3, n", " 2, p", " 271-82, Aug 2002", " BABST, M", "; KATZMANN, D", " J", "; SNYDER, W", " B", "; WENDLAND, B", "; EMR, S", " D", " Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body", " Dev Cell, v", " 3, n", " 2, p", " 283-9, Aug 2002", " BABST, M", "; SATO, T", " K", "; BANTA, L", " M", "; EMR, S", " D", " Endosomal transport function in yeast requires a novel AAA-type ATPase, Vps4p", " EMBO J, v", " 16, n", " 8, p", " 1820-31, Apr 15 1997", " BABST, M", "; WENDLAND, B", "; ESTEPA, E", " J", "; EMR, S", " D", " The Vps4p AAA ATPase regulates membrane association of a Vps protein complex required for normal endosome function", " EMBO J, v", " 17, n", " 11, p", " 2982-93, Jun 1 1998", " BACHE, K", " G", "; RAIBORG, C", "; MEHLUM, A", "; STENMARK, H", " STAM and Hrs are subunits of a multivalent ubiquitin-binding complex on early endosomes", " J Biol Chem, v", " 278, n", " 14, p", " 12513-21, Apr 4 2003", " BARBOSA, F", " M", "; FONSECA, F", " L", "; FIGUEIREDO, R", " T", "; BOZZA, M", " T", "; CASADEVALL, A", "; NIMRICHTER, L", "; RODRIGUES, M", " L", " Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin-8 production", " Clin Vaccine Immunol, v", " 14, n", " 1, p", " 94-8, Jan 2007", " BARLOWE, C", "; ORCI, L", "; YEUNG, T", "; HOSOBUCHI, M", "; HAMAMOTO, S", "; SALAMA, N", "; REXACH, M", " F", "; RAVAZZOLA, M", "; AMHERDT, M", "; SCHEKMAN, R", " COPII: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum", " Cell, v", " 77, n", " 6, p", " 895-907, Jun 17 1994", " BASKOVA, L", "; BUCHTA, V", " Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach", " Folia Microbiol (Praha), v", " 57, n", " 5, p", " 421-30, Sep 2012", " BENDTSEN, J", " D", "; NIELSEN, H", "; VON HEIJNE, G", "; BRUNAK, S", " Improved prediction of signal peptides: SignalP 3", "0", " J Mol Biol, v", " 340, n", " 4, p", " 783-95, Jul 16 2004", " 43 BLOOMFIELD, N", "; GORDON, M", " A", "; ELMENDORF, D", " F", ", JR", " Detection of Cryptococcus Neoformans Antigen in Body Fluids by Latex Particle Agglutination", " Proc Soc Exp Biol Med, v", " 114, p", " 64-7, Oct 1963", " BLOTT, E", " J", "; BOSSI, G", "; CLARK, R", "; ZVELEBIL, M", "; GRIFFITHS, G", " M", " Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail", " J Cell Sci, v", " 114, n", " Pt 13, p", " 2405-16, Jul 2001", " BLOTT, E", " J", "; GRIFFITHS, G", " M", " Secretory lysosomes", " Nat Rev Mol Cell Biol, v", " 3, n", " 2, p", " 122-31, Feb 2002", " BOCK, J", " B", "; MATERN, H", " T", "; PEDEN, A", " A", "; SCHELLER, R", " H", " A genomic perspective on membrane compartment organization", " Nature, v", " 409, n", " 6822, p", " 839-41, Feb 15 2001", " BONIFACINO, J", " S", "; GLICK, B", " S", " The mechanisms of vesicle budding and fusion", " Cell, v", " 116, n", " 2, p", " 153-66, Jan 23 2004", " BONIFACINO, J", " S", "; LIPPINCOTT-SCHWARTZ, J", " Coat proteins: shaping membrane transport", " Nat Rev Mol Cell Biol, v", " 4, n", " 5, p", " 409-14, May 2003", " BOSSI, G", "; GRIFFITHS, G", " M", " Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells", " Nat Med, v", " 5, n", " 1, p", " 90-6, Jan 1999", " BOWERS, K", "; STEVENS, T", " H", " Protein transport from the late Golgi to the vacuole in the yeast Saccharomyces cerevisiae", " Biochim Biophys Acta, v", " 1744, n", " 3, p", " 438-54, Jul 10 2005", " BRUNS, C", "; MCCAFFERY, J", " M", "; CURWIN, A", " J", "; DURAN, J", " M", "; MALHOTRA, V", " Biogenesis of a novel compartment for autophagosome-mediated unconventional protein secretion", " J Cell Biol, v", " 195, n", " 6, p", " 979-92, Dec 12 2011", " BURGOYNE, T", "; JOLLY, R", "; MARTIN-MARTIN, B", "; SEABRA, M", " C", "; PICCIRILLO, R", "; SCHIAFFINO, M", " V", "; FUTTER, C", " E", " Expression of OA1 limits the fusion of a subset of MVBs with lysosomes - a mechanism potentially involved in the initial biogenesis of melanosomes", " J Cell Sci, v", " 126, n", " Pt 22, p", " 5143-52, Nov 15 2013", " 44 BYRNES, E", " J", ", 3RD; BARTLETT, K", " H", "; PERFECT, J", " R", "; HEITMAN, J", " Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals", " Microbes Infect, v", " 13, n", " 11, p", " 895-907, Oct 2011", " BYRNES, E", " J", ", 3RD; BILDFELL, R", " J", "; FRANK, S", " A", "; MITCHELL, T", " G", "; MARR, K", " A", "; HEITMAN, J", " Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States", " J Infect Dis, v", " 199, n", " 7, p", " 1081-6, Apr 1 2009", " CARLSON, M", "; OSMOND, B", " C", "; BOTSTEIN, D", " Mutants of yeast defective in sucrose utilization", " Genetics, v", " 98, n", " 1, p", " 25-40, May 1981", " CASADEVALL, A", "; PIROFSKI, L", " Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans", " Curr Mol Med, v", " 5, n", " 4, p", " 421-33, Jun 2005a", " CASADEVALL, A", "; PIROFSKI, L", " A", " Feasibility and prospects for a vaccine to prevent cryptococcosis", " Med Mycol, v", " 43, n", " 8, p", " 667-80, Dec 2005b", " ______", " The potential of antibody-mediated immunity in the defence against biological weapons", " Expert Opin Biol Ther, v", " 5, n", " 10, p", " 1359-72, Oct 2005c", " CHAPMAN, S", " W", "; SULLIVAN, D", " C", "; CLEARY, J", " D", " In search of the holy grail of antifungal therapy", " Trans Am Clin Climatol Assoc, v", " 119, p", " 197-215; discussion 215-6, 2008", " CHAYAKULKEEREE, M", "; JOHNSTON, S", " A", "; OEI, J", " B", "; LEV, S", "; WILLIAMSON, P", " R", "; WILSON, C", " F", "; ZUO, X", "; LEAL, A", " L", "; VAINSTEIN, M", " H", "; MEYER, W", "; SORRELL, T", " C", "; MAY, R", " C", "; DJORDJEVIC, J", " T", " SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans", " Mol Microbiol, v", " 80, n", " 4, p", " 1088-101, May 2011", " CHAYAKULKEEREE, M", "; PERFECT, J", " R", " Cryptococcosis", " Infect Dis Clin North Am, v", " 20, n", " 3, p", " 507-44, v-vi, Sep 2006", " 45 CHEN, L", " C", "; GOLDMAN, D", " L", "; DOERING, T", " L", "; PIROFSKI, L", "; CASADEVALL, A", " Antibody response to Cryptococcus neoformans proteins in rodents and humans", " Infect Immun, v", " 67, n", " 5, p", " 2218-24, May 1999", " CHEN, Y", " A", "; SCHELLER, R", " H", " SNARE-mediated membrane fusion", " Nat Rev Mol Cell Biol, v", " 2, n", " 2, p", " 98-106, Feb 2001", " CHOI, J", "; VOGL, A", " W", "; KRONSTAD, J", " W", " Regulated expression of cyclic AMP-dependent protein kinase A reveals an influence on cell size and the secretion of virulence factors in Cryptococcus neoformans", " Mol Microbiol, v", " 85, n", " 4, p", " 700-15, Aug 2012", " CORDERO, R", " J", "; PONTES, B", "; GUIMARAES, A", " J", "; MARTINEZ, L", " R", "; RIVERA, J", "; FRIES, B", " C", "; NIMRICHTER, L", "; RODRIGUES, M", " L", "; VIANA, N", " B", "; CASADEVALL, A", " Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans", " Infect Immun, v", " 79, n", " 12, p", " 4990-5000, Dec 2011", " COURTNEY, A", " H", "; BENNETT, N", " R", "; ZWICK, D", " B", "; HUDON, J", "; KIESSLING, L", " L", " Synthetic antigens reveal dynamics of BCR endocytosis during inhibitory signaling", " ACS Chem Biol, v", " 9, n", " 1, p", " 202-10, Jan 17 2014", " COX, G", " M", "; MCDADE, H", " C", "; CHEN, S", " C", "; TUCKER, S", " C", "; GOTTFREDSSON, M", "; WRIGHT, L", " C", "; SORRELL, T", " C", "; LEIDICH, S", " D", "; CASADEVALL, A", "; GHANNOUM, M", " A", "; PERFECT, J", " R", " Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans", " Mol Microbiol, v", " 39, n", " 1, p", " 166-75, Jan 2001", " COX, G", " M", "; MUKHERJEE, J", "; COLE, G", " T", "; CASADEVALL, A", "; PERFECT, J", " R", " Urease as a virulence factor in experimental cryptococcosis", " Infect Immun, v", " 68, n", " 2, p", " 443-8, Feb 2000", " CROSS, B", " C", "; SINNING, I", "; LUIRINK, J", "; HIGH, S", " Delivering proteins for export from the cytosol", " Nat Rev Mol Cell Biol, v", " 10, n", " 4, p", " 255-64, Apr 2009", " D'SOUZA, C", " A", "; HEITMAN, J", " Conserved cAMP signaling cascades regulate fungal development and virulence", " FEMS Microbiol Rev, v", " 25, n", " 3, p", " 349-64, May 2001", " DE JESUS, M", "; NICOLA, A", " M", "; RODRIGUES, M", " L", "; JANBON, G", "; CASADEVALL, A", " Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan", " Eukaryot Cell, v", " 8, n", " 1, p", " 96-103, Jan 2009", " 46 DJORDJEVIC, J", " T", " Role of phospholipases in fungal fitness, pathogenicity, and drug development - lessons from cryptococcus neoformans", " Front Microbiol, v", " 1, p", " 125, 2010", " DOERING, T", " L", " How does Cryptococcus get its coat? Trends Microbiol, v", " 8, n", " 12, p", " 547-53, Dec 2000", " DONG, Z", " M", "; MURPHY, J", " W", " Cryptococcal polysaccharides bind to CD18 on human neutrophils", " Infect Immun, v", " 65, n", " 2, p", " 557-63, Feb 1997", " DONLIN, M", " J", "; UPADHYA, R", "; GERIK, K", " J", "; LAM, W", "; VANARENDONK, L", " G", "; SPECHT, C", " A", "; SHARMA, N", " K", "; LODGE, J", " K", " Cross talk between the cell wall integrity and cyclic AMP/protein kinase A pathways in Cryptococcus neoformans", " MBio, v", " 5, n", " 4, 2014", " DURAN, J", " M", "; ANJARD, C", "; STEFAN, C", "; LOOMIS, W", " F", "; MALHOTRA, V", " Unconventional secretion of Acb1 is mediated by autophagosomes", " J Cell Biol, v", " 188, n", " 4, p", " 527-36, Feb 22 2010", " EISENMAN, H", " C", "; CASADEVALL, A", " Synthesis and assembly of fungal melanin", " Appl Microbiol Biotechnol, v", " 93, n", " 3, p", " 931-40, Feb 2012", " EISENMAN, H", " C", "; FRASES, S", "; NICOLA, A", " M", "; RODRIGUES, M", " L", "; CASADEVALL, A", " Vesicle-associated melanization in Cryptococcus neoformans", " Microbiology, v", " 155, n", " Pt 12, p", " 3860-7, Dec 2009", " ELLIS, D", " H", "; PFEIFFER, T", " J", " Ecology, life cycle, and infectious propagule of Cryptococcus neoformans", " Lancet, v", " 336, n", " 8720, p", " 923-5, Oct 13 1990", " EMANUELSSON, O", "; VON HEIJNE, G", " Prediction of organellar targeting signals", " Biochim Biophys Acta, v", " 1541, n", " 1-2, p", " 114-9, Dec 12 2001", " FALKOW, S", " Molecular Koch's postulates applied to microbial pathogenicity", " Rev Infect Dis, v", " 10 Suppl 2, p", " S274-6, Jul-Aug 1988", " ______", " Molecular Koch's postulates applied to bacterial pathogenicity--a personal recollection 15 years later", " Nat Rev Microbiol, v", " 2, n", " 1, p", " 67-72, Jan 2004", " 47 FASSHAUER, D", "; SUTTON, R", " B", "; BRUNGER, A", " T", "; JAHN, R", " Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs", " Proc Natl Acad Sci U S A, v", " 95, n", " 26, p", " 15781-6, Dec 22 1998", " FELDMESSER, M", "; KRESS, Y", "; CASADEVALL, A", " Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection", " Microbiology, v", " 147, n", " Pt 8, p", " 2355-65, Aug 2001", " FONSECA, F", " L", "; GUIMARAES, A", " J", "; KMETZSCH, L", "; DUTRA, F", " F", "; SILVA, F", " D", "; TABORDA, C", " P", "; ARAUJO GDE, S", "; FRASES, S", "; STAATS, C", " C", "; BOZZA, M", " T", "; SCHRANK, A", "; VAINSTEIN, M", " H", "; NIMRICHTER, L", "; CASADEVALL, A", "; RODRIGUES, M", " L", " Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis", " Fungal Genet Biol, v", " 60, p", " 64-73, Nov 2013", " FONSECA, F", " L", "; NIMRICHTER, L", "; CORDERO, R", " J", "; FRASES, S", "; RODRIGUES, J", "; GOLDMAN, D", " L", "; ANDRUSZKIEWICZ, R", "; MILEWSKI, S", "; TRAVASSOS, L", " R", "; CASADEVALL, A", "; RODRIGUES, M", " L", " Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans", " Eukaryot Cell, v", " 8, n", " 10, p", " 1543-53, Oct 2009", " FONSECA, F", " L", "; NOHARA, L", " L", "; CORDERO, R", " J", "; FRASES, S", "; CASADEVALL, A", "; ALMEIDA, I", " C", "; NIMRICHTER, L", "; RODRIGUES, M", " L", " Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter", " Infect Immun, v", " 78, n", " 9, p", " 3861-70, Sep 2010", " FRASES, S", "; NIMRICHTER, L", "; VIANA, N", " B", "; NAKOUZI, A", "; CASADEVALL, A", " Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences", " Eukaryot Cell, v", " 7, n", " 2, p", " 319-27, Feb 2008", " FRASES, S", "; PONTES, B", "; NIMRICHTER, L", "; VIANA, N", " B", "; RODRIGUES, M", " L", "; CASADEVALL, A", " Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules", " Proc Natl Acad Sci U S A, v", " 106, n", " 4, p", " 1228-33, Jan 27 2009", " GARCIA-RIVERA, J", "; CHANG, Y", " C", "; KWON-CHUNG, K", " J", "; CASADEVALL, A", " Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan", " Eukaryot Cell, v", " 3, n", " 2, p", " 385-92, Apr 2004", " GEHRMANN, U", "; QAZI, K", " R", "; JOHANSSON, C", "; HULTENBY, K", "; KARLSSON, M", "; LUNDEBERG, L", "; GABRIELSSON, S", "; SCHEYNIUS, A", " Nanovesicles from Malassezia 48 sympodialis and host exosomes induce cytokine responses--novel mechanisms for host-microbe interactions in atopic eczema", " PLoS One, v", " 6, n", " 7, p", " e21480, 2011", " GHANNOUM, M", " A", " Potential role of phospholipases in virulence and fungal pathogenesis", " Clin Microbiol Rev, v", " 13, n", " 1, p", " 122-43, table of contents, Jan 2000", " GIL-BONA, A", "; LLAMA-PALACIOS, A", "; PARRA, C", " M", "; VIVANCO, F", "; NOMBELA, C", "; MONTEOLIVA, L", "; GIL, C", " Proteomics Unravels Extracellular Vesicles as Carriers of Classical Cytoplasmic Proteins in Candida albicans", " J Proteome Res, Nov 12 2014", " GILL, D", " J", "; TEO, H", "; SUN, J", "; PERISIC, O", "; VEPRINTSEV, D", " B", "; EMR, S", " D", "; WILLIAMS, R", " L", " Structural insight into the ESCRT-I/-II link and its role in MVB trafficking", " EMBO J, v", " 26, n", " 2, p", " 600-12, Jan 24 2007", " GLEESON, P", " A", "; ANDERSON, T", " J", "; STOW, J", " L", "; GRIFFITHS, G", "; TOH, B", " H", "; MATHESON, F", " p230 is associated with vesicles budding from the trans-Golgi network", " J Cell Sci, v", " 109 ( Pt 12), p", " 2811-21, Dec 1996", " GODBOLE, G", "; GANT, V", " Respiratory tract infections in the immunocompromised", " Curr Opin Pulm Med, v", " 19, n", " 3, p", " 244-50, May 2013", " GODINHO, R", " M", "; CRESTANI, J", "; KMETZSCH, L", "; ARAUJO GDE, S", "; FRASES, S", "; STAATS, C", " C", "; SCHRANK, A", "; VAINSTEIN, M", " H", "; RODRIGUES, M", " L", " The vacuolar-sorting protein Snf7 is required for export of virulence determinants in members of the Cryptococcus neoformans complex", " Sci Rep, v", " 4, p", " 6198, 2014", " GOLDBERG, J", " Structural and functional analysis of the ARF1-ARFGAP complex reveals a role for coatomer in GTP hydrolysis", " Cell, v", " 96, n", " 6, p", " 893-902, Mar 19 1999", " GOMEZ, B", " L", "; NOSANCHUK, J", " D", " Melanin and fungi", " Curr Opin Infect Dis, v", " 16, n", " 2, p", " 91-6, Apr 2003", " GRANGER, D", " L", "; PERFECT, J", " R", "; DURACK, D", " T", " Virulence of Cryptococcus neoformans", " Regulation of capsule synthesis by carbon dioxide", " J Clin Invest, v", " 76, n", " 2, p", " 508-16, Aug 1985", " 49 GRECHI, J", "; MARINHO-CARVALHO, M", "; ZANCAN, P", "; CINELLI, L", " P", "; GOMES, A", " M", "; RODRIGUES, M", " L", "; NIMRICHTER, L", "; SOLA-PENNA, M", " Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages", " J Biol Chem, v", " 286, n", " 17, p", " 14820-9, Apr 29 2011", " GRUENBERG, J", "; STENMARK, H", " The biogenesis of multivesicular endosomes", " Nat Rev Mol Cell Biol, v", " 5, n", " 4, p", " 317-23, Apr 2004", " HAGEN, F", "; CERESINI, P", " C", "; POLACHECK, I", "; MA, H", "; VAN NIEUWERBURGH, F", "; GABALDON, T", "; KAGAN, S", "; PURSALL, E", " R", "; HOOGVELD, H", " L", "; VAN IERSEL, L", " J", "; KLAU, G", " W", "; KELK, S", " M", "; STOUGIE, L", "; BARTLETT, K", " H", "; VOELZ, K", "; PRYSZCZ, L", " P", "; CASTANEDA, E", "; LAZERA, M", "; MEYER, W", "; DEFORCE, D", "; MEIS, J", " F", "; MAY, R", " C", "; KLAASSEN, C", " H", "; BOEKHOUT, T", " Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest", " PLoS One, v", " 8, n", " 8, p", " e71148, 2013", " HANSON, P", " I", "; CASHIKAR, A", " Multivesicular body morphogenesis", " Annu Rev Cell Dev Biol, v", " 28, p", " 337-62, 2012", " HARDING, C", "; HEUSER, J", "; STAHL, P", " Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding", " Eur J Cell Biol, v", " 35, n", " 2, p", " 256-63, Nov 1984", " HARDING, C", "; LEVY, M", " A", "; STAHL, P", " Morphological analysis of ligand uptake and processing: the role of multivesicular endosomes and CURL in receptor-ligand processing", " Eur J Cell Biol, v", " 36, n", " 2, p", " 230-8, Mar 1985", " HARTER, C", "; PAVEL, J", "; COCCIA, F", "; DRAKEN, E", "; WEGEHINGEL, S", "; TSCHOCHNER, H", "; WIELAND, F", " Nonclathrin coat protein gamma, a subunit of coatomer, binds to the cytoplasmic dilysine motif of membrane proteins of the early secretory pathway", " Proc Natl Acad Sci U S A, v", " 93, n", " 5, p", " 1902-6, Mar 5 1996", " HASAN, N", "; CORBIN, D", "; HU, C", " Fusogenic pairings of vesicle-associated membrane proteins (VAMPs) and plasma membrane t-SNAREs--VAMP5 as the exception", " PLoS One, v", " 5, n", " 12, p", " e14238, 2010", " HEITMAN, J", "; AMERICAN SOCIETY FOR MICROBIOLOGY", " Cryptococcus : from human pathogen to model yeast", " Washington, DC: ASM Press, 2011", " xvii, 620 p", " ISBN 9781555815011", " 50 HENNE, W", " M", "; BUCHKOVICH, N", " J", "; EMR, S", " D", " The ESCRT pathway", " Dev Cell, v", " 21, n", " 1, p", " 77-91, Jul 19 2011", " HENNE, W", " M", "; BUCHKOVICH, N", " J", "; ZHAO, Y", "; EMR, S", " D", " The endosomal sorting complex ESCRT-II mediates the assembly and architecture of ESCRT-III helices", " Cell, v", " 151, n", " 2, p", " 356-71, Oct 12 2012", " HIERRO, A", "; SUN, J", "; RUSNAK, A", " S", "; KIM, J", "; PRAG, G", "; EMR, S", " D", "; HURLEY, J", " H", " Structure of the ESCRT-II endosomal trafficking complex", " Nature, v", " 431, n", " 7005, p", " 221-5, Sep 9 2004", " HU, G", "; CAZA, M", "; CADIEUX, B", "; CHAN, V", "; LIU, V", "; KRONSTAD, J", " Cryptococcus neoformans requires the ESCRT protein Vps23 for iron acquisition from heme, for capsule formation, and for virulence", " Infect Immun, v", " 81, n", " 1, p", " 292-302, Jan 2013", " HU, G", "; KRONSTAD, J", " W", " A putative P-type ATPase, Apt1, is involved in stress tolerance and virulence in Cryptococcus neoformans", " Eukaryot Cell, v", " 9, n", " 1, p", " 74-83, Jan 2010", " HU, G", "; STEEN, B", " R", "; LIAN, T", "; SHAM, A", " P", "; TAM, N", "; TANGEN, K", " L", "; KRONSTAD, J", " W", " Transcriptional regulation by protein kinase A in Cryptococcus neoformans", " PLoS Pathog, v", " 3, n", " 3, p", " e42, Mar 2007", " HUANG, S", " H", "; WU, C", " H", "; CHANG, Y", " C", "; KWON-CHUNG, K", " J", "; BROWN, R", " J", "; JONG, A", " Cryptococcus neoformans-derived microvesicles enhance the pathogenesis of fungal brain infection", " PLoS One, v", " 7, n", " 11, p", " e48570, 2012", " HUME, A", " N", "; SEABRA, M", " C", " Melanosomes on the move: a model to understand organelle dynamics", " Biochem Soc Trans, v", " 39, n", " 5, p", " 1191-6, Oct 2011", " HURLEY, J", " H", "; EMR, S", " D", " The ESCRT complexes: structure and mechanism of a membrane-trafficking network", " Annu Rev Biophys Biomol Struct, v", " 35, p", " 277-98, 2006", " IKONEN, E", "; PARTON, R", " G", "; LAFONT, F", "; SIMONS, K", " Analysis of the role of p200-containing vesicles in post-Golgi traffic", " Mol Biol Cell, v", " 7, n", " 6, p", " 961-74, Jun 1996", " JACOBSON, E", " S", " Pathogenic roles for fungal melanins", " Clin Microbiol Rev, v", " 13, n", " 4, p", " 708-17, Oct 2000", " 51 JAHN, R", "; LANG, T", "; SUDHOF, T", " C", " Membrane fusion", " Cell, v", " 112, n", " 4, p", " 519-33, Feb 21 2003", " JANBON, G", " Cryptococcus neoformans capsule biosynthesis and regulation", " FEMS Yeast Res, v", " 4, n", " 8, p", " 765-71, Sep 2004", " JOHNSTONE, R", " M", "; ADAM, M", "; HAMMOND, J", " R", "; ORR, L", "; TURBIDE, C", " Vesicle formation during reticulocyte maturation", " Association of plasma membrane activities with released vesicles (exosomes)", " J Biol Chem, v", " 262, n", " 19, p", " 9412-20, Jul 5 1987", " JONES, C", " B", "; OTT, E", " M", "; KEENER, J", " M", "; CURTISS, M", "; SANDRIN, V", "; BABST, M", " Regulation of membrane protein degradation by starvation-response pathways", " Traffic, v", " 13, n", " 3, p", " 468-82, Mar 2012", " JONG, A", "; WU, C", " H", "; GONZALES-GOMEZ, I", "; KWON-CHUNG, K", " J", "; CHANG, Y", " C", "; TSENG, H", " K", "; CHO, W", " L", "; HUANG, S", " H", " Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection", " J Biol Chem, v", " 287, n", " 19, p", " 15298-306, May 4 2012", " JONG, A", "; WU, C", " H", "; SHACKLEFORD, G", " M", "; KWON-CHUNG, K", " J", "; CHANG, Y", " C", "; CHEN, H", " M", "; OUYANG, Y", "; HUANG, S", " H", " Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells", " Cell Microbiol, v", " 10, n", " 6, p", " 1313-26, Jun 2008", " KATZMANN, D", " J", "; BABST, M", "; EMR, S", " D", " Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I", " Cell, v", " 106, n", " 2, p", " 145-55, Jul 27 2001", " KATZMANN, D", " J", "; STEFAN, C", " J", "; BABST, M", "; EMR, S", " D", " Vps27 recruits ESCRT machinery to endosomes during MVB sorting", " J Cell Biol, v", " 162, n", " 3, p", " 413-23, Aug 4 2003", " KIDD, S", " E", "; HAGEN, F", "; TSCHARKE, R", " L", "; HUYNH, M", "; BARTLETT, K", " H", "; FYFE, M", "; MACDOUGALL, L", "; BOEKHOUT, T", "; KWON-CHUNG, K", " J", "; MEYER, W", " A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)", " Proc Natl Acad Sci U S A, v", " 101, n", " 49, p", " 17258-63, Dec 7 2004", " 52 KIM, D", " K", "; LEE, J", "; KIM, S", " R", "; CHOI, D", " S", "; YOON, Y", " J", "; KIM, J", " H", "; GO, G", "; NHUNG, D", "; HONG, K", "; JANG, S", " C", "; KIM, S", " H", "; PARK, K", " S", "; KIM, O", " Y", "; PARK, H", " T", "; SEO, J", " H", "; AIKAWA, E", "; BAJ-KRZYWORZEKA, M", "; VAN BALKOM, B", " W", "; BELTING, M", "; BLANC, L", "; BOND, V", "; BONGIOVANNI, A", "; BORRAS, F", " E", "; BUEE, L", "; BUZAS, E", " I", "; CHENG, L", "; CLAYTON, A", "; COCUCCI, E", "; DELA CRUZ, C", " S", "; DESIDERIO, D", " M", "; DI VIZIO, D", "; EKSTROM, K", "; FALCON-PEREZ, J", " M", "; GARDINER, C", "; GIEBEL, B", "; GREENING, D", " W", "; GROSS, J", " C", "; GUPTA, D", "; HENDRIX, A", "; HILL, A", " F", "; HILL, M", " M", "; NOLTE-'T HOEN, E", "; HWANG, D", " W", "; INAL, J", "; JAGANNADHAM, M", " V", "; JAYACHANDRAN, M", "; JEE, Y", " K", "; JORGENSEN, M", "; KIM, K", " P", "; KIM, Y", " K", "; KISLINGER, T", "; LASSER, C", "; LEE, D", " S", "; LEE, H", "; VAN LEEUWEN, J", "; LENER, T", "; LIU, M", " L", "; LOTVALL, J", "; MARCILLA, A", "; MATHIVANAN, S", "; MOLLER, A", "; MORHAYIM, J", "; MULLIER, F", "; NAZARENKO, I", "; NIEUWLAND, R", "; NUNES, D", " N", "; PANG, K", "; PARK, J", "; PATEL, T", "; POCSFALVI, G", "; DEL PORTILLO, H", "; PUTZ, U", "; RAMIREZ, M", " I", "; RODRIGUES, M", " L", "; ROH, T", " Y", "; ROYO, F", "; SAHOO, S", "; SCHIFFELERS, R", "; SHARMA, S", "; SILJANDER, P", "; SIMPSON, R", " J", "; SOEKMADJI, C", "; STAHL, P", "; STENSBALLE, A", "; STEPIEN, E", "; TAHARA, H", "; TRUMMER, A", "; VALADI, H", "; VELLA, L", " J", "; WAI, S", " N", "; WITWER, K", "; YANEZ-MO, M", "; YOUN, H", "; ZEIDLER, R", "; GHO, Y", " S", " EVpedia: A Community Web Portal for Extracellular Vesicles Research", " Bioinformatics, Nov 10 2014", " KIM, S", " J", "; BRANDIZZI, F", " The Plant Secretory Pathway: An Essential Factory for Building the Plant Cell Wall", " Plant Cell Physiol, Jan 27 2014", " KIRCHHAUSEN, T", " Three ways to make a vesicle", " Nat Rev Mol Cell Biol, v", " 1, n", " 3, p", " 187-98, Dec 2000", " KLUTTS, J", " S", "; YONEDA, A", "; REILLY, M", " C", "; BOSE, I", "; DOERING, T", " L", " Glycosyltransferases and their products: cryptococcal variations on fungal themes", " FEMS Yeast Res, v", " 6, n", " 4, p", " 499-512, Jun 2006", " KMETZSCH, L", "; JOFFE, L", " S", "; STAATS, C", " C", "; DE OLIVEIRA, D", " L", "; FONSECA, F", " L", "; CORDERO, R", " J", "; CASADEVALL, A", "; NIMRICHTER, L", "; SCHRANK, A", "; VAINSTEIN, M", " H", "; RODRIGUES, M", " L", " Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence", " Mol Microbiol, v", " 81, n", " 1, p", " 206-18, Jul 2011", " KORNFELD, S", "; MELLMAN, I", " The biogenesis of lysosomes", " Annu Rev Cell Biol, v", " 5, p", " 483-525, 1989", " KOSTELANSKY, M", " S", "; SUN, J", "; LEE, S", "; KIM, J", "; GHIRLANDO, R", "; HIERRO, A", "; EMR, S", " D", "; HURLEY, J", " H", " Structural and functional organization of the ESCRT-I trafficking complex", " Cell, v", " 125, n", " 1, p", " 113-26, Apr 7 2006", " 53 KRIENGKAUYKIAT, J", "; ITO, J", " I", "; DADWAL, S", " S", " Epidemiology and treatment approaches in management of invasive fungal infections", " Clin Epidemiol, v", " 3, p", " 175-91, 2011", " KULLAS, A", " L", "; LI, M", "; DAVIS, D", " A", " Snf7p, a component of the ESCRT-III protein complex, is an upstream member of the RIM101 pathway in Candida albicans", " Eukaryot Cell, v", " 3, n", " 6, p", " 1609-18, Dec 2004", " KUMAR, P", "; YANG, M", "; HAYNES, B", " C", "; SKOWYRA, M", " L", "; DOERING, T", " L", " Emerging themes in cryptococcal capsule synthesis", " Curr Opin Struct Biol, v", " 21, n", " 5, p", " 597-602, Oct 2011", " KWON-CHUNG, K", " J", "; BENNETT, J", " E", " High prevalence of Cryptococcus neoformans var", " gattii in tropical and subtropical regions", " Zentralbl Bakteriol Mikrobiol Hyg A, v", " 257, n", " 2, p", " 213-8, Jul 1984", " KWON-CHUNG, K", " J", "; FRASER, J", " A", "; DOERING, T", " L", "; WANG, Z", "; JANBON, G", "; IDNURM, A", "; BAHN, Y", " S", " Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis", " Cold Spring Harb Perspect Med, v", " 4, n", " 7, p", " a019760, Jul 2014", " KWON-CHUNG, K", " J", "; RHODES, J", " C", " Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans", " Infect Immun, v", " 51, n", " 1, p", " 218-23, Jan 1986", " LAKKARAJU, A", "; RODRIGUEZ-BOULAN, E", " Itinerant exosomes: emerging roles in cell and tissue polarity", " Trends Cell Biol, v", " 18, n", " 5, p", " 199-209, May 2008", " LAMB, T", " M", "; MITCHELL, A", " P", " The transcription factor Rim101p governs ion tolerance and cell differentiation by direct repression of the regulatory genes NRG1 and SMP1 in Saccharomyces cerevisiae", " Mol Cell Biol, v", " 23, n", " 2, p", " 677-86, Jan 2003", " LAMB, T", " M", "; XU, W", "; DIAMOND, A", "; MITCHELL, A", " P", " Alkaline response genes of Saccharomyces cerevisiae and their relationship to the RIM101 pathway", " J Biol Chem, v", " 276, n", " 3, p", " 1850-6, Jan 19 2001", " LANGELIER, C", "; VON SCHWEDLER, U", " K", "; FISHER, R", " D", "; DE DOMENICO, I", "; WHITE, P", " L", "; HILL, C", " P", "; KAPLAN, J", "; WARD, D", "; SUNDQUIST, W", " I", " Human ESCRT-II complex and its role in human immunodeficiency virus type 1 release", " J Virol, v", " 80, n", " 19, p", " 9465-80, Oct 2006", " 54 LATOUCHE, G", " N", "; HUYNH, M", "; SORRELL, T", " C", "; MEYER, W", " PCR-restriction fragment length polymorphism analysis of the phospholipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates", " Appl Environ Microbiol, v", " 69, n", " 4, p", " 2080-6, Apr 2003", " LEE, H", " C", "; BERNSTEIN, H", " D", " The targeting pathway of Escherichia coli presecretory and integral membrane proteins is specified by the hydrophobicity of the targeting signal", " Proc Natl Acad Sci U S A, v", " 98, n", " 6, p", " 3471-6, Mar 13 2001", " LENDVAI, N", "; QU, X", " W", "; HSUEH, W", "; CASADEVALL, A", " Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice", " J Immunol, v", " 164, n", " 8, p", " 4367-74, Apr 15 2000", " LI, W", "; MITCHELL, A", " P", " Proteolytic activation of Rim1p, a positive regulator of yeast sporulation and invasive growth", " Genetics, v", " 145, n", " 1, p", " 63-73, Jan 1997", " LIAW, S", " J", "; WU, H", " C", "; HSUEH, P", " R", " Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility", " Clin Microbiol Infect, v", " 16, n", " 6, p", " 696-703, Jun 2010", " LIN, X", " Cryptococcus neoformans: morphogenesis, infection, and evolution", " Infect Genet Evol, v", " 9, n", " 4, p", " 401-16, Jul 2009", " LIN, X", "; HEITMAN, J", " The biology of the Cryptococcus neoformans species complex", " Annu Rev Microbiol, v", " 60, p", " 69-105, 2006", " LIU, J", "; GUO, W", " The exocyst complex in exocytosis and cell migration", " Protoplasma, v", " 249, n", " 3, p", " 587-97, Jul 2012", " LIU, L", "; TEWARI, R", " P", "; WILLIAMSON, P", " R", " Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages", " Infect Immun, v", " 67, n", " 11, p", " 6034-9, Nov 1999", " LONG, M", "; HUANG, S", " H", "; WU, C", " H", "; SHACKLEFORD, G", " M", "; JONG, A", " Lipid raft/caveolae signaling is required for Cryptococcus neoformans invasion into human brain microvascular endothelial cells", " J Biomed Sci, v", " 19, p", " 19, 2012", " 55 LOSEV, E", "; REINKE, C", " A", "; JELLEN, J", "; STRONGIN, D", " E", "; BEVIS, B", " J", "; GLICK, B", " S", " Golgi maturation visualized in living yeast", " Nature, v", " 441, n", " 7096, p", " 1002-6, Jun 22 2006", " LU, Q", "; HOPE, L", " W", "; BRASCH, M", "; REINHARD, C", "; COHEN, S", " N", " TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation", " Proc Natl Acad Sci U S A, v", " 100, n", " 13, p", " 7626-31, Jun 24 2003", " LUHTALA, N", "; ODORIZZI, G", " Bro1 coordinates deubiquitination in the multivesicular body pathway by recruiting Doa4 to endosomes", " J Cell Biol, v", " 166, n", " 5, p", " 717-29, Aug 30 2004", " LUPAS, A", "; VAN DYKE, M", "; STOCK, J", " Predicting coiled coils from protein sequences", " Science, v", " 252, n", " 5010, p", " 1162-4, May 24 1991", " LYMAN, S", " K", "; SCHEKMAN, R", " Polypeptide translocation machinery of the yeast endoplasmic reticulum", " Experientia, v", " 52, n", " 12, p", " 1042-9, Dec 15 1996", " MA, H", "; MAY, R", " C", " Virulence in Cryptococcus species", " Adv Appl Microbiol, v", " 67, p", " 131-90, 2009", " MALHOTRA, V", " Unconventional protein secretion: an evolving mechanism", " EMBO J, v", " 32, n", " 12, p", " 1660-4, Jun 12 2013", " MALHOTRA, V", "; MAYOR, S", " Cell biology: the Golgi grows up", " Nature, v", " 441, n", " 7096, p", " 939-40, Jun 22 2006", " MALLABIABARRENA, A", "; MALHOTRA, V", " Vesicle biogenesis: the coat connection", " Cell, v", " 83, n", " 5, p", " 667-9, Dec 1 1995", " MARSH, B", " J", "; HOWELL, K", " E", " The mammalian Golgi--complex debates", " Nat Rev Mol Cell Biol, v", " 3, n", " 10, p", " 789-95, Oct 2002", " MAXSON, M", " E", "; COOK, E", "; CASADEVALL, A", "; ZARAGOZA, O", " The volume and hydration of the Cryptococcus neoformans polysaccharide capsule", " Fungal Genet Biol, v", " 44, n", " 3, p", " 180-6, Mar 2007", " 56 MAYER, A", "; WICKNER, W", "; HAAS, A", " Sec18p (NSF)-driven release of Sec17p (alpha-SNAP) can precede docking and fusion of yeast vacuoles", " Cell, v", " 85, n", " 1, p", " 83-94, Apr 5 1996", " MCCLELLAND, E", " E", "; BERNHARDT, P", "; CASADEVALL, A", " Coping with multiple virulence factors: which is most important? PLoS Pathog, v", " 1, n", " 4, p", " e40, Dec 2005", " MCFADDEN, D", "; ZARAGOZA, O", "; CASADEVALL, A", " The capsular dynamics of Cryptococcus neoformans", " Trends Microbiol, v", " 14, n", " 11, p", " 497-505, Nov 2006", " MCFADDEN, D", " C", "; DE JESUS, M", "; CASADEVALL, A", " The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction", " J Biol Chem, v", " 281, n", " 4, p", " 1868-75, Jan 27 2006", " MCNEW, J", " A", "; PARLATI, F", "; FUKUDA, R", "; JOHNSTON, R", " J", "; PAZ, K", "; PAUMET, F", "; SOLLNER, T", " H", "; ROTHMAN, J", " E", " Compartmental specificity of cellular membrane fusion encoded in SNARE proteins", " Nature, v", " 407, n", " 6801, p", " 153-9, Sep 14 2000", " MEDNICK, A", " J", "; NOSANCHUK, J", " D", "; CASADEVALL, A", " Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection", " Infect Immun, v", " 73, n", " 4, p", " 2012-9, Apr 2005", " MEYER, W", "; AANENSEN, D", " M", "; BOEKHOUT, T", "; COGLIATI, M", "; DIAZ, M", " R", "; ESPOSTO, M", " C", "; FISHER, M", "; GILGADO, F", "; HAGEN, F", "; KAOCHAROEN, S", "; LITVINTSEVA, A", " P", "; MITCHELL, T", " G", "; SIMWAMI, S", " P", "; TRILLES, L", "; VIVIANI, M", " A", "; KWON-CHUNG, J", " Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii", " Med Mycol, v", " 47, n", " 6, p", " 561-70, 2009", " MEYER, W", "; MITCHELL, T", " G", " Polymerase chain reaction fingerprinting in fungi using single primers specific to minisatellites and simple repetitive DNA sequences: strain variation in Cryptococcus neoformans", " Electrophoresis, v", " 16, n", " 9, p", " 1648-56, Sep 1995", " MICHELET, X", "; DJEDDI, A", "; LEGOUIS, R", " Developmental and cellular functions of the ESCRT machinery in pluricellular organisms", " Biol Cell, v", " 102, n", " 3, p", " 191-202, Mar 2010", " MIGNATTI, P", "; RIFKIN, D", " B", " Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem, v", " 47, n", " 3, p", " 201-7, Nov 1991", " 57 MITCHELL, T", " G", "; PERFECT, J", " R", " Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans", " Clin Microbiol Rev, v", " 8, n", " 4, p", " 515-48, Oct 1995", " MONARI, C", "; PAGANELLI, F", "; BISTONI, F", "; KOZEL, T", " R", "; VECCHIARELLI, A", " Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms", " Cell Microbiol, v", " 10, n", " 10, p", " 2129-37, Oct 2008", " NAGGIE, S", "; PERFECT, J", " R", " Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis", " Clin Chest Med, v", " 30, n", " 2, p", " 337-53, vii-viii, Jun 2009", " NEGRONI, R", " Cryptococcosis", " Clin Dermatol, v", " 30, n", " 6, p", " 599-609, Nov-Dec 2012", " NEOFYTOS, D", "; HORN, D", "; ANAISSIE, E", "; STEINBACH, W", "; OLYAEI, A", "; FISHMAN, J", "; PFALLER, M", "; CHANG, C", "; WEBSTER, K", "; MARR, K", " Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry", " Clin Infect Dis, v", " 48, n", " 3, p", " 265-73, Feb 1 2009", " NICKEL, W", " Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells", " Traffic, v", " 6, n", " 8, p", " 607-14, Aug 2005", " NICKEL, W", "; RABOUILLE, C", " Mechanisms of regulated unconventional protein secretion", " Nat Rev Mol Cell Biol, v", " 10, n", " 2, p", " 148-55, Feb 2009", " NIMRICHTER, L", "; FRASES, S", "; CINELLI, L", " P", "; VIANA, N", " B", "; NAKOUZI, A", "; TRAVASSOS, L", " R", "; CASADEVALL, A", "; RODRIGUES, M", " L", " Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations", " Eukaryot Cell, v", " 6, n", " 8, p", " 1400-10, Aug 2007", " NOSANCHUK, J", " D", "; NIMRICHTER, L", "; CASADEVALL, A", "; RODRIGUES, M", " L", " A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis", " Commun Integr Biol, v", " 1, n", " 1, p", " 37-39, 2008", " NOSANCHUK, J", " D", "; RUDOLPH, J", "; ROSAS, A", " L", "; CASADEVALL, A", " Evidence that Cryptococcus neoformans is melanized in pigeon excreta: implications for pathogenesis", " Infect Immun, v", " 67, n", " 10, p", " 5477-9, Oct 1999", " 58 NOSANCHUK, J", " D", "; VALADON, P", "; FELDMESSER, M", "; CASADEVALL, A", " Melanization of Cryptococcus neoformans in murine infection", " Mol Cell Biol, v", " 19, n", " 1, p", " 745-50, Jan 1999", " NOVERR, M", " C", "; COX, G", " M", "; PERFECT, J", " R", "; HUFFNAGLE, G", " B", " Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production", " Infect Immun, v", " 71, n", " 3, p", " 1538-47, Mar 2003", " NOVICK, P", "; FIELD, C", "; SCHEKMAN, R", " Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway", " Cell, v", " 21, n", " 1, p", " 205-15, Aug 1980", " NOVICK, P", "; GARRETT, M", " D", "; BRENNWALD, P", "; KABCENELL, A", " K", " Purification of Sec4 protein from Saccharomyces cerevisiae and Escherichia coli", " Methods Enzymol, v", " 219, p", " 352-62, 1992", " NOVICK, P", "; SCHEKMAN, R", " Secretion and cell-surface growth are blocked in a temperature-sensitive mutant of Saccharomyces cerevisiae", " Proc Natl Acad Sci U S A, v", " 76, n", " 4, p", " 1858-62, Apr 1979", " O'MEARA, T", " R", "; ALSPAUGH, J", " A", " The Cryptococcus neoformans capsule: a sword and a shield", " Clin Microbiol Rev, v", " 25, n", " 3, p", " 387-408, Jul 2012", " O'MEARA, T", " R", "; NORTON, D", "; PRICE, M", " S", "; HAY, C", "; CLEMENTS, M", " F", "; NICHOLS, C", " B", "; ALSPAUGH, J", " A", " Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule", " PLoS Pathog, v", " 6, n", " 2, p", " e1000776, Feb 2010", " O'MEARA, T", " R", "; XU, W", "; SELVIG, K", " M", "; O'MEARA, M", " J", "; MITCHELL, A", " P", "; ALSPAUGH, J", " A", " The Cryptococcus neoformans Rim101 transcription factor directly regulates genes required for adaptation to the host", " Mol Cell Biol, v", " 34, n", " 4, p", " 673-84, Feb 2014", " ODOM, A", "; MUIR, S", "; LIM, E", "; TOFFALETTI, D", " L", "; PERFECT, J", "; HEITMAN, J", " Calcineurin is required for virulence of Cryptococcus neoformans", " EMBO J, v", " 16, n", " 10, p", " 2576-89, May 15 1997", " ODORIZZI, G", "; KATZMANN, D", " J", "; BABST, M", "; AUDHYA, A", "; EMR, S", " D", " Bro1 is an endosome-associated protein that functions in the MVB pathway in Saccharomyces cerevisiae", " J Cell Sci, v", " 116, n", " Pt 10, p", " 1893-903, May 15 2003", " 59 OHYA, T", "; MIACZYNSKA, M", "; COSKUN, U", "; LOMMER, B", "; RUNGE, A", "; DRECHSEL, D", "; KALAIDZIDIS, Y", "; ZERIAL, M", " Reconstitution of Rab- and SNARE-dependent membrane fusion by synthetic endosomes", " Nature, v", " 459, n", " 7250, p", " 1091-7, Jun 25 2009", " OLIVEIRA, D", "; RIZZO, J", "; JOFFE, L", "; GODINHO, R", "; RODRIGUES, M", " Where Do They Come from and Where Do They Go: Candidates for Regulating Extracellular Vesicle Formation in Fungi", " International Journal of Molecular Sciences, v", " 14, n", " 5, p", " 9581-9603, 2013", " OLIVEIRA, D", " L", "; FREIRE-DE-LIMA, C", " G", "; NOSANCHUK, J", " D", "; CASADEVALL, A", "; RODRIGUES, M", " L", "; NIMRICHTER, L", " Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions", " Infect Immun, v", " 78, n", " 4, p", " 1601-9, Apr 2010", " OLIVEIRA, D", " L", "; NAKAYASU, E", " S", "; JOFFE, L", " S", "; GUIMARAES, A", " J", "; SOBREIRA, T", " J", "; NOSANCHUK, J", " D", "; CORDERO, R", " J", "; FRASES, S", "; CASADEVALL, A", "; ALMEIDA, I", " C", "; NIMRICHTER, L", "; RODRIGUES, M", " L", " Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis", " PLoS One, v", " 5, n", " 6, p", " e11113, 2010", " OLIVEIRA, D", " L", "; NIMRICHTER, L", "; MIRANDA, K", "; FRASES, S", "; FAULL, K", " F", "; CASADEVALL, A", "; RODRIGUES, M", " L", " Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan", " Fungal Genet Biol, v", " 46, n", " 12, p", " 956-63, Dec 2009", " OLSZEWSKI, M", " A", "; NOVERR, M", " C", "; CHEN, G", " H", "; TOEWS, G", " B", "; COX, G", " M", "; PERFECT, J", " R", "; HUFFNAGLE, G", " B", " Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion", " Am J Pathol, v", " 164, n", " 5, p", " 1761-71, May 2004", " ORCI, L", "; STAMNES, M", "; RAVAZZOLA, M", "; AMHERDT, M", "; PERRELET, A", "; SOLLNER, T", " H", "; ROTHMAN, J", " E", " Bidirectional transport by distinct populations of COPI-coated vesicles", " Cell, v", " 90, n", " 2, p", " 335-49, Jul 25 1997", " ORSI, C", " F", "; COLOMBARI, B", "; ARDIZZONI, A", "; PEPPOLONI, S", "; NEGLIA, R", "; POSTERARO, B", "; MORACE, G", "; FADDA, G", "; BLASI, E", " The ABC transporter-encoding gene AFR1 affects the resistance of Cryptococcus neoformans to microglia-mediated antifungal activity by delaying phagosomal maturation", " FEMS Yeast Res, v", " 9, n", " 2, p", " 301-10, Mar 2009", " 60 PALADE, G", " Intracellular aspects of the process of protein synthesis", " Science, v", " 189, n", " 4206, p", " 867, Sep 12 1975", " PAN, B", " T", "; TENG, K", "; WU, C", "; ADAM, M", "; JOHNSTONE, R", " M", " Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes", " J Cell Biol, v", " 101, n", " 3, p", " 942-8, Sep 1985", " PANEPINTO, J", "; KOMPERDA, K", "; FRASES, S", "; PARK, Y", " D", "; DJORDJEVIC, J", " T", "; CASADEVALL, A", "; WILLIAMSON, P", " R", " Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans", " Mol Microbiol, v", " 71, n", " 5, p", " 1165-76, Mar 2009", " PAPANIKOU, E", "; GLICK, B", " S", " Golgi compartmentation and identity", " Curr Opin Cell Biol, v", " 29, p", " 74-81, Aug 2014", " PARK, B", " J", "; WANNEMUEHLER, K", " A", "; MARSTON, B", " J", "; GOVENDER, N", "; PAPPAS, P", " G", "; CHILLER, T", " M", " Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS", " AIDS, v", " 23, n", " 4, p", " 525-30, Feb 20 2009", " PASQUALOTTO, A", " C", "; DENNING, D", " W", " New and emerging treatments for fungal infections", " J Antimicrob Chemother, v", " 61 Suppl 1, p", " i19-30, Jan 2008", " PEÑALVA, M", " A", "; ARST, H", " N", " Regulation of gene expression by ambient pH in filamentous fungi and yeasts", " Microbiol Mol Biol Rev, v", " 66, n", " 3, p", " 426-46, table of contents, Sep 2002", " PERFECT, J", " R", " Cryptococcus neoformans: a sugar-coated killer with designer genes", " FEMS Immunol Med Microbiol, v", " 45, n", " 3, p", " 395-404, Sep 1 2005", " ______", " Cryptococcosis: a model for the understanding of infectious diseases", " J Clin Invest, v", " 124, n", " 5, p", " 1893-5, May 1 2014", " PERFECT, J", " R", "; CASADEVALL, A", " Cryptococcosis", " Infect Dis Clin North Am, v", " 16, n", " 4, p", " 837-74, v-vi, Dec 2002", " PERLROTH, J", "; CHOI, B", "; SPELLBERG, B", " Nosocomial fungal infections: epidemiology, diagnosis, and treatment", " Med Mycol, v", " 45, n", " 4, p", " 321-46, Jun 2007", " 61 PFALLER, M", " A", "; BOYKEN, L", "; HOLLIS, R", " J", "; MESSER, S", " A", "; TENDOLKAR, S", "; DIEKEMA, D", " J", " In vitro susceptibilities of Candida spp", " to caspofungin: four years of global surveillance", " J Clin Microbiol, v", " 44, n", " 3, p", " 760-3, Mar 2006", " PFALLER, M", " A", "; DIEKEMA, D", " J", " Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus", " J Clin Microbiol, v", " 42, n", " 10, p", " 4419-31, Oct 2004", " ______", " Epidemiology of invasive candidiasis: a persistent public health problem", " Clin Microbiol Rev, v", " 20, n", " 1, p", " 133-63, Jan 2007", " ______", " Epidemiology of invasive mycoses in North America", " Crit Rev Microbiol, v", " 36, n", " 1, p", " 1-53, 2010", " PIPER, R", " C", "; KATZMANN, D", " J", " Biogenesis and function of multivesicular bodies", " Annu Rev Cell Dev Biol, v", " 23, p", " 519-47, 2007", " PITARCH, A", "; DIEZ-OREJAS, R", "; MOLERO, G", "; PARDO, M", "; SANCHEZ, M", "; GIL, C", "; NOMBELA, C", " Analysis of the serologic response to systemic Candida albicans infection in a murine model", " Proteomics, v", " 1, n", " 4, p", " 550-9, Apr 2001", " POOL, M", " R", " Signal recognition particles in chloroplasts, bacteria, yeast and mammals (review)", " Mol Membr Biol, v", " 22, n", " 1-2, p", " 3-15, Jan-Apr 2005", " PRADO, M", "; DA SILVA, M", " B", "; LAURENTI, R", "; TRAVASSOS, L", " R", "; TABORDA, C", " P", " Mortality due to systemic mycoses as a primary cause of death or in association with AIDS in Brazil: a review from 1996 to 2006", " Mem Inst Oswaldo Cruz, v", " 104, n", " 3, p", " 513-21, May 2009", " PROCOP, G", " W", "; ROBERTS, G", " D", " Emerging fungal diseases: the importance of the host", " Clin Lab Med, v", " 24, n", " 3, p", " 691-719, vi-vii, Sep 2004", " QIU, Y", "; DAVIS, M", " J", "; DAYRIT, J", " K", "; HADD, Z", "; MEISTER, D", " L", "; OSTERHOLZER, J", " J", "; WILLIAMSON, P", " R", "; OLSZEWSKI, M", " A", " Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice", " PLoS One, v", " 7, n", " 10, p", " e47853, 2012", " 62 RAETZ, C", " R", "; WHITFIELD, C", " Lipopolysaccharide endotoxins", " Annu Rev Biochem, v", " 71, p", " 635-700, 2002", " RAIBORG, C", "; BREMNES, B", "; MEHLUM, A", "; GILLOOLY, D", " J", "; D'ARRIGO, A", "; STANG, E", "; STENMARK, H", " FYVE and coiled-coil domains determine the specific localisation of Hrs to early endosomes", " J Cell Sci, v", " 114, n", " Pt 12, p", " 2255-63, Jun 2001", " RAMOS, C", " L", "; FONSECA, F", " L", "; RODRIGUES, J", "; GUIMARAES, A", " J", "; CINELLI, L", " P", "; MIRANDA, K", "; NIMRICHTER, L", "; CASADEVALL, A", "; TRAVASSOS, L", " R", "; RODRIGUES, M", " L", " Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties", " Eukaryot Cell, v", " 11, n", " 9, p", " 1086-94, Sep 2012", " RETINI, C", "; VECCHIARELLI, A", "; MONARI, C", "; BISTONI, F", "; KOZEL, T", " R", " Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes", " Infect Immun, v", " 66, n", " 2, p", " 664-9, Feb 1998", " RHOME, R", "; SINGH, A", "; KECHICHIAN, T", "; DRAGO, M", "; MORACE, G", "; LUBERTO, C", "; DEL POETA, M", " Surface localization of glucosylceramide during Cryptococcus neoformans infection allows targeting as a potential antifungal", " PLoS One, v", " 6, n", " 1, p", " e15572, 2011", " RICE, L", " M", "; BRUNGER, A", " T", " Crystal structure of the vesicular transport protein Sec17: implications for SNAP function in SNARE complex disassembly", " Mol Cell, v", " 4, n", " 1, p", " 85-95, Jul 1999", " RICHARDSON, M", "; LASS-FLORL, C", " Changing epidemiology of systemic fungal infections", " Clin Microbiol Infect, v", " 14 Suppl 4, p", " 5-24, May 2008", " RIZZO, J", "; OLIVEIRA, D", " L", "; JOFFE, L", " S", "; HU, G", "; GAZOS-LOPES, F", "; FONSECA, F", " L", "; ALMEIDA, I", " C", "; FRASES, S", "; KRONSTAD, J", " W", "; RODRIGUES, M", " L", " Role of the Apt1 Protein in Polysaccharide Secretion by Cryptococcus neoformans", " Eukaryot Cell, v", " 13, n", " 6, p", " 715-26, Jun 2014", " RODRIGUES, M", " L", "; ALVAREZ, M", "; FONSECA, F", " L", "; CASADEVALL, A", " Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan", " Eukaryot Cell, v", " 7, n", " 4, p", " 602-9, Apr 2008", " 63 RODRIGUES, M", " L", "; FONSECA, F", " L", "; FRASES, S", "; CASADEVALL, A", "; NIMRICHTER, L", " The still obscure attributes of cryptococcal glucuronoxylomannan", " Med Mycol, p", " 1-7, Apr 3 2009", " RODRIGUES, M", " L", "; FRANZEN, A", " J", "; NIMRICHTER, L", "; MIRANDA, K", " Vesicular mechanisms of traffic of fungal molecules to the extracellular space", " Curr Opin Microbiol, v", " 16, n", " 4, p", " 414-20, Aug 2013", " RODRIGUES, M", " L", "; NAKAYASU, E", " S", "; OLIVEIRA, D", " L", "; NIMRICHTER, L", "; NOSANCHUK, J", " D", "; ALMEIDA, I", " C", "; CASADEVALL, A", " Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence", " Eukaryot Cell, v", " 7, n", " 1, p", " 58-67, Jan 2008", " RODRIGUES, M", " L", "; NIMRICHTER, L", "; OLIVEIRA, D", " L", "; FRASES, S", "; MIRANDA, K", "; ZARAGOZA, O", "; ALVAREZ, M", "; NAKOUZI, A", "; FELDMESSER, M", "; CASADEVALL, A", " Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport", " Eukaryot Cell, v", " 6, n", " 1, p", " 48-59, Jan 2007", " RUBARTELLI, A", "; COZZOLINO, F", "; TALIO, M", "; SITIA, R", " A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence", " EMBO J, v", " 9, n", " 5, p", " 1503-10, May 1990", " SAKSENA, S", "; EMR, S", " D", " ESCRTs and human disease", " Biochem Soc Trans, v", " 37, n", " Pt 1, p", " 167-72, Feb 2009", " SAKSENA, S", "; SUN, J", "; CHU, T", "; EMR, S", " D", " ESCRTing proteins in the endocytic pathway", " Trends Biochem Sci, v", " 32, n", " 12, p", " 561-73, Dec 2007", " SANCHEZ, A", "; ESCANDON, P", "; CASTANEDA, E", " [In vitro determination of virulence factors activity associated with several Cryptococcus neoformans clinical isolates]", " Rev Iberoam Micol, v", " 25, n", " 3, p", " 145-9, Sep 30 2008", " SANGUINETTI, M", "; POSTERARO, B", "; LA SORDA, M", "; TORELLI, R", "; FIORI, B", "; SANTANGELO, R", "; DELOGU, G", "; FADDA, G", " Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans", " Infect Immun, v", " 74, n", " 2, p", " 1352-9, Feb 2006", " SANTANGELO, R", "; ZOELLNER, H", "; SORRELL, T", "; WILSON, C", "; DONALD, C", "; DJORDJEVIC, J", "; SHOUNAN, Y", "; WRIGHT, L", " Role of extracellular phospholipases and 64 mononuclear phagocytes in dissemination of cryptococcosis in a murine model", " Infect Immun, v", " 72, n", " 4, p", " 2229-39, Apr 2004", " SCALES, S", " J", "; CHEN, Y", " A", "; YOO, B", " Y", "; PATEL, S", " M", "; DOUNG, Y", " C", "; SCHELLER, R", " H", " SNAREs contribute to the specificity of membrane fusion", " Neuron, v", " 26, n", " 2, p", " 457-64, May 2000", " SCHAFER, T", "; ZENTGRAF, H", "; ZEHE, C", "; BRUGGER, B", "; BERNHAGEN, J", "; NICKEL, W", " Unconventional secretion of fibroblast growth factor 2 is mediated by direct translocation across the plasma membrane of mammalian cells", " J Biol Chem, v", " 279, n", " 8, p", " 6244-51, Feb 20 2004", " SCHEKMAN, R", "; NOVICK, P", " 23 genes, 23 years later", " Cell, v", " 116, n", " 2 Suppl, p", " S13-5, 1 p following S19, Jan 23 2004", " SCHNEIDER, P", "; HOLLER, N", "; BODMER, J", " L", "; HAHNE, M", "; FREI, K", "; FONTANA, A", "; TSCHOPP, J", " Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity", " J Exp Med, v", " 187, n", " 8, p", " 1205-13, Apr 20 1998", " SCHOREY, J", " S", "; BHATNAGAR, S", " Exosome function: from tumor immunology to pathogen biology", " Traffic, v", " 9, n", " 6, p", " 871-81, Jun 2008", " SCOTT, A", "; GASPAR, J", "; STUCHELL-BRERETON, M", " D", "; ALAM, S", " L", "; SKALICKY, J", " J", "; SUNDQUIST, W", " I", " Structure and ESCRT-III protein interactions of the MIT domain of human VPS4A", " Proc Natl Acad Sci U S A, v", " 102, n", " 39, p", " 13813-8, Sep 27 2005", " SEGEV, N", " Ypt/rab gtpases: regulators of protein trafficking", " Sci STKE, v", " 2001, n", " 100, p", " re11, Sep 18 2001", " SEGHIR, A", "; BOUCHERIT-OTMANI, Z", "; BELKHERROUBI-SARI, L", "; BOUCHERIT, K", " [Catheterization and fungal infection risk in the University Hospital of Tlemcen: Epidemiology and susceptibility to antifungals", "]", " J Mycol Med, Oct 25 2014", " SHESTAKOVA, A", "; HANONO, A", "; DROSNER, S", "; CURTISS, M", "; DAVIES, B", " A", "; KATZMANN, D", " J", "; BABST, M", " Assembly of the AAA ATPase Vps4 on ESCRT-III", " Mol Biol Cell, v", " 21, n", " 6, p", " 1059-71, Mar 15 2010", " 65 SHI, M", "; LI, S", " S", "; ZHENG, C", "; JONES, G", " J", "; KIM, K", " S", "; ZHOU, H", "; KUBES, P", "; MODY, C", " H", " Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain", " J Clin Invest, v", " 120, n", " 5, p", " 1683-93, May 2010", " SHIELDS, S", " B", "; PIPER, R", " C", " How ubiquitin functions with ESCRTs", " Traffic, v", " 12, n", " 10, p", " 1306-17, Oct 2011", " SHIH, S", " C", "; KATZMANN, D", " J", "; SCHNELL, J", " D", "; SUTANTO, M", "; EMR, S", " D", "; HICKE, L", " Epsins and Vps27p/Hrs contain ubiquitin-binding domains that function in receptor endocytosis", " Nat Cell Biol, v", " 4, n", " 5, p", " 389-93, May 2002", " SILVA, B", " M", "; PRADOS-ROSALES, R", "; ESPADAS-MORENO, J", "; WOLF, J", " M", "; LUQUE-GARCIA, J", " L", "; GONCALVES, T", "; CASADEVALL, A", " Characterization of Alternaria infectoria extracellular vesicles", " Med Mycol, v", " 52, n", " 2, p", " 202-10, Feb 2014", " SILVEIRA, C", " P", "; PIFFER, A", " C", "; KMETZSCH, L", "; FONSECA, F", " L", "; SOARES, D", " A", "; STAATS, C", " C", "; RODRIGUES, M", " L", "; SCHRANK, A", "; VAINSTEIN, M", " H", " The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells", " Fungal Genet Biol, v", " 60, p", " 53-63, Nov 2013", " SIMONS, M", "; RAPOSO, G", " Exosomes--vesicular carriers for intercellular communication", " Curr Opin Cell Biol, v", " 21, n", " 4, p", " 575-81, Aug 2009", " SONNICHSEN, B", "; DE RENZIS, S", "; NIELSEN, E", "; RIETDORF, J", "; ZERIAL, M", " Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11", " J Cell Biol, v", " 149, n", " 4, p", " 901-14, May 15 2000", " SPANG, A", "; SCHEKMAN, R", " Reconstitution of retrograde transport from the Golgi to the ER in vitro", " J Cell Biol, v", " 143, n", " 3, p", " 589-99, Nov 2 1998", " STEENBERGEN, J", " N", "; CASADEVALL, A", " The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans", " Microbes Infect, v", " 5, n", " 7, p", " 667-75, Jun 2003", " STEIN, K", "; CHIANG, H", " L", " Exocytosis and Endocytosis of Small Vesicles across the Plasma Membrane in Saccharomyces cerevisiae", " Membranes (Basel), v", " 4, n", " 3, p", " 608-29, 2014", " 66 SUTTON, R", " B", "; FASSHAUER, D", "; JAHN, R", "; BRUNGER, A", " T", " Crystal structure of a SNARE complex involved in synaptic exocytosis at 2", "4 A resolution", " Nature, v", " 395, n", " 6700, p", " 347-53, Sep 24 1998", " SYME, R", " M", "; BRUNO, T", " F", "; KOZEL, T", " R", "; MODY, C", " H", " The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody", " Infect Immun, v", " 67, n", " 9, p", " 4620-7, Sep 1999", " TAKEO, K", "; UESAKA, I", "; UEHIRA, K", "; NISHIURA, M", " Fine structure of Cryptococcus neoformans grown in vitro as observed by freeze-etching", " J Bacteriol, v", " 113, n", " 3, p", " 1442-8, Mar 1973", " TANAKA, M", "; ITAI, T", "; ADACHI, M", "; NAGATA, S", " Downregulation of Fas ligand by shedding", " Nat Med, v", " 4, n", " 1, p", " 31-6, Jan 1998", " TEIS, D", "; SAKSENA, S", "; EMR, S", " D", " Ordered assembly of the ESCRT-III complex on endosomes is required to sequester cargo during MVB formation", " Dev Cell, v", " 15, n", " 4, p", " 578-89, Oct 2008", " TEIS, D", "; SAKSENA, S", "; JUDSON, B", " L", "; EMR, S", " D", " ESCRT-II coordinates the assembly of ESCRT-III filaments for cargo sorting and multivesicular body vesicle formation", " EMBO J, v", " 29, n", " 5, p", " 871-83, Mar 3 2010", " TEO, H", "; GILL, D", " J", "; SUN, J", "; PERISIC, O", "; VEPRINTSEV, D", " B", "; VALLIS, Y", "; EMR, S", " D", "; WILLIAMS, R", " L", " ESCRT-I core and ESCRT-II GLUE domain structures reveal role for GLUE in linking to ESCRT-I and membranes", " Cell, v", " 125, n", " 1, p", " 99-111, Apr 7 2006", " TEO, H", "; PERISIC, O", "; GONZALEZ, B", "; WILLIAMS, R", " L", " ESCRT-II, an endosome-associated complex required for protein sorting: crystal structure and interactions with ESCRT-III and membranes", " Dev Cell, v", " 7, n", " 4, p", " 559-69, Oct 2004", " THERY, C", "; OSTROWSKI, M", "; SEGURA, E", " Membrane vesicles as conveyors of immune responses", " Nat Rev Immunol, v", " 9, n", " 8, p", " 581-93, Aug 2009", " TILBURN, J", "; SÁNCHEZ-FERRERO, J", " C", "; REOYO, E", "; ARST, H", " N", "; PEÑALVA, M", " A", " Mutational analysis of the pH signal transduction component PalC of Aspergillus nidulans supports distant similarity to BRO1 domain family members", " Genetics, v", " 171, n", " 1, p", " 393-401, Sep 2005", " 67 TOFFALETTI, D", " L", "; DEL POETA, M", "; RUDE, T", " H", "; DIETRICH, F", "; PERFECT, J", " R", " Regulation of cytochrome c oxidase subunit 1 (COX1) expression in Cryptococcus neoformans by temperature and host environment", " Microbiology, v", " 149, n", " Pt 4, p", " 1041-9, Apr 2003", " TRAMS, E", " G", "; LAUTER, C", " J", "; SALEM, N", ", JR", "; HEINE, U", " Exfoliation of membrane ecto-enzymes in the form of micro-vesicles", " Biochim Biophys Acta, v", " 645, n", " 1, p", " 63-70, Jul 6 1981", " TU, J", "; VALLIER, L", " G", "; CARLSON, M", " Molecular and genetic analysis of the SNF7 gene in Saccharomyces cerevisiae", " Genetics, v", " 135, n", " 1, p", " 17-23, Sep 1993", " TUREL, O", " Newer antifungal agents", " Expert Rev Anti Infect Ther, v", " 9, n", " 3, p", " 325-38, Mar 2011", " VALADI, H", "; EKSTROM, K", "; BOSSIOS, A", "; SJOSTRAND, M", "; LEE, J", " J", "; LOTVALL, J", " O", " Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", " Nat Cell Biol, v", " 9, n", " 6, p", " 654-9, Jun 2007", " VALLEJO, M", " C", "; MATSUO, A", " L", "; GANIKO, L", "; MEDEIROS, L", " C", "; MIRANDA, K", "; SILVA, L", " S", "; FREYMULLER-HAAPALAINEN, E", "; SINIGAGLIA-COIMBRA, R", "; ALMEIDA, I", " C", "; PUCCIA, R", " The pathogenic fungus Paracoccidioides brasiliensis exports extracellular vesicles containing highly immunogenic alpha-Galactosyl epitopes", " Eukaryot Cell, v", " 10, n", " 3, p", " 343-51, Mar 2011", " VALLIER, L", " G", "; CARLSON, M", " New SNF genes, GAL11 and GRR1 affect SUC2 expression in Saccharomyces cerevisiae", " Genetics, v", " 129, n", " 3, p", " 675-84, Nov 1991", " VARGAS, G", "; ROCHA, J", " D", "; OLIVEIRA, D", " L", "; ALBUQUERQUE, P", " C", "; FRASES, S", "; SANTOS, S", " S", "; NOSANCHUK, J", " D", "; GOMES, A", " M", "; SOARES MEDEIROS, L", " C", "; MIRANDA, K", " R", "; SOBREIRA, T", "; NAKAYASU, E", " S", "; ARIGI, E", " A", "; CASADEVALL, A", "; GUIMARAES, A", " J", "; RODRIGUES, M", " L", "; FREIRE-DE-LIMA, C", " G", "; ALMEIDA, I", " C", "; NIMRICHTER, L", " Compositional and immunobiological analyses of extracellular vesicles released by Candida albicans", " Cell Microbiol, Oct 6 2014", " VARTIVARIAN, S", " E", "; REYES, G", " H", "; JACOBSON, E", " S", "; JAMES, P", " G", "; CHERNIAK, R", "; MUMAW, V", " R", "; TINGLER, M", " J", " Localization of mannoprotein in Cryptococcus neoformans", " J Bacteriol, v", " 171, n", " 12, p", " 6850-2, Dec 1989", " 68 VECCHIARELLI, A", "; PIETRELLA, D", "; LUPO, P", "; BISTONI, F", "; MCFADDEN, D", " C", "; CASADEVALL, A", " The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation", " J Leukoc Biol, v", " 74, n", " 3, p", " 370-8, Sep 2003", " VECCHIARELLI, A", "; RETINI, C", "; PIETRELLA, D", "; MONARI, C", "; TASCINI, C", "; BECCARI, T", "; KOZEL, T", " R", " Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes", " Infect Immun, v", " 63, n", " 8, p", " 2919-23, Aug 1995", " VILLENA, S", " N", "; PINHEIRO, R", " O", "; PINHEIRO, C", " S", "; NUNES, M", " P", "; TAKIYA, C", " M", "; DOSREIS, G", " A", "; PREVIATO, J", " O", "; MENDONCA-PREVIATO, L", "; FREIRE-DE-LIMA, C", " G", " Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand", " Cell Microbiol, v", " 10, n", " 6, p", " 1274-85, Jun 2008", " WEISS, P", "; HUPPERT, S", "; KOLLING, R", " Analysis of the dual function of the ESCRT-III protein Snf7 in endocytic trafficking and in gene expression", " Biochem J, v", " 424, n", " 1, p", " 89-97, Nov 15 2009", " WHITE, P", " L", "; PERRY, M", " D", "; BARNES, R", " A", " An update on the molecular diagnosis of invasive fungal disease", " FEMS Microbiol Lett, v", " 296, n", " 1, p", " 1-10, Jul 2009", " WHITFIELD, C", " Biosynthesis and assembly of capsular polysaccharides in Escherichia coli", " Annu Rev Biochem, v", " 75, p", " 39-68, 2006", " WHITFIELD, C", "; KANIUK, N", "; FRIRDICH, E", " Molecular insights into the assembly and diversity of the outer core oligosaccharide in lipopolysaccharides from Escherichia coli and Salmonella", " J Endotoxin Res, v", " 9, n", " 4, p", " 244-9, 2003", " WILLIAMS, R", " L", "; URBE, S", " The emerging shape of the ESCRT machinery", " Nat Rev Mol Cell Biol, v", " 8, n", " 5, p", " 355-68, May 2007", " WILLIAMSON, P", " R", " Laccase and melanin in the pathogenesis of Cryptococcus neoformans", " Front Biosci, v", " 2, p", " e99-107, 1997", " WILSON, L", " S", "; REYES, C", " M", "; STOLPMAN, M", "; SPECKMAN, J", "; ALLEN, K", "; BENEY, J", " The direct cost and incidence of systemic fungal infections", " Value Health, v", " 5, n", " 1, p", " 26-34, Jan-Feb 2002", " 69 WOLF, J", "; ESPADAS-MORENO, J", "; LUQUE-GARCIA, J", " L", "; CASADEVALL, A", " Interaction of Cryptococcus neoformans extracellular vesicles with the cell wall", " Eukaryot Cell, Jun 6 2014", " WOLF, J", " M", "; DAVIS, D", " A", " Mutational analysis of Candida albicans SNF7 reveals genetically separable Rim101 and ESCRT functions and demonstrates divergence in bro1-domain protein interactions", " Genetics, v", " 184, n", " 3, p", " 673-94, Mar 2010", " WRIGHT, L", " C", "; PAYNE, J", "; SANTANGELO, R", " T", "; SIMPANYA, M", " F", "; CHEN, S", " C", "; WIDMER, F", "; SORRELL, T", " C", " Cryptococcal phospholipases: a novel lysophospholipase discovered in the pathogenic fungus Cryptococcus gattii", " Biochem J, v", " 384, n", " Pt 2, p", " 377-84, Dec 1 2004", " WUESTEHUBE, L", " J", "; DUDEN, R", "; EUN, A", "; HAMAMOTO, S", "; KORN, P", "; RAM, R", "; SCHEKMAN, R", " New mutants of Saccharomyces cerevisiae affected in the transport of proteins from the endoplasmic reticulum to the Golgi complex", " Genetics, v", " 142, n", " 2, p", " 393-406, Feb 1996", " XU, W", "; SMITH, F", " J", "; SUBARAN, R", "; MITCHELL, A", " P", " Multivesicular body-ESCRT components function in pH response regulation in Saccharomyces cerevisiae and Candida albicans", " Mol Biol Cell, v", " 15, n", " 12, p", " 5528-37, Dec 2004", " YAUCH, L", " E", "; MANSOUR, M", " K", "; SHOHAM, S", "; ROTTMAN, J", " B", "; LEVITZ, S", " M", " Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo", " Infect Immun, v", " 72, n", " 9, p", " 5373-82, Sep 2004", " YONEDA, A", "; DOERING, T", " L", " A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis", " Mol Biol Cell, v", " 17, n", " 12, p", " 5131-40, Dec 2006", " ______", " An unusual organelle in Cryptococcus neoformans links luminal pH and capsule biosynthesis", " Fungal Genet Biol, v", " 46, n", " 9, p", " 682-7, Sep 2009", " ZARAGOZA, O", "; RODRIGUES, M", " L", "; DE JESUS, M", "; FRASES, S", "; DADACHOVA, E", "; CASADEVALL, A", " The capsule of the fungal pathogen Cryptococcus neoformans", " Adv Appl Microbiol, v", " 68, p", " 133-216, 2009a", " 70 ______", " Chapter 4 the capsule of the fungal pathogen Cryptococcus neoformans", " Adv Appl Microbiol, v", " 68, p", " 133-216, 2009b", " ZILBERBERG, M", " D", "; SHORR, A", " F", "; KOLLEF, M", " H", " Secular trends in candidemia-related hospitalization in the United States, 2000-2005", " Infect Control Hosp Epidemiol, v", " 29, n", " 10, p", " 978-80, Oct 2008", " 71 Trabalho não relacionado publicado durante o período • Regulation of HIV-Gag Expression and Targeting to the Endolysosomal/Secretory Pathway by the Luminal Domain of Lysosomal-Associated Membrane Protein (LAMP-1) Enhance Gag-Specific Immune Response Regulation of HIV-Gag Expression and Targeting to the Endolysosomal/Secretory Pathway by the Luminal Domain of Lysosomal-Associated Membrane Protein (LAMP-1) Enhance Gag-Specific Immune Response Rodrigo Maciel da Costa Godinho1", ", Flavio Lemos Matassoli1", ", Carolina Gonc ¸alves de Oliveira Lucas1, Paula Ordonhez Rigato , Jorge Luiz Santos Gonc2¸alves,MariaNotomiSato,MiltonMaciel Jr", "3 2 4,5, Ligia Maria Torres Pec ¸anha , J", " Thomas August , Ernesto Torres de Azevedo Marques Jr", "3 5 5,6,7, Luciana Barros de Arruda1* 1Departamento de Virologia, Instituto de Microbiologia Paulo de Go ´es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 2Laboratorio de Dermatologia e Imunodeficiencias, LIM-56, Departamento de Dermatologia, Faculdade de Medicina, Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Brazil, 3Departamento de Imunologia, Instituto de Microbiologia Paulo de Go ´es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 4Enteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland, United States of America, 5Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America, 6Department of Infectious Diseases and Microbiology, Center for Vaccine Research, Pittsburgh, Pennsylvania, United States of America, 7Departamento de Virologia, Fiocruz – Pernambuco, Recife, Brazil Abstract We have previously demonstrated that a DNA vaccine encoding HIV-p55 gag in association with the lysosomal associated membrane protein-1 (LAMP-1) elicited a greater Gag-specific immune response, in comparison to a DNA encoding the native gag", " In vitro studies have also demonstrated that LAMP/Gag was highly expressed and was present in MHCII containing compartments in transfected cells", " In this study, the mechanisms involved in these processes and the relative contributions of the increased expression and altered traffic for the enhanced immune response were addressed", " Cells transfected with plasmid DNA constructs containing p55 gag attached to truncated sequences of LAMP-1 showed that the increased expression of gag mRNA required p55 gag in frame with at least 741 bp of the LAMP-1 luminal domain", " LAMP luminal domain also showed to be essential for Gag traffic through lysosomes and, in this case, the whole sequence was required", " Further analysis of the trafficking pathway of the intact LAMP/Gag chimera demonstrated that it was secreted, at least in part, associated with exosome-like vesicles", " Immunization of mice with LAMP/ gag chimeric plasmids demonstrated that high expression level alone can induce a substantial transient antibody response, but targeting of the antigen to the endolysosomal/secretory pathways was required for establishment of cellular and memory response", " The intact LAMP/ gag construct induced polyfunctional CD4+T cell response, which presence at the time of immunization was required for CD8+T cell priming", " LAMP-mediated targeting to endolysosomal/secretory pathway is an important new mechanistic element in LAMP-mediated enhanced immunity with applications to the development of novel anti-HIV vaccines and to general vaccinology field", "", "Citation: Godinho RMdC, Matassoli FL, Lucas CGdO, Rigato PO, Gonc ¸alves JLS, et al. (2014) Regulation of HIV-Gag Expression and Targeting to the Endolysosomal/Secretory Pathway by the Luminal Domain of Lysosomal-Associated Membrane Protein (LAMP-1) Enhance Gag-Specific Immune Response. PLoS Editor: Xiao-Fang Yu, Johns Hopkins School of Public Health, United States of America Received February 5, 2013; Accepted May 19, 2014; Published June 16, 2014 Copyright: /C2232014 Godinho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported by Grants R37-AI41908 and R21-AI44317 from the National Institute of Allergy and Infectious Diseases, National Institutes o f Health; and by Brazilian Ministry of Health, CAPES, CNPq, FAPERJ, and FINEP. R.M.C. Godinho and F.L. Matassoli were the recipients of a CNPq fellowshi p; C.G.O. Lucas was the recipient of a FAPERJ fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparat ion of the manuscript.", "Competing Interests: The authors have declared that no competing interests exist.", "* Email: arruda@micro.ufrj.br .These authors contributed equally to this work.", "Introduction The magnitude and quality of the cellular and humoral immunological responses are crucial attributes for the develop- ment of an anti-HIV vaccine. Viral components can elicit a substantial immune response, as observed in long-term nonpro- gressors patients, and HIV-Gag structural protein seems to be particularly important in this context [1–3]. The presence ofcellular immune responses directed towards this protein has been associated to the control of HIV infection both in the acute and asymptomatic stages and a strong anti-Gag CTL response is inversely correlated with the viral load in HIV-infected patients [3–6]. In addition, Gag is a well-conserved protein among different virus strains and subtypes, indicating that this protein is a target for the development of vaccines [7–9].PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e99887 DNA plasmid based immunization has been shown to be a promising strategy in inducing immune response in different models [10–15]. The development of an anti-HIV DNA vaccine, however, is hampered by the fact that the expression of some viral proteins is dependent on viral regulatory elements. Specifically, the expression of HIV-Gag is critically dependent on Rev and Rev Responsive Elements (RREs) interactions for an efficient mRNA stability and translocation to the cytoplasm. Consequently, Gag protein expression is severely impaired in mammalian cells [16].", "Several strategies have been used to overcome this Rev- dependence, like codon optimization and mutation of inhibitory sequences elements (INS) present along gag-pol sequence [17–19].", "DNA immunization with these optimized sequences has been shown to elicit antibody and cytotoxic responses [20–22].", "Stimulation of CD4+helper T cells is essential for the induction of sustained CTL and antibody responses [23]. In this regard, an impaired ability to generate CD8+T cells has been noticed in DNA vaccination systems, unless a CD4+T cell response is also stimulated [24,25]. Since Gag-specific CD4+and CD8+T cells proliferative responses are related to lower viral loads, an enhanced CD4+T cell activation may be particularly critical for an effective HIV vaccine and for maintaining functional CD8+T cell during chronic viral infection [5,6,26,27].", "The intracellular localization of an antigen can influence the magnitude and quality of humoral immune response and can also target the response to CD8+or CD4+T cells. In this regard, antigen targeting to different cellular processing compartments may improve its presentation by MHC I or MHC II molecules and enhance specific immune response [28–32]. In addition, the secretion of cellular proteins was reported to modulate the immunological responses. For instance, it was observed that a secreted form of HIV-Gag can induce a higher cellular response after DNA immunization than plasmids encoding a cytoplasmic form of this antigen [33]. Exosomes are endosome-derived vesicles commonly exploited by several cell types to secrete proteins. These vesicles are characterized by the presence of molecules related to the lysosomes, like CD81 tetraspanin, CD63, LAMP-1 and LAMP-2 [34–36]. Depending on the cell type, the exosomes may be originated from the invagination of the MIIC compart- ments and may also present proteins related to antigen presen- tation, such as MHC II, and co-stimulatory molecules, like CD86, what has been associated to increased vaccine efficiency [37,38].", "Indeed, exosomes derived from antigen presenting cells, such as B lymphocytes and dendritic cells are capable of antigen presenta- tion and stimulation of T cells [39,40]. Also, exosome derived from other cell types had been demonstrated to be directed to APCs, mediating antigen cross priming [41,42].", "We have previously shown that association of HIV-p55 gag with mouse lysosomal associated protein-1 (LAMP-1), in a form of DNA vaccine chimera, promoted an enhanced Gag-specific immune response, in comparison to native gag DNA [28,43,44].", "In vitro studies had also demonstrated that LAMP/Gag chimera was highly expressed and colocalized with MHCII in transfected cell lines [43]. However, the mechanisms regulating protein expression and intracellular targeting, as well as the relevance of each phenomenon in the enhanced immune response were not addressed yet. In the present study, we investigated the LAMP sequences necessary to modulate protein expression and intracel- lular targeting, and addressed which of these effects was associated to the increased immune response induced by LAMP/ gag DNA vaccine. We observed that the association with LAMP-1 increases chimeric gag mRNA levels. The increased Gag expression in the LAMP/Gag context was dependent on LAMP-1 luminal domain and a minimum of 247aa of this region was necessary to increaseantigen expression. The luminal domain also showed to be essential to target Gag to lysosomes and to induce Gag secretion.", "Increased expression was sufficient to induce a high acute antibody response in immunized mice. However, the enhanced CD4+and CD8+T cells activation, and prolonged antibody responses seemed to depend on Gag targeting to the endolysosomal/ secretory pathway. We believe that the mechanistic study of the immune response induced by LAMP/ gagis an essential step for the development of novel anti-HIV vaccines and may also contribute to the development of other LAMP-based vaccines.", "Materials and Methods Plasmids Eukaryotic expression plasmids were constructed using nucle- otides 1–1503 of the HIV-1 HXB2 p55 gag gene (GenBank K03455) (HIV sequence Database, 1997, Los Alamos National Laboratory Theoretical Biology and Biophysics, Los Alamos, NM), inserted into pITR vector [45], which contains adeno- associated virus inverted terminal repeats (AAV-ITR) flanking the expression elements (CMV promoter and BGH polyadenylation signal). The LAMP/ gag construct was made by inserting the p55gag (XhoI and EcoRI) sequence between the luminal domain (lum, between NheI and XhoI) and the transmembrane domain and cytoplasmic tail (TM-Cyt, between EcoRI and KpnI) of mouse LAMP-1 (GenBank J03881), as described previously [43].", "The LAMP lum/gag construct was made by the same strategy, without the TM-Cyt insert.", "The LAMP REV-lum /gag construct was made by replacing the luminal domain of LAMP-1 by its oriented reverse sequence. The LAMP-1 luminal domain in the reverse orientation was made by PCR, using the sequence 5 9ccg.ctc.gag.atg.gcg.gcc.ccc.ggc.", "gcc.cgg.c 3 9, (with the XhoI site) as the sense primer and the sequence 5 9cta.gct.agc.cat.gtt.gtt.acc.atc.ctg.aac 3 9, (with the NheI site) as the anti-sense primer. In this plasmid, a kozak sequence was added in the 5 9end of p55 gag sequence. The plasmids containing the truncated LAMP-1 luminal domain were con- structed by maintaining one third (372 bp; 124aa) or two thirds (741 bp; 247aa) from the 5 9end of the luminal domain. Therefore, the same sense primer used for the construction of LAMP/ gag plasmid was used to make the truncated ones. The anti-sense primers used to make these plasmids were the following sequences:", "LAMP TM-Cyt /gag (24aa of LAMP lum): 5 9ccg.ctc.gag.agc.t- ga.ggc.gcc.atg.tgc 3 9; LAMP T1-lum /gag (124aa of LAMP lum):", "59ccg.ctc.gag.att.ggg.aaa.atg.ttc.tgt.atc 3 9; LAMP T2-lum /gag (247aa", "of LAMP lum): 5 9ccg.ctc.gag.gaa.cgc.tct.ggt.cac.cgt.ctt 3 9. All the plasmids were produced by transforming DH5 aE. coli (Invitro- gen, Carlsbad, CA) and purified with endotoxin-free columns (Qiagen Inc., Valencia, CA).", "Pulse and chase and immunoprecipitation Cells from 293 cell line (HEK293, ATCC, Rockville, MD) were cultured in 6 well plates, at 5 6105cells/well, in RPMI-1640 medium, containing 10% FCS, 2 mM L-glutamine and 100 U/ml of penicillin/streptomycin (Invitrogen). The cellswere transfected with pITR gag or pITR LAMP/ gag (2 wells/plasmid), using Lipofectamine-2000 transfection reagent (Invitrogen), according to the manufacturers’ protocol. Following 24 hours of culture, the medium was changed by a methionine-free RPMI medium (Invitrogen) and the cells were starved for 45 min/37 uC. Then,", "25mCi of S35labeled methionine (Amersham Pharmacia Biotech)", "were added to each well and the plates were incubated for", "45 min/37 uC. The cells were washed, the medium changed by a", "cold RPMI, and the cells and supernatants of these cultures wereLAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e99887 collected after 20 min, 1 hour and 6 hours. The cell samples were lysed with lysis buffer and both the cell lysates and supernatants were immunoprecipitated with anti-Gag antibody. Initially, the samples were pre-cleared by incubation with fixed SaC (Calbio- chem-Novabiochem Corporation, San Diego, CA) for 1 hour, on ice, pelleted and incubated with normal goat serum (NGS) and SaC for 1 hour more, on ice. The pellets were incubated with mouse anti-Gag at 20 mg/ml in PBS, containing 1% BSA, overnight at 4 uC and, then, incubated with 10 mg of purified goat anti-mouse IgG, on ice, for 1 h. The SaC was, then, added and the samples incubated for 20 min/ice, after what, the samples were washed twice with Pastan buffer (50 mM Tris, 5 mM EDTA,", "100 mM NaCl, 2 M KCl, pH 7.5). The pellets were resuspended", "in TEN buffer (100 mM Tris, 5 mM EDTA, 150 mM NaCl, pH 8.0) with 1% NP-40, centrifuged and the obtained pellets were resuspended in SDS-PAGE sample buffer. Each sample was resolved in SDS-polyacrylamide gels and transferred to Immobi- lon P membranes (Millipore, Bedford, MA). A molecular weight marker was used as a standard (Amersham Pharmacia Biotech).", "The amount of radioactivity in the bands corresponding to native Gag or LAMP/Gag was measured in a phosphoimager.", "Analysis of gag mRNA by quantitative real time RT-PCR HEK293 cells were transfected with the indicated plasmids.", "After 24 hours, mRNA was obtained either from total cell preparation or from isolated nuclear and cytoplasmic fractions using trizol reagent (Invitrogen), as indicated by the manufacturer.", "To isolate nuclear and cytoplasmic fractions, the cells were incubated for 10 minutes with lysis buffer (50 mM TrisHCl pH 8.0, 100 mM NaCl, 5 mM MgCl 2, 0.5% vol/vol Nonidet p40) followed by centrifugation for 10 minutes at 10.000 RPM at 4 uC.", "The pelleted fraction corresponded to the nucleus and the supernatant to the cytoplasm. The obtained mRNA was treated with DNAfree kit (Applied Biosystems, Carlsbad, CA, USA) to remove any plasmid contamination. The cDNA synthesis was conducted using the AMV first strand cDNA synthesis kit (Invitrogen), according to manufacturer’s protocol. The cDNA from total cell lysate or nucleus and cytoplasm fractions were quantified for HIV-gag presence using the SYBR green method (Applied Biosystems), according to the manufacturer’s instructions using the specific HIV-gag primers P24-7r (5 9CCC.TGA.- CAT.GCT.GTC.ATC.A3 9) and P24inf (5 9GTC.CAA.AAG.C- GA.ACC.CAG.ATT.GTA.A 3 9). For cycling and quantification a StepOne equipment and software (Applied Biosystems) were used.", "Analysis of protein expression by western blotting HEK293 cells were transfected with the indicated plasmids, as described above. After 48 h of culture, the supernatant and cells were harvested, the cells were disrupted with lysis buffer (10 mM Tris-HCl (pH 7.5) with 150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100 and premixed protease inhibitors (Complete, Roche Applied Science, Mannheim, Germany), for 15 min on ice, and cellular debris was removed by centrifugation.", "The amount of Gag protein in the cell lysate and supernatant fractions was analyzed by western blotting. Initially, the samples were normalized according to the total protein concentration, as determined by BCA (Pierce, Rockford, IL). They were then resolved on 10% polyacrylamide gels, transferred to Immobilon membranes (Millipore, Bedford, MA), and blocked with PBS containing 5% nonfat dried milk. Molecular weight markers (Amersham Pharmacia Biotech, Piscataway, NJ) were used as standards. After washing with PBS-0.05% Tween 20 (PBS-T), the blot was probed with mouse anti-Gag (kindly provided by Dr.", "James K. Hildreth, The Johns Hopkins School of Medicine,Baltimore, MD) at a 1:50 dilution for 2 h, washed three times and then incubated with peroxidase-conjugated goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) at a 1:10,000 dilution for 1 h. The membranes were also probed with anti- b-actin antibody (Santa Cruz Biotechnology, Dallas, TX), followed by anti-mouse IgG, as a loading control.", "Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific) was used for protein detection according to the manufacturer’s instructions. The ratio of interest protein/consti- tutive protein was determined using ScionImage software.", "Exosome isolation HEK293 cells were transfected with the indicated plasmids, as described above and, after 48 hours the culture medium was changed by serum-free Hybridoma-SFM (Invitrogen), containing 2 mM L-glutamine and 100 U/ml of penicillin/streptomycin.", "After 48 hours more, exosomes were isolated, as described elsewhere [46,47]. Briefly, the cells were separated and the supernatant centrifuged for 10 min at 200 g(pellet P1). The supernatant was removed and centrifuged twice for 10 min at 500g(the pellets were pooled and are referred to as P2).", "Supernatants were sequentially centrifuged at 2,000 gtwice for", "15 min (the pooled pellets are referred to as P3), once at 10,000 g", "for 30 min (pellet P4) and once at 70,000 gfor 60 min (pellet P5), being P5 enriched in exosomes. The amount of Gag protein in P1–P5 samples was analyzed by western blot or p24-ELISA (see below). Western blot analyses were performed as described previously. The membranes were probed with anti-Gag, or anti- CD81 (1:500; Santa Cruz Biotechnology), or anti-CD63 (1:1000; Santa Cruz Biotechnology); followed by anti-mouse IgG (Jackson ImmunoResearch Laboratories) at a 1:10,000 dilution for 1 h. For further purification of exosomes, P5 was resuspended in 5 ml of", "2.5 M sucrose, 20 mM HEPES/NaOH, pH 7.2. A linear sucrose", "gradient (2.0–0.25 M sucrose, 20 mM HEPES/NaOH, pH 7.2) was layered on the top of the exosome suspension in a SW32Ti tube (Beckman Instruments, Inc.). Gradients were centrifuged for", "15 h at 100,000 g, after which 2-ml fractions were collected from", "the bottom of the tube. To collect membranes from these fractions, they were diluted with 3 mL of PBS and centrifuged for 60 min at 200,000 g, using a Sw55Ti rotor (Beckman Instruments, Inc.). The fractions were washed once more and each one was analyzed by dot blot, since this technique is more sensitive than western blot and residual sugar did not interfere in the detection (see below).", "Detection of p24 by ELISA HEK293 cells were transfected with the indicated plasmids for", "48 h and the content of p24Gag in the cell lysates and", "supernatants was analyzed by ELISA. ELISA plates were coated overnight with anti-Gag M1 antibody (kindly given by Dr. James K. Hildreth, JHU), diluted in 50 mM Tris, pH 9.5, at 10 mg/ml.", "The plates were washed with PBS-T and blocked with PBS 3% BSA for 2 h, at 37 uC. The samples and HIV p24 standard were diluted in RPMI, supplemented with 10% FCS and 1% Triton X- 100, and incubated in the ELISA plates overnight, at 4 uC. After several washes with PBS-T, the plates were incubated with biotinylated anti-p24Gag (kindly given by Dr. James Hildreth, JHU), diluted at 1:4,000 in PBS with 5% normal goat serum, 1% BSA and 0.05% Tween 20, for 2 h at room temperature (RT).", "The plates were then incubated with HRP-streptavidin, for", "30 min, at RT, washed and developed with TMB (BD PharMin-", "gen, San Diego, CA, EUA). The reaction was stopped with 1 M H2SO 4and read at 450 nm analyzed using an ELISA reader (BioRad Laboratories Inc., Hercules, CA, EUA).LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e99887 Confocal microscopy For the analysis of the intracellular trafficking of the constructed chimeras, we used the MHCII-expressing DCEK.ICAM.Hi7 mouse cells [43,48] (kindly given by Dr. Susan Swain, The Trudeau Institute, Saranac Lake, NY). These cells were maintained in RPMI-1640 medium, and were selected every other week by adding to the culture 6 mg/mL micophenolic acid;", "250 mg/mL xantin; 15 mg/mL hipoxantin (Sigma, St. Louis, MO)", "and 800 mg/mL geneticin (Invitrogen). For immunofluorescence assay, the cells were plated in 6 well plates over poly-D-lysin pre- treated coverslips and were maintained overnight in RPMI medium, at 37 uC/5% CO 2. The cells were, then, transfected with the indicated plasmids, and, after 48 hours, the coverslips were transferred to a 24 well plate, washed with PBS, fixed with 2% paraformaldehyde and blocked with 4% normal goat serum and 0.1% saponin. To analyze Gag localization, the cells were stained with mouse anti-Gag antibody at 1:50 dilution, washed with 0.1% saponin and stained with texas-red conjugated anti- mouse-IgG at 1 mg/mL (Jackson ImmunoResearch Laboratories Inc.). Endogenous LAMP molecules were detected by incubating the coverslips for 1 hour with rat anti-mouse LAMP-2 (ABL-93) supernatant medium, diluted 1:50, and endogenous Golgi compartments were detected by staining with ABL-85 supernatant medium, diluted 1:50. The coverslips were, then, incubated for", "1 hour with FITC-conjugated anti-rat IgG at 1 mg/mL (Jackson", "ImmunoResearch Laboratories Inc.). The coverslips were washed with PBS and mounted onto glass slides, using ProLong antifade reagent (Molecular Probes, Eugene, Oregon). Confocal microsco- py was performed using the Wallac confocal Laser Scanning Microscope and the images were captured individually and digitally coloured by using Photoshop 5.0 (Adobe, San Jose).", "Mice CD4+T cell depletion Female BALB/c mice, 6–8weeks age, were obtained from the mice facility of the Instituto de Microbiologia, Universidade Federal do Rio de Janeiro (IMPPG, UFRJ), Brazil. The animals were bred and housed according to institutional policies for animal care and usage and the protocol was approved by The Ethics Committee of Animal Care and Use (Comite de Etica no Uso de Animais-CEUA) from Centro de Ciencias da Saude, UFRJ (Permit Number: IMPPG 025). The mice (4 mice/group) were treated with purified rat IgG against mice CD4 molecule obtained from GK1.5 hybridoma (ATCC TIB-207; kindly provided by Dr.", "Jose´ Mauro Peralta, Universidade Federal do Rio de Janeiro, Brazil). Each animal received an intraperitoneal injection of", "100 mg/100 mL/mouse for 3 days followed by a 4 days’ rest. The", "injections continued along the whole experiment with an interval of 4 days between treatments. The efficacy of this procedure was evaluated by flow cytometry achieving 70–85% T CD4+depletion (data not shown).", "Mice immunization Female BALB/c mice, 6–8 weeks old, were immunized twice, i.d., with the indicated plasmids at 50 mg/50 mL/mouse, at a 3-4 weeks interval.", "Antibody response Mice sera were obtained from the tail vein before the first immunization (pre-bleed) and at different time points after the second immunization, and the individual serum IgG levels were measured by ELISA. Briefly, ELISA plates were coated with", "50mL of HIV IIIBlysate at 5 mg/ml (ABI, Rockville, MD) and", "incubated at 4 uC, overnight. The plates were blocked with PBScontaining 10% FCS for 2 hours/37 uC, washed with PBS-T and the serum samples were added, in serial dilutions, and incubated at", "4uC/overnight. The plates were, then, incubated with HRP-", "conjugated anti-mouse IgG (1:5,000; Jackson ImmunoResearch Laboratories Inc.) for 2 hours/37 uC, washed and developed using TMB substrate (Pharmingen, San Diego, CA). After 30 minutes, the reaction was stopped with 1 M H 2SO 4and read at 450 nm using an ELISA reader (BioRad Laboratories Inc.).", "T lymphocyte activation ELISPOT assay. The activation of CD4+and CD8+T lymphocytes was analyzed by ELISPOT assays, using the IFN- c ELISPOT set from BD-Biosciences Pharmingen (San Diego, CA), according to manufacturer’s protocol. Initially, ELISPOT plates were coated with anti-IFN- cantibody at 5 mg/mL and incubated at 4uC/overnight. The plates were blocked with RPMI 1640, containing 10% FCS, for 2 hours at RT and then, total splenocytes (106cells/well), obtained from each immunized mouse, were cultured in the presence of culture medium (RPMI", "1640 medium supplemented with 5% FCS, 100 units/mL", "penicillin/streptomycin, 2 mM L-glutamine, 50 mM 2-mercapto- ethanol and 1 M HEPES buffer) or recombinant baculovirus HIV SF2p55 Gag (5 mg/mL; NIH AIDS Research and Reference Reagent Program), to analyze the CD4+response; or with the MHC I restricted Gag epitope AMQMLKETI 65-73 (10mg/mL), to analyze the CD8+response, as indicated in the results. After", "24 hours of culture, the plates were washed and incubated with", "biotinylated anti-IFN- cantibody for 2 hours at room temperature, followed by incubation with HRP-conjugated avidin, for 1 hour/ RT. The reaction was developed with AEC substrate (Calbio- chem-Novabiochem Corporation, San Diego, CA). Analysis of the IFN- clevels was performed using the Immunospot Analyzer software (BD Biosciences, San Diego, CA). The data indicate the average number of spot forming cells (SFC) obtained from individual mice.", "Analysis of cytokine production by ELISA. Splenocytes (106106cells/mL) were cultured in triplicate in a 96-well plate in the presence of recombinant baculovirus HIV SF2p55 Gag, or 15- mers spanning the whole Gag protein, or T CD4+-restricted Gag peptide pools, or T CD8+-restricted Gag peptide pools [28]. All peptide pools were at the same concentration (5 mg/mL; NIH AIDS Research and Reference Reagent Program). As negative and positive controls, cells were incubated with culture medium alone or concanavalin A (ConA) (BD Biosciences), respectively.", "Culture supernatants were harvested after 72 h for the quantita- tion of secreted TNF- aor IFN- cusing an OPTEIA ELISA kit (BD Biosciences).", "Analysis of CCR7 expression and intracellular cytokine staining by flow cytometry. Splenocytes harvested from the immunized mice were incubated with the described Gag peptides, in the presence of brefeldin A (eBiosciences Inc, San Diego, CA) for 10 h, at 37 uC. After incubation, cells were washed twice with FACS buffer (HBSS, supplemented 2% FCS, 1 mM Hepes, 0.1% NaN 3), and nonspecific binding was blocked by incubating cells with anti-Fc cR antibody (BD Pharmingen) at 10 mg/mL for", "15 min at 4 uC. The splenocytes (1 6106cells/well) were stained in", "duplicate with PerCP-conjugated rat anti-mouse CD4+antibody, and/or PE-conjugated anti CCR7 (BD Pharmingen) at a dilution of 1:100 for 30 min at 4 uC. The cells were washed twice with FACS buffer and resuspended in 200 mL of Cytofix/Cytoperm solution at 4 uC for 20 min. Cells were then washed twice with Perm/Wash solution and stained with APC-conjugated anti-IFN- c, or APC-conjugated anti-IL-2 and PE-conjugated anti-TNF- a antibodies (BD Biosciences) diluted 1:100. Events acquisition wasLAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99887 performed with a FACScalibur flow cytometer instrument and data was analyzed with CellQuest software (BD Biosciences). A minimum of 50,000 events were analyzed.", "Statistical analysis Statistical analysis of the results was based on unpaired t-tests and chi-squared independence tests. p values ,0.05 were considered statistically significant.", "Results Association of HIV-Gag with LAMP-1 increases gag mRNA transcription We have previously demonstrated that a DNA plasmid construct containing the sequence of HIV-p55 gaginserted between the luminal and the transmembrane and cytoplasmic tail of LAMP-1 was highly expressed after transfection of different cell lines [28,43]. In order to verify whether the increased Gag expression was related to a higher stability of LAMP/Gag protein chimera, in comparison to native Gag, we performed pulse and chase experiments and determined the degradation rate of each protein. HEK293 cells were transfected with either native gag(gag N) or LAMP/ gagDNA plasmids. After 24 hours, the cells were pulsed with S35and, then, chased for 20 minutes, 1 hour or 6 hours in cold medium, and the samples were immunoprecipitated with anti-Gag antibody. We observed that, while the amount of protein produced following transfection with the native gag DNA was much lower than the one produced by LAMP/ gag [28,43] (Figure 1A), their degradation curves were very similar (Figure 1B). The degradation rate of LAMP/Gag chimera was slightly higher, but this could be associated to the lysosomal targeting and secretion of this protein, since LAMP/Gag was also observed in the supernatant of transfected cells, whereas there was no appreciable amount of native Gag in the supernatant (Figure 1B, insert).", "We then investigated if the modulation of Gag expression by LAMP would be correlated either to mRNA transcription or translocation to the cytoplasm. HEK293 cells were transfected with gag Nor LAMP/ gag plasmids and the mRNA was extracted from the whole cell lysate, or from isolated nuclear or cytoplasmic fractions. HIV- gag mRNA was then quantified. We observed a significant difference in the total mRNA concentration between gag and LAMP/ gag (Figure 1C), but the distribution between the nucleus and the cytoplasm was very similar for both chimeric genes (Figure 1D), indicating that there was no difference in the translocation rate between these mRNAs. These results suggest that the presence of LAMP signals in the chimeric construct increased mRNA transcription or stability, resulting in higher steady state levels of LAMP/ gag mRNA.", "The increased LAMP/Gag expression is mediated by LAMP-1 luminal domain We analyzed the role of the different LAMP-1 domains in the regulation of Gag expression. Several DNA plasmids were constructed by deleting either the transmembrane-cytoplasmic tail (TM-Cyt) (plasmid LAMP lum/gag), or the luminal domain of LAMP in the LAMP/ gag chimera (plasmid LAMP TM-Cyt /gag) (Figure 2). In the latter construct (LAMP TM-Cyt /gag), we maintained 24aa of the 5 9terminal of LAMP, correspondent to ER signal sequence. HEK293 cells were transfected with these plasmids and Gag expression was analyzed by western blot (Figure 3). The result presented in figure 3A confirms our previous observation of an increased LAMP/Gag expression in comparison to native Gag, and demonstrated that the deletion of LAMPcytoplasmic domain did not affect Gag expression. In contrast, deletion of the luminal domain led to a decreased Gag expression to the level obtained with native Gag. Additionally, cell transfection with a chimeric plasmid containing the LAMP luminal domain in a reverse orientation at the 5 9end of the start site of the gag gene also showed a decreased Gag expression, comparable to native Gag (Figure 3B).", "To identify the minimum sequence of LAMP luminal domain necessary to increase Gag expression, we generated two other truncated LAMP/Gag chimeras, with deleted sequences from the", "39end of the LAMP luminal domain. One of the constructs,", "LAMP T1-lum /gag, contained one third (372 bp–124aa) of the luminal domain; and the other, LAMP T2-lum /gag, contained two thirds (741 bp–247aa) of the luminal domain (Figure 2). HEK293 cells were transfected with these chimeras and their expression in the cell lysate or culture supernatant were compared with the ones Figure 1. Association of HIV-1 gag with LAMP-1 does not protect Gag protein from degradation, but increases Gag mRNA production. A) HEK 293 cells were transfected with native gag (gag N) or LAMP/ gag . After 48 hours, the expression of Gag protein was analyzed by western blotting, by staining with mouse anti-Gag antibody, followed by HRP-conjugated anti-mouse IgG. B) HEK 293 cells were transfected with gag Nor LAMP/ gag . After 24 hours, the cells were pulsed with S35and, then, chased for 20 min, 1 h and 6 h. The cells and supernatants were collected and immunoprecipitated with anti-Gag antibody. The protein content in each sample was analyzed in a phosphoimager and the curves represent the proportion of protein observed at each time point in relation to the maximum value (100%); the insert indicates the values obtained in the supernatant (sup) of LAMP/ gag transfected cultures. C and D) HEK 293 cells were transfected with the indicated plasmids and, after 48 h, total RNA was obtained from either whole cells (C) or from isolated nuclear (nuc) and cytoplasmic (cyt) fractions (D). After reverse transcription using oligodT primers, the amount of gag cDNA was evaluated by qPCR. Gag concentration were normalized using the b-actin CT number. Data is representative of three independent experiments. * p ,0.05.", "Figure 2. Schematic representation of the constructed plas- mids containing different domains of LAMP-1 associated to p55 gag.p55gag (black rectangles) sequence was inserted between the intact or truncated luminal domain of LAMP (gray rectangle) and the transmembrane and cytoplasmic tail of LAMP (TM/Cyt; striped rectangles).", "doi:10.1371/journal.pone.0099887.g002LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e99887 observed with the complete LAMP/ gag construct and with the construct containing only the whole luminal domain (LAMP lum/ gag). The amount of protein detected was proportional to the length of LAMP luminal domain and a minimum of 247aa of the luminal sequence was necessary to achieve an optimal expression level (Figure 3C). In addition, cell transfection with the intact LAMP/ gag or with LAMP lum/gag induced the secretion of high levels of Gag protein and, similarly, a minimum of 247aa was required to induce Gag secretion, although at a lower level (Figure 3C).", "An intact LAMP luminal domain is necessary to target Gag to lysosomes and exosome secretory pathway We analyzed how much of the LAMP luminal domain was required to promote Gag-targeting to the lysosomal compart- ments. Mouse DCEK cells were transfected with the truncated LAMP/Gag chimeras and their localization in lysosomes or Golgi complex were analyzed by confocal microscopy, using anti- LAMP-2 and anti-gp125 (ABL85 hybridoma) antibodies, respec- tively. We observed that the truncated LAMP/Gag chimeras were scarcely present at lysosomes in transfected cells, but they all showed strong colocalization with Golgi apparatus (Figure 4), suggesting that without essential sequences present in luminal domain, the chimeras are retained at these compartments and are not able to traffic through lysosomal/secretory pathway.", "Since previous reports demonstrated the presence of LAMP in exosomes in some cell types [34,49], we investigated whether LAMP/Gag was being secreted in these vesicles. The supernatant of LAMP/Gag-transfected cells was submitted to serial centrifu- gations up to 70,000 g (pellet 5-P5), where the exosomes are usually enriched. Western blot analysis demonstrated that Gag was present in all supernatant fractions, including P5, where the CD81tetraspanin was also enriched, strongly suggesting that this is actually related to exosomes (Figure 5A). Still, since Gag protein can form aggregates, and these could be pelleted in the same fraction as the exosomes, we further purified the P5 fraction in sucrose gradients and observed the presence of Gag in the fractions related to membrane conjugates, confirming that LAMP/Gag is partially secreted in exosomes (Figure 5B). To further confirm the importance of the LAMP-1 luminal domain in promoting Gag traffic through lysosomes/exosomes vesicles, we also investigated fractionated supernatants form HEK293 cells transfected with LAMP lum/gag, which contain only the luminal domain of LAMP. Similar to complete LAMP/gag, LAMP lum/ Gag chimera was strongly expressed in all supernatant fractions, including P5 (Figure 5C). The membranes were also probed with anti-CD63, another exosome marker, which was also enriched in P5 fraction, corroborating the previous data. These data suggest that the whole LAMP luminal is necessary and maybe sufficient to target Gag to the exosome secretory pathway.", "We could not detect the LAMP T2-lum /Gag chimera in the fractionated supernatants by western blot (data not shown).", "Therefore, we also analyzed the Gag protein amount in the cellular lysate and in all supernatant fractions isolated from LAMP T2-lum /gag, LAMP/ gag or LAMP lum/gag transfected cells by p24 ELISA. Initially, we determined the proportion of Gag in the total supernatant in comparison with cell lysates. After cell transfection with LAMP T2-lum /Gag, 15% of total Gag was present in the supernatants and around 85% was present in the cell lysates.", "In contrast, samples obtained from LAMP/ gag and LAMP lum/gag- transfected cells showed around 70 and 75% of Gag in the supernatants, respectively (Figure 5D). After fractionating the supernatants, we observed that LAMP T2-lum /gag were highly enriched in the P4 fraction, differently from LAMP/ gag or LAMP lum/gag, that were also enriched in P5 (Figure 5E).", "Figure 3. LAMP-mediated increased Gag expression is depen- dent on LAMP luminal domain. A –B) HEK293 cells were transfected with the plasmids represented in Figure 2. After 48 h, the amount of Gag protein was analyzed by western blotting, by staining with mouse anti-Gag antibody, followed by HRP-conjugated anti-mouse IgG. The membranes were also probed with b-actin, as a loading control. Bars indicate the ration between Gag expression and b-actin, as measured with ImageJ software. C) HEK293 cells were transfected with the indicated plasmids and, 48 h later, the amount of Gag protein in the cell lysates (cell) and culture supernatants (sup) were analyzed as in ( A).", "Data is representative of four independent experiments.", "Figure 4. Truncated LAMP/ Gag chimeras poorly colocalize with endogenous LAMP. Mouse DCEK cells were transfected with the indicated plasmids. After 48 h, intracellular localization of Gag was analyzed by confocal microscopy after incubating the cells with mouse anti-Gag antibody, followed by incubation with texas-red anti-mouse IgG. Colocalization with Golgi compartments was analyzed by staining with a rat anti-mouse golgi gp125, followed by incubation with a FITC- conjugated goat-anti-rat IgG. Colocalization with endogenous LAMP was analyzed by staining with a rat anti-mouse LAMP-2, followed by incubation with a FITC-conjugated goat-anti-rat IgG. Data is represen- tative of four independent experiments.", "doi:10.1371/journal.pone.0099887.g004LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e99887 LAMP luminal domain-mediated high expression and targeting to lysosomal/secretory pathway promote an enhanced anti-Gag immune response We verified here that 247aa of the luminal sequence was necessary to promote high levels of Gag expression but only the complete and intact luminal domain was able to induce Gag- targeting to the endolysosomal/secretory pathway. In order to determine the effects of protein expression and cellular traffic on immune responses, mice were immunized with the native gag and with the different LAMP/ gag constructs, and both the antibody and the cellular responses were analyzed (Figure 6). The amount of anti-HIV IgG was measured ten days after two DNA immunizations, and we observed that the construct containing", "247aa of the luminal domain (LAMP T2-lum /gag) induced an", "antibody response level similar to the intact LAMP/ gag(Figure 6A).", "In contrast, both the CD4 and, mostly, the CD8 T cell response, were remarkably impaired in the mice immunized with any of the truncated LAMP/ gag constructs, in comparison to the DNA encoding the intact LAMP/ gag (Figures 6B and 6C). These datasuggest that high protein expression is sufficient to elicit a significant antibody response, but not cellular activation, which seems to depend on intracellular traffic. Interestingly, immuniza- tion of with LAMP lum/gag also increased production of IFN- cby CD4+and CD8+T cells, as measured by ELISA and flow cytometry. The T cell response observed in LAMP lum/gag immunized mice were similar than the one induced by complete LAMP/ gag plasmid, which was much higher than the response induced by native gag immunization (Figure S1A and B). These data indicate that, in the system presented here, association of Gag antigen with LAMP-1 luminal domain was sufficient to elicit a potent Gag-specific T and B cell-mediated immune response.", "Since T cell, particularly CD4+T cell priming, is important to induce and maintain memory response in general, we questioned whether the increased antibody production induced by truncated LAMP T2-lum /Gag construct would be sustained for longer periods of time.", "Thirty days after the second immunization, the titer of anti-HIV serum IgG antibodies was similar between LAMP T1-lum /gag, LAMP T2-lum /gag and native gag immunized mice, and none of them were comparable to the ones induced by intact LAMP/ gag construct. Consistent with our previous data, antigen-specific IgG antibody response induced by the LAMP/ gag chimera was sustained at titers greater than 1:3,000 for at least three months Figure 5. LAMP luminal domain induces LAMP/ Gag secretion through exosomes. A ) HEK293 cells were transfected with LAMP/ gag and, after 48 hours, the supernatants were harvested and subjected to differential centrifugations as described in Material and Methods. Cell lysates (cell), the intermediate pellets obtained after each centrifugation step (P1–P4), and the exosome fraction (P5) were obtained and Gag expression was analyzed by western blotting. The membranes were also probed with anti-CD81, as an exosome marker. B) P5 fraction obtained as in ( A) was brought to 2.5 M sucrose, overlaid with a continuous sucrose gradient and subjected to equilibrium centrifuga- tion. Fifteen fractions were collected and subjected to dot blot analysis using anti-Gag antibody. Densitometry analysis was performed using phosphoimager software and the results indicate the percentage of each dot intensity in relation to the sum of all dots. Membrane- associated fractions are indicated with a line in the bottom. C) HEK293 cells were transfected with LAMP/ gag or HEK293 cells were transfected with LAMP lum/gag . After 48 hours, the supernatants were harvested and subjected to differential centrifugations as described. P1–P5 fractions were analyzed by western blotting, using anti-Gag or anti- CD63 antibodies D–E) HEK293 cells were transfected with LAMP T2-lum / gag , LAMP/ gag or LAMP lum/gag . After 48 h, cells and supernatants were harvested, fractionated as in ( A), and the concentration of Gag was measured by p24-ELISA. The proportion of Gag protein in the cell lysates and total supernatant fraction is demonstrated in ( D); the percentage of Gag in each supernatant fraction in relation to total supernatant is demonstrated in ( E). Data is representative of three independent experiments.", "Figure 6. High protein expression and targeting to secretory pathway induced by LAMP luminal domain potentiate the immune response to HIV-Gag. Balb/c mice were immunized twice with the indicated plasmids, i.d, at 50 mg/mouse. A) The serum of each mouse was collected before the immunization (pre-bleed) and 10 days after the second immunization and the amount of anti-HIV IgG was measured by ELISA. The curves indicate the average O.D. levels obtained at different serum dilutions. B–C) Total splenocytes obtained from individual mice were cultured with p55Gag protein (B), or with the MHC I restricted Gag epitope AMQMLKETI65-73 (C) and IFN- c production was analyzed by ELISPOT assay. The bars indicate the average of SFC/106cells, subtracting the values obtained with medium only. D) Mouse serum of individual mice was collected at the indicated time points after immunization with the indicated plasmids. The amount of anti-HIV IgG was measured by ELISA as in (A). The bars indicate the dilution point relative to 50% of the maximum O.D. (IgG titer). The data are representative of three independent experiments. * doi:10.1371/journal.pone.0099887.g006LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e99887 after the immunization (Figure 6D). Taken together, these results indicate that a combination of high expression and targeting to secretory cellular pathway promote more complete and long lasting responses.", "Immunization with LAMP/ gag induces polyfunctional T cell response An efficient vaccine response against HIV infection requires the activation of polyfunctional T cells and the development of central memory T cells [50–54]. Therefore, to further investigate the effect of LAMP/ gag immunization on the T cell response, we analyzed the phenotype and the expression of different cytokines by Gag-specific T cells (Figure 7). We observed that T cells obtained from mice immunized with LAMP/ gag produced IFN- c, IL-2 and TNF- a, as detected by intracellular cytokine staining (Figure 7A, B). TNF- asecretion was also evaluated by ELISA after T cell culture with either CD4- or CD8-restricted peptides and we confirmed that immunization with LAMP/ gag induced an enhanced secretion of this cytokine by both T cell subpopulations, in comparison to immunization with native gag (Figure 7C).", "Central memory T cells are characterized by the expression of chemokine receptors targeting to lymphoid organs. Therefore, we analyzed the expression of CCR7 in the CD4+T cells obtainedfrom native gag and LAMP/ gag immunized mice and observed that LAMP/ gaginduced an increased expression of this receptor in CD4+T cells (Figure 7D). Since naı ¨ve T cells also express this receptor we investigated whether the CCR7+were primed cells by measuring IFN- cproduction. Indeed, 5.15% of CD4+T cells obtained from LAMP/ gag immunized mice were CCR7hiIFN- c+, in comparison to only 3.14% of the cells obtained from mice immunized with native gag (Figure 7E).", "CD8+T cell activation induced by LAMP/ gag immunization is dependent on CD4+T cells In an effort to elucidate the importance of CD4+T cell activation in our vaccination model we evaluated whether the activation markers detected in LAMP/ gag immunized mice would also be elicited in the absence of CD4+T cells. Mice were depleted of CD4+T cells using specific anti-CD4 antibody and, then, immunized with LAMP/ gag. After 2 DNA immunizations, total splenocytes were cultured with CD8-restricted Gag peptides and the secretion of TNF- awas evaluated. We observed that T cells obtained from animals immunized with LAMP/ gag in the absence of CD4+cells produced much lower amounts of TNF- a, comparable to the levels induced by immunization with native gag or pITR vector (Figure 8A). In addition, we observed a decrease in the expression of CCR7 in the CD4-depleted mice and a lower expression of IFN- camong CCR7hiCD42or CCR7luCD42cells (Figure 8B). The data demonstrated that CD4+T cells were essential for the enhanced T cell response elicited by LAMP/ gag.", "Discussion Here, we dissected the roles of protein expression and cellular localization on the anti-HIV immune response. We have previously demonstrated that immunization of mice with a chimeric DNA plasmid containing HIV-1 p55 gag inserted between luminal and transmembrane/cytoplasmic tail domains of LAMP-1 (LAMP/ gag) elicited a much greater and prolonged Gag-specific immune response, when compared to immunization with native Figure 7. LAMP/ gag immunization induces polyfunctional and memory CD4+T cells. Balb/c mice were immunized twice with the indicated plasmids. Fifteen days after the second immunization, the splenocytes were cultured with CD4- or CD8-restricted Gag peptides and the phenotype and cytokine production were analyzed. A–B) The cells were stained with PercP-anti-CD4 and APC-anti-IFN- c, or with PercP-anti-CD4, APC-anti-IL-2 and PE-anti-TNF- a, and analyzed by FACS.", "Dot blots indicate CD4 and IFN- cstaining ( A) or TNF- aand IL-2 staining among CD4+cells ( B). C ) Culture supernatants were collected and the amount of TNF- awas analyzed by ELISA. D–E) Cells were stained with PercP-anti-CD4, PE-anti-CCR7 and APC-anti- IFN- c. CD4+cells were gated and the percentage and/or mean fluorescence intensity (MFI) of CD4+CCR7+IFN-c+cells were analyzed by FACS. D) Histograms indicate CCR7 expression among CD4+cells. pITR vectors are in black; gag Nare in dashed line and LAMP/ gag are in line histogram. The numbers indicated MFI values. E) Dot blots indicate the percentage of CCR7 and IFN-cexpression among CD4+cells. Numbers indicate the percentage of IFN- c+cells among CCR7hiand CCR7luCD4+gated cells. The data are representative of three independent experiments. * p ,0,05.", "Figure 8. Enhanced immune response induced by LAMP/ gag immunization is dependent on CD4+T cells. Balb/c mice were treated or not with anti-CD4 antibody and immunized with LAMP/ gag , as described in Material and Methods. Mice were also immunized with pITR vector or gag N, as controls. Fifteen days after the second immunization, total splenocytes were cultured with CD8-restricted gag peptide and cytokine production was analyzed. A) TNF- asecretion was analyzed by ELISA. B) The cells were incubated with PercP-anti- CD8, PE-anti-CCR7 and FITC-anti-IFN- cand the expression of CCR7 and IFN-camong CD8+cells were analyzed by FACS. The data are representative of two independent experiments. * p ,0,05.", "doi:10.1371/journal.pone.0099887.g008LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e99887 gag [28,43,44]. Given that increased protein expression/stability and differential antigen targeting can both influence the elicited immune response [21,33,55], we evaluated the mechanisms involved in these processes. We made several plasmid DNA constructs, in which the sequence of HIVp55 gag was associated with intact or truncated domains of LAMP-1. The expression level and intracellular localization of the chimeric antigens were investigated in transfected cells and constructs inducing different patterns of expression and cellular targeting were inoculated in mice for analysis of the immune response.", "We observed that the luminal domain was essential to LAMP- mediated increased expression of Gag, which was associated to an increased mRNA level in comparison to native gag. HIV structural proteins, including Gag, are poorly translocated to the cytoplasm [56]. The expression of Gag is hampered by the presence of inhibitory elements that are binding sites for cellular factors associated to mRNA instability, nuclear retention, and inefficient translation [57,58]. During HIV infection, Gag expression requires the activity of the viral Rev protein, which is postulated to counteract the action of these factors [59]. Different strategies had been used to overcome gag poor translation in order to obtain an efficient protein expression [20-22,60]. These strategies were supposed to either enhance translational efficiency, or to alter RNA export to the cytoplasm. The effect of LAMP on Gag expression, on the other hand, did not seem to be associated to protein stability or mRNA export to the cytoplasm. Our data suggests that addition of LAMP luminal domain upstream gag promoted enhanced increased levels of mRNA either by increased transcription or mRNA stability. Since no modification of the Gag inhibitory elements or codon usage was attempted, it is possible that the synthesis of LAMP/Gag chimera was being regulated by cellular mechanisms involved in the LAMP expression directed by signals present in the luminal domain.", "The LAMP luminal domain also showed to be essential to Gag targeting to lysosomal compartments. Our previous studies showed that association of gag Nwith the transmembrane/ cytoplasmic domain of LAMP was not sufficient to target the antigen to the MHCII-containing cellular compartments [43].", "Therefore, we investigated the intracellular localization of the chimeras containing truncated sequences of the luminal domain.", "We observed that, different from native Gag, the truncated chimeras were present in cellular vesicles and were able to traffic to Golgi compartments. However, in spite of the presence of the LAMP targeting signal, they barely reached the lysosomal compartments, in contrast to the construct containing the whole luminal domain, which had been largely demonstrated to colocalize with endogenous LAMP [28,43,61].", "The targeting of Gag mediated by the intact LAMP luminal domain also culminated in the secretion of the chimera partly associated to exosome-like vesicles. Several studies have associated antigen-containing exosomes to enhanced antigen presentation and activation of T cells. In fact, exosome-based cell free vaccines demonstrated to induce specific T cell responses in vivo [37].", "Exosomes derived from antigen presenting cells (APC) contain MHC II and co-stimulatory molecules, and can directly stimulate CD4+T cells [39,40,49]. Even when secreted by other cell types, the exosomes may transfer intracellular antigens directly to APCs and promote antigen cross-presentation [42]. This is particularly interesting in the context of a DNA vaccine. Although inoculation of DNA plasmids can induce immune response after direct transfection of APCs, most of the inoculated DNA is probably captured by other cell types. In this case, antigens that remain cell- associated may not be efficiently delivered to APCs and need to be secreted or transferred to APC by cross-priming to induce immuneresponse [62,63]. Indeed, association of tumor-derived antigens, HIV-gp120, and other antigens with signal delivering to exosomes was shown to increase T and B cell responses [37,38,64,65].", "We could not detect native Gag in the supernatant of transfected cells, in spite of its well-known ability to generate secreted virus-like particles (VLP). It is possible that the amount of synthesized protein in its native form, in the absence of Rev, was not sufficient to allow VLP generation and release. Secreted HIV Gag VLPs usually bud from the plasma membrane and not from vesicles originated from endolysosomes [17]. Accordingly, LAMP T2-lum /Gag chimera, which showed to be strongly ex- pressed, was secreted by the transfected cells, although not significantly detected in the exosome fraction. These data suggest that the targeting of Gag to endolysosomal vesicle by the whole luminal domain of LAMP influenced its secretion pathway.", "Given that we constructed plasmids that differ in their expression level and cellular traffic, we were able to evaluate the relative importance of these features for the Gag-specific immune response elicited by LAMP/ gag DNA vaccines. Mice were immunized with (i) native gag, (ii) the truncated LAMP/ gag chimeras (LAMP T1-lum /gagor LAMP T2-lum /gag), and (iii) the intact LAMP/ gag, and the T and B cell responses were analyzed. It was observed that the anti-HIV antibody response elicited by these plasmids was proportional to the length of the luminal domain.", "Immunization with the truncated LAMP T2-lum /gag plasmid, which induced the same expression level as the intact LAMP/ gag, elicited a similar level of anti-HIV serum IgG antibodies, indicating that protein expression level was proportional to the magnitude of acute antibody response. Analysis of the induced T cell response, however, demonstrated that, although the level of activation was also proportional to Gag expression, all the truncated plasmids elicited a significantly lower IFN- cproduction by CD4+or CD8+ T cells than the plasmid containing the whole LAMP luminal domain.", "Gag targeting to the endolysosomal compartments may not only facilitate its presentation by MHC II molecules and increase CD4+ T cells activation, but also, the secretion of Gag may improve cross-priming and directly activation CD8+T cells. It has been described that dendritic cells pulsed with a particulate form of the hepatitis B antigen processed the antigen in the endolysosomal compartment and efficiently primed CTL, inducing a higher T cell response in comparison to equimolar concentration of the peptide in a non-particulate form [66]. Although there is no experimental evidence demonstrating Gag secretion in vivo , the fact that the truncated LAMP T2-lum /gag plasmid did not induce the same level of T cell response, in spite of a high level of Gag expression, indicates that Gag traffic may be the main event regulating the potent T cell activation mediated by LAMP/ gag.", "Accordingly, previous studies demonstrated that DNA vaccines that generate Gag secreted as VLP, or in a soluble form, induce different levels of T and B cell activation, which were also different from the response induced by cytoplasmic Gag [33].", "Since T cell activation is essential to induce memory response, we evaluated whether the level of antigen-specific IgG antibodies induced by LAMP T2-lum /gag would be sustained in spite of the low T cell activation induced. Analyses of the IgG antibody titer at different time points after immunization demonstrated that the anti-HIV IgG levels induced by LAMP T2-lum /gag rapidly de- creased, in contrast to the levels induced by intact LAMP/ gag, which was maintained for at least three months after vaccination.", "These data demonstrated that the T cell activation associated to differential antigen traffic was essential to promote prolonged antibody response after immunization.LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e99887 CD4+T cells have also been reported to be essential for the activation of CD8+T cells. We demonstrated here that LAMP/ gag immunization induced polyfunctional CD4+T cells able to produce IFN- c, TNF- aand IL-2. Furthermore, those cells presented a phenotype of central memory T cells, expressing CCR7 and IFN- c. The importance of CD4+T cells for the whole T cell activation was clearly evidenced after immunization of mice depleted of CD4+T cells, where we observed almost total abrogation of the TNF- aand IFN- cproduction by CD8+T cells.", "Finally, we demonstrated that the association of Gag with LAMP luminal domain, in the absence of transmembrane/ cytoplasmic domain, was sufficient to modulate Gag traffic and anti-Gag immune response. Therefore, the traffic signals present in this region seemed to be the main event regulating the immune response.", "In summary, we described the mechanisms involved in the immune response induced by LAMP/ gag chimeric DNA and demonstrated that the luminal domain of LAMP is a key element in this construct, inducing higher Gag expression, and its traffic through the endolysosomal and secretory pathways. Analysis of the immune response elicited by chimeric DNA plasmids containing truncated sequences of LAMP-1 suggested that increased protein expression was sufficient to induce an enhanced, but transitory antibody response; however, increased T cell response depended on antigen targeting. These findings further enhance our knowledge regarding LAMP-mediated enhanced immunity and may contribute not only for the development of novel anti-HIV vaccines, but also to general vaccinology field.Supporting Information Figure S1 Association of p55 gag with LAMP luminal domain is sufficient to induce a T cell immune response.", "A-B) Balb/c mice were immunized twice with the indicated plasmids, and fifteen days later, total splenocytes were cultured with p55Gag protein and IFN- csecretion was analyzed by ELISA (A); or the cells were cultured with MHC I restricted Gag epitope AMQMLKETI65-73 and the expression of IFN- camong CD8+ cells were evaluated by FACS ( B). The data are representative of three independent experiments. * p ,0,05.", "(TIF) Acknowledgments The authors wish to thank Dr. James Hildreth (The Johns Hopkins University School of Medicine) for kindly providing the anti-Gag antibodies; and Dr. Susan Swain (The Trudeau Institute, Saranac Lake, NY) for the fibroblast cell line DCEK.ICAM.Hi7. We also thank Dr. Jose Mauro Peralta, responsible for the laboratory of Hybridoma and Cell Culture (Instituto de Microbiologia Paulo de Go ´es, UFRJ, RJ, Brazil) for the production and purification of anti-CD4 antibody (GK1.5). We acknowledge Betty Earls Hart, Joa ˜o Baltazar and Sidney Gomes da Costa for technical support. Several reagents were obtained through the AIDS Research Reagents Program, Division of AIDS, NIAID, National Institutes of Health: purified p55Gag protein and peptides.", "Author Contributions Conceived and designed the experiments: MNS LMTP JTA ETAM LBA.", "Performed the experiments: RMCG CGOL FLM POR LBA. Analyzed the data: MM LMTP JTA ETAM LBA. Contributed reagents/materials/ analysis tools: JLG. Wrote the paper: RMCG LBA.", "References", "1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific", "CD8+cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 (9), 6103–", "2. Ferre AL, Lemongello D, Hunt PW, Morri MM, Garcia JC, et al. (2010)", "Immunodominant HIV-specific CD8+T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J. Virol. 84 (19), 10354–10365.", "3. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, et al. (2010)", "HIV+elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS. 24(8),1095–10105.", "4. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal", "association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68 (7), 4650–", "5. Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, et al. (1998)", "Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178(4), 1008–1018.", "6. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997)", "Vigorous HIV-1-specific CD4+T cell responses associated with control of", "7. Bertoletti A, Cham F, McAdam S, Rostron T, Rowland-Jones S, et al. (1998)", "Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1", "8. Durali D, Morvan J, Letourneur F, Schmitt D, Guegan N, et al. (1998) Cross-", "reactions between the cytotoxic T-lymphocyte responses of human immunode- ficiency virus-infected African and European patients. J. Virol.72 (5), 3547–", "9. McAdam S, Kaleebu P, Krausa P, Goulder P, French N, et al. (1998) Cross-", "clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS.", "10. Shedlock DJ, Weiner DB (2000) DNA vaccination: antigen presentation and the", "induction of immunity. J. Leukoc. Biol. 68(6), 793–806.", "11. Bivas-Benita M, Gillard GO, Bar L, White KA, Webby RJ, et al. (2012) Airway", "CD8( +) T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity. Mucosal Immunol.; 6(1):156–66.", "12. Bo ¨ckl K, Wild J, Bredl S, Kindsmu ¨ller K, Ko ¨stler J, et al. (2012) Altering an", "artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine. PLoS One. 7 (4), e34723.13. Fuller DH, Rajakumar P, Che JW, Narendran A, Nyaundi J, et al. (2012) Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One. 7 (3), e33715.", "14. Pissani F, Malherbe DC, Robins H, Defilippis VR, Park B, et al. (2012) Motif-", "optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine. 30(37), 5519–", "15. Schliehe C, Bitzer A, van den Broek M, Groettrup M (2012) Stable antigen is", "most effective for eliciting CD8+T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J. Virol. 86(18), 9782–9793.", "16. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN", "(1989) Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86, 1495–1499.", "17. Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN (1997)", "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle", "18. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA", "(2000) A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74 (10), 19. Ngumbela KC, Ryan KP, Sivamurthy R, Brockman MA, Gandhi RT, et al.", "(2008) Quantitative effect of suboptimal codon usage on translational efficiency of mRNA encoding HIV-1 gag in intact T cells. PLoS One. 3(6),e2356.", "20. Qiu JT, Song R, Dettenhofer M, Tian C, August T, et al. (1999) Evaluation of", "novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J. Virol.", "21. Deml L, Bojak A, Steck S, Graf M, Wild J, et al. (2001) Multiple effects of codon", "usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J.", "22. Bojak A, Wild J, Deml L, Wagner R (2002) Impact of codon usage modification", "on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines.", "23. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, et al. (2010) HIV", "controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+T-cell responses. J. Virol. 84 (21), 11020–11029.LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e99887", "24. Maecker HT, Umetsu DT, DeKruyff RH, Levy S (1998) Cytotoxic T cell", "responses to DNA vaccination: dependence on antigen presentation via class II", "25. Langlade-Demoyen P, Garcia-Pons F, Castiglioni P, Garcia Z, Cardinaud S, et", "al. (2003) Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur. J. Immunol. 33 (3), 720–728.", "26. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, et al.", "(1995) Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181 (4), 1365–1372.", "27. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, et al. (2009)", "Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of", "28. Arruda LB, Sim D, Chikhlikar PR, Maciel M Jr, Akasaki K, et al. (2006)", "Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1- HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J. Immunol. 177 (4), 2265–", "29. Kaur M, Rai A, Bhatnagar R (2009) Rabies DNA vaccine: no impact of MHC", "class I and class II targeting sequences on immune response and protection against lethal challenge. Vaccine. 27 (15), 2128–2137.", "30. Midha S, Bhatnagar R (2009) Anthrax protective antigen administered by DNA", "vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur. J. Immunol. 39 (1), 159–177.", "31. Bazhan SI, Karpenko LI, Ilyicheva TN, Belavin PA, Seregin SV, et al. (2010)", "Rational design based synthetic polyepitope DNA vaccine for eliciting HIV- specific CD8+T cell responses. Mol Immunol. 47(7–8), 1507–1515.", "32. Wang Q, Lei C, Wan H, Liu Q (2012) Improved cellular immune response", "elicited by a ubiquitin-fused DNA vaccine against Mycobacterium tuberculosis.", "33. Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF (2000) Enhancement of primary", "and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J. Virol. 74(13), 5997–6005.", "34. The ´ry C, Boussac M, Ve ´ron P, Ricciardi-Castagnoli P, Raposo G, et al. (2001)", "Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 166(12), 7309–7318.", "35. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z (2005) Induction of heat", "shock proteins in B-cell exosomes. J. Cell Sci. 118 (Pt 16), 3631–3638.", "36. Zhang H, Xie Y, Li W, Chibbar R, Xiong S, et al. (2011) CD4( +) T cell-released", "exosomes inhibit CD8( +) cytotoxic T-lymphocyte responses and antitumor immunity. Cell Mol Immunol. 8(1), 23–30.", "37. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, et al. (1998) Eradication", "of established murine tumors using a novel cell-free vaccine: dendritic cell- derived exosomes. Na.t Med. 4(5), 594–600.", "38. Hartman ZC, Wei J, Glass OK, Guo H, Lei G, et al. (2011) Increasing vaccine", "potency through exosome antigen targeting. Vaccine. 29 (50), 9361–9367.", "39. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, et al.", "(1996) B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183(3),", "40. The ´ry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis", "and function. Nat Rev Immunol. 2(8), 569–79.", "41. Wolfers J, Lozier A, Raposo G, Regnault A, The ´ry C, et al. (2001) Tumor-", "derived exosomes are a source of shared tumor rejection antigens for CTL cross-", "42. Delcayre A, Estelles A, Sperinde J, Roulon T, Paz P, et al. (2005) Exosome", "display technology: applications to the development of new diagnostics and therapeutics. Blood Cells Mol. Dis. 35 (2), 158–168.", "43. Marques ET Jr, Chikhlikar P, Arruda LB, Leao IC, Lu Y, et al. (2003) HIV-1", "p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompat- ibility class II compartment, and elicits enhanced immune responses. J. Biol.", "44. Arruda LB, Chikhlikar PR, August JT, Marques ET Jr (2004) DNA vaccine", "encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology. 112(1), 126–133.45. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, et al. (1996)", "46. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, et al. (1998)", "Selective enrichment of tetraspan pr oteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes.", "47. Nguyen DG, Booth A, Gould SJ, Hildreth JE (2003) Evidence that HIV budding", "in primary macrophages occurs through the exosome release pathway. J. Biol.", "48. Dubey C, Croft M, Swain SL (1995) Costimulatory requirements of naive CD4 +", "T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol. 155(1):45–57.", "49. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ (2000)", "Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. s113 (Pt 19), 3365–3374.", "50. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G (2005) Vaccine-", "induced CD8 +central memory T cells in protection from simian AIDS. J.", "51. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. (2006) Preserved", "CD4+central memory T cells and survival in vaccinated SIV-challenged", "52. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, et al. (2010) Innate and", "adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. USA. 107(21), 9843–", "53. Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M", "(2012) NK and CD4 +T Cell Cooperative Immune Responses Correlate with Control of Disease in a Macaque Simian Immunodeficiency Virus Infection", "54. Thakur A, Pedersen LE, Jungersen G (2012) Immune markers and correlates of", "protection for vaccine induced immune responses. Vaccine. 30(33), 4907–4920.", "PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long- lasting neutralizing antibodies. Vaccine. 21(17–18), 2178–2189.", "56. Chang DD, Sharp PA (1989) Regulation by HIV Rev depends upon recognition", "of splice sites. Cell. 59, 789–795.", "57. Cochrane AW, Jones KS, Beidas S, Dillon PJ, Skalka AM, et al. (1991)", "Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression. J. Virol. 65, 5305–5313.", "58. Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, et al. (1992)", "Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1results in Rev-independent gag expression. J. Virol. 66, 7176–7182.", "59. Pollard VW, Malim MH (1998) The HIV-1 Rev protein. Annu. Rev. Microbiol.", "60. Graf M, Bojak A, Deml L, Bieler K, Wolf H, et al. (2000) Concerted action of", "multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74 (22), 10822–10826.", "61. Chikhlikar P, Arruda LB, Maciel M Jr, Silvera P, Lewis MG, et al. (2006) DNA", "encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS One. 1, e135.", "62. Fu TM, Ulmer JB, Caulfield MJ, Deck RR, Friedman A, et al. (1997) Priming of", "cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3", "63. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, et al. (1998)", "Predominant role for directly transfected dendritic cells in antigen presentation to CD8+T cells after gene gun immunization. J. Exp. Med. 188(6), 1075–1082.", "64. Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Chibbar R, et al. (2011)", "GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4( +) T-independent CTL responses. Vaccine. 29(19), 3538–3547.", "65. Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Xiang J (2012) Novel", "CD8+T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Vaccine.", "66. Stober D, Trobonjaca Z, Reimann J, Schirmbeck R (2002) Dendritic cells pulsed", "with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur. J. Immunol. 32 (4)., 1099–1108LAMP-1 Luminal Domain Enhances Anti-Gag Immune Response PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e99887"]}